WO2002057302A2 - A virus causing respiratory tract illness in susceptible mammals - Google Patents

A virus causing respiratory tract illness in susceptible mammals Download PDF

Info

Publication number
WO2002057302A2
WO2002057302A2 PCT/NL2002/000040 NL0200040W WO02057302A2 WO 2002057302 A2 WO2002057302 A2 WO 2002057302A2 NL 0200040 W NL0200040 W NL 0200040W WO 02057302 A2 WO02057302 A2 WO 02057302A2
Authority
WO
WIPO (PCT)
Prior art keywords
virus
mpv
apv
protein
orf
Prior art date
Application number
PCT/NL2002/000040
Other languages
French (fr)
Other versions
WO2002057302A8 (en
WO2002057302A3 (en
Inventor
Jan Cornelius De Jong
Ronaldus Adrianus Maria Fouchier
Bernadetta Gerarda Van Den Hoogen
Albertus Dominicus Marcellinus Erasmus Osterhaus
Jan Groen
Original Assignee
Vironovative B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26076820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002057302(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to ES02710551T priority Critical patent/ES2393468T3/en
Priority to CA2435180A priority patent/CA2435180C/en
Priority to BR0206591-6A priority patent/BR0206591A/en
Priority to KR10-2003-7009602A priority patent/KR20040002853A/en
Priority to CN028067630A priority patent/CN1524088B/en
Priority to KR1020117020851A priority patent/KR101412317B1/en
Priority to EA200300810A priority patent/EA006879B1/en
Priority to US10/466,811 priority patent/US8927206B2/en
Priority to EP02710551A priority patent/EP1351981B1/en
Application filed by Vironovative B.V. filed Critical Vironovative B.V.
Priority to NZ527221A priority patent/NZ527221A/en
Priority to DK02710551.9T priority patent/DK1351981T3/en
Priority to JP2002557978A priority patent/JP5503096B2/en
Priority to IL15700302A priority patent/IL157003A0/en
Priority to MXPA03006430A priority patent/MXPA03006430A/en
Priority to HU0500244A priority patent/HUP0500244A3/en
Priority to UA2003087814A priority patent/UA93981C2/en
Priority to KR1020107005359A priority patent/KR101105984B1/en
Priority to AU2002228471A priority patent/AU2002228471B2/en
Publication of WO2002057302A2 publication Critical patent/WO2002057302A2/en
Publication of WO2002057302A3 publication Critical patent/WO2002057302A3/en
Priority to US10/371,264 priority patent/US20030232061A1/en
Priority to US10/371,122 priority patent/US7531342B2/en
Priority to NO20033272A priority patent/NO335551B1/en
Priority to ZA200305655A priority patent/ZA200305655B/en
Publication of WO2002057302A8 publication Critical patent/WO2002057302A8/en
Priority to US10/722,045 priority patent/US8715922B2/en
Priority to HK05101405.2A priority patent/HK1068898A1/en
Priority to US12/001,458 priority patent/US20100278813A1/en
Priority to AU2008202111A priority patent/AU2008202111B2/en
Priority to US12/317,496 priority patent/US20100297730A1/en
Priority to US12/319,152 priority patent/US8722341B2/en
Priority to US14/270,237 priority patent/US9376726B2/en
Priority to US14/553,957 priority patent/US9334543B2/en
Priority to US15/147,653 priority patent/US9593386B2/en
Priority to US15/453,764 priority patent/US9803252B2/en
Priority to US15/796,500 priority patent/US10167524B2/en
Priority to US16/235,030 priority patent/US10519517B2/en
Priority to US16/730,429 priority patent/US11162148B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18341—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • a virus causing respiratory tract illness in susceptible mammals A virus causing respiratory tract illness in susceptible mammals.
  • the invention relates to the field of virology.
  • RTI respiratory tract illnesses
  • Classical etiological agents of RTI with mammals are respiratory syncytial viruses belonging to the genus Pneumovirus found with humans (h ⁇ tSV) and ruminants such as cattle or sheep (bRSV and/or oRSV).
  • h ⁇ tSV respiratory syncytial viruses belonging to the genus Pneumovirus found with humans
  • bRSV and/or oRSV ruminants
  • bRSV and/or oRSV ruminants
  • bRSV and/or oRSV ruminants
  • aa sequences show 94 % (subgroup A) or 98% (subgroup B) identity, while only 53% aa sequence identity is found between the subgroups. Additional variability is observed within subgroups based on monoclonal antibodies, RT-PCR assays and RNAse protection assays. Viruses from both subgroups have a worldwide distribution and may occur during a single season. Infection may occur in presence of pre-existing immunity and the antigenic variation is not strictly required to allow re-infection. See for example Sullender, W.M., Respiratory Syncytial Virus Genetic and Antigenic Diversity. Clinical Microbiology Reviews, 2000. 13(1): p.
  • Another classical Pneumovirus is the pneumonia virus of mice (PVM), in general only found with laboratory mice.
  • PVM pneumonia virus of mice
  • the invention provides an isolated essentially mammalian negative-sense single stranded RNA virus (MPV) belonging to the sub-family Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus.
  • Said virus is identifiable as phylogenetically corresponding to the genus Metapneumovirus by determining a nucleic acid sequence of said virus and testing it in phylogenetic analyses, for example wherein maximum likelihood trees are generated using 100 bootstraps and 3 jumbles and finding it to be more closely phylogenetically corresponding to a virus isolate deposited as 1-2614 with CNCM, Paris than it is corresponding to a essentially avian virus isolate of avian pneumovirus (APV) also known as turkey rhinotracheitis virus (TRTV), the aetiological agent of avian rhinotracheitis.
  • ADV avian pneumovirus
  • TRTV turkey rhinotracheitis virus
  • a very useful outgroup isolate can be obtained from avian pneumovirus serotype C (APV-C), as is for example demonstrated in figure 5 herein.
  • AMV-C avian pneumovirus serotype C
  • phylogenetic analyses provides a convenient method of identifying a virus as an MPV several other possibly more straightforward albeit somewhat more course methods for identifying said virus or viral proteins or nucleic acids from said virus are herein also provided.
  • an MPV can be identified by the percentages of a homology of the virus, proteins or nucleic acids to be identified in comparison with isolates, viral proteins, or nucleic acids identified herein by sequence or deposit.
  • virus species especially RNA virus species, often constitute a quasi species wherein a cluster of said viruses displays heterogeneity among its members.
  • each isolate may have a somewhat different percentage relationship with one of the various isolates as provided herein.
  • the invention provides an isolated essentially mammalian negative-sense single stranded RNA virus (MPV) belonging to the sub-family Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus by determining an amino acid sequence of said virus and determining that said amino acid sequence has a percentage amino acid homology to a virus isolate deposited as 1-2614 with CNCM, Paris which is essentially higher than the percentages provided herein for the L protein, the M protein, the N protein, the P protein, or the F protein, in comparison with APV-C or, likewise, an isolated essentially mammalian negative-sense single stranded RNA virus (MPV) belonging to the sub-family Pneumovirinae of the family Paramyxoviridae is provided as identifiable as phylogenetically corresponding to the genus Metapneumovirus by determining a nucle
  • P protein or the F protein as identified herein below in comparison with APV-C.
  • an MPV may consider an MPV as belonging to one of the two serological groups of MPV as identified herein when the isolates or the viral proteins or nuclear acids of the isolates that need to be identified have percentages homology that fall within the bounds and metes of the percentages of homology identified herein for both separate groups, taking isolates 00-1 or 99-1 as the respective isolates of comparison.
  • the percentages of homology are smaller or there is more need to distinguish the viral isolates from for example APV- C it is better advised to resort to the phylogenetic analyses as identified herein. Again one should keep in mind that said percentages can vary somewhat when other isolates are selected in the determination of the percentage of homology.
  • the invention provides diagnostic means and methods and therapeutic means and methods to be employed in the diagnosis and/or treatment of disease, in particular of respiratory disease, in particular of mammals, more in particular in humans.
  • the invention also provides means and methods to be employed in the diagnosis and treatment of avian disease.
  • diagnosis and/or treatment of a specific viral infection is performed with reagents that are most specific for said specific virus causing said infection.
  • a particular useful test for this purpose is an ELISA test designed for the detection of APV antibodies (e.g in serum or egg yolk), one commercialy available version of which is known as APV-Ab SVANOVIR ® which is manufactured by SVANOVA Biotech AB, Uppsal Science Park Glunten SE-751 83 Uppsala Sweden.
  • APV-Ab SVANOVIR ® which is manufactured by SVANOVA Biotech AB, Uppsal Science Park Glunten SE-751 83 Uppsala Sweden.
  • the reverse situation is also the case, herein it is for example provided to perform virological and/or serological diagnosis of APV infections in mammals with reagents derived from MPV, in the detailed description herein it is for example shown that sufficiently trustworthy serological diagnosis of APV infections in birds can be achieved by using an ELISA designed to detect MPV antibodies.
  • antigens and antibodies have a lock-and-key relationship
  • detection of the various antigens can be achieved by selecting the appropriate antibody having sufficient cross-reactivity.
  • the reagents such as antigens or antibodies
  • nucleic aciddetection it is even more straightforward, instead of designing primers or probes based on heterologous nucleic acid sequences of the various viruses and thus that detect differences between the essentially mammalian or avian Metapneumoviruses, it suffices to design or select primers or probes based on those stretches of virus-specific nucleic acid sequences that show high homology. In general, for nucleic acid sequences, homology percentages of 90% or higher guarantee sufficient cross-reactivity to be relied upon in diagnostic tests utilizing stingent conditions of hybridisation.
  • the invention for example provides a method for virologically diagnosing a MPV infection of an animal, in particular of a mammal, more in particular of a human being, comprising determining in a sample of said animal the presence of a viral isolate or component thereof by reacting said sample with a MPV specific nucleic acid a or antibody according to the invention, and a method for serologically diagnosing an MPV infection of a mammal comprising determining in a sample of said mammal the presence of an antibody specifically directed against an MPV or component thereof by reacting said sample with a MPV-specific proteinaceous molecule or fragment thereof or an antigen according to the invention.
  • the invention also provides a diagnostic kit for diagnosing an MPV infection comprising an MPV, an MPV-specific nucleic acid, proteinaceous molecule or fragment thereof, antigen and/or an antibody according to the invention, and preferably a means for detecting said MPV, MPV-specific nucleic acid, proteinaceous molecule or fragment thereof, antigen and/or an antibody, said means for example comprising an excitable group such as a fluorophore or enzymatic detection system used in the art (examples of suitable diagnostic kit format comprise IF, ELISA, neutrahzation assay, RT-PCR assay).
  • an as yet unidentified virus component or synthetic analogue thereof such as nucleic acid, proteinaceous molecule or fragment thereof can be identified as MPV-specific
  • it suffices to analyse the nucleic acid or amino acid sequence of said component for example for a stretch of said nucleic acid or amino acid, preferably of at least 10, more preferably at least 25, more preferably at least 40 nucleotides or amino acids (respectively), by sequence homology comparison with known MPV sequences and with known non-MPV sequences APV-C is preferably used) using for example phylogenetic analyses as provided herein.
  • the component or synthetic analogue can be identified.
  • the invention also provides method for virologically diagnosing an MPV infection of a mammal comprising determining in a sample of said mammal the presence of a viral isolate or component thereof by reacting said sample with a cross- reactive nucleic acid derived from APV (preferably serotype C) or a cross-reactive antibody reactive with said APV, and a method for serologically diagnosing an MPV infection of a mammal comprising determining in a sample of said mammal the presence of a cross-reactive antibody that is also directed against an APV or component thereof by reacting said sample with a proteinaceous molecule or fragment thereof or an antigen derived from APV.
  • the invention provides the use of a diagnostic kit initially designed for AVP or AVP-antibody detection for diagnosing an MPV infection, in particular for detecting said MPV infection in humans.
  • the invention also provides method for virologically diagnosing an APV infection in a bird comprising determining in a sample of said bird the presence of a viral isolate or component thereof by reacting said sample with a cross-reactive nucleic acid derived from MPV or a cross-reactive antibody reactive with said MPV, and a method for serologically diagnosing an APV infection of a bird comprising determining in a sample of said bird the presence of a cross-reactive antibody that is also directed against an MPV or component thereof by reacting said sample with a proteinaceous molecule or fragment thereof or an antigen derived from MPV.
  • the invention provides the use of a diagnostic kit initially designed for
  • MPV or MPV-antibody detection for diagnosing an APV infection, in particular for detecting said APV infection in poultry such as a chicken, duck or turkey.
  • Vaccinations that can not wait can for example be performed with vaccine preparations derived from APV(preferably type C) isolates when a more homologous MPV vaccine is not available, and, vice versa, vaccinations against APV infections can be contemplated with vaccine preparations derived from MPV.
  • reverse genetic techniques make it possible to generate chimeric APV-MPV virus constructs that are useful as a vaccine, being sufficiently dissimilar to field isolates of each of the respective strains to be attenuated to a desirable level.
  • the invention thus provides a novel etiological agent, an isolated essentially mammalian negative-sense single stranded RNA virus (herein also called MPV) belonging to the subfamily Pneumovirinae of the family Paramyxoviridae but not identifiable as a classical pneumovirus, and belonging to the genus Metapneumovirus, and MPV-specific components or synthetic analogues thereof.
  • MPV isolated essentially mammalian negative-sense single stranded RNA virus
  • Metapneumoviruses in general thought to be essentially restricted to poultry as natural host or aetiological agent of disease, are also known as avian pneumoviruses. Recently, an APV isolate of duck was described (FR 2 801 607), further demonstrating that APV infections are essentially restricted to birds as natural hosts.
  • the invention provides an isolated mammalian pneumovirus (herein also called MPV) comprising a gene order and amino acid sequence distinct from that of the genus Pneumovirus and which is closely related and considering its phylogenetic relatedness likely belonging to the genus Metapneumovirus within the subfamily Pneumovirinae of the family Paramyxoviridae.
  • MPV mammalian pneumovirus
  • metapneumoviruses have only been isolated from birds, it is now shown that related, albeit materially distinct, viruses can be identified in other animal species such as mammals.
  • APV essentially does not or only little replicates in chickens and turkeys where it easily does in cynomolgous macaques. No reports have been found on replication of APV in mammals.
  • specific anti-sera raised against MPV neutralize MPV
  • anti-sera raised against APV A, B or C do not neutralize MPV to the same extent, and this lack of full cross reactivity provides another proof for MPV being a different metapneumovirus.
  • the G and SH proteins of MPV are largely different from the ones known of APV in that they show no significant sequence homologies on both the amino acid or nucleic acid level. Diagnostic assays to discriminate between APV and MPV isolates or . antibodies directed against these different viruses can advantageously be developed based on one or both of these proteins (examples are IF, ELISA, neutrahzation assay, RT-PCR assay). However, also sequence and/or antigenic information obtained from the more related N, P, M, F and L proteins of MPV and analyses of sequence homologies with the respective proteins of APV, can also be used to discriminate between APV and MPV.
  • phylogenetic analyses of sequence information obtained from MPV revealed that MPV and APV are two different viruses.
  • the phylogenetic trees show that APV and MPV are two different lineages of virus.
  • MPV is circulating in the human population for at least 50 years, therefore interspecies transmission has probably taken place at least 50 years ago and is not an everyday event.
  • Stince MPV CPE was virtually indistinguishable from that caused by hRSV or hPIV-1 in tMK or other cell cultures, the MPV may have well gone unnoticed until now.
  • tMK tertiary mon ey kidney cells, i.e.
  • MK cells in a third passage in cell culture are preferably used due to their lower costs in comparison to primary or secondary culltures.
  • the CPE is, as well as with some of the classical Paramyxoviridae, characterized by syncytium formation after which the cells showed rapid internal disruption, followed by detachment of the cells from the monolayer.
  • the cells usually (but not always) displayed CPE after three passages of virus from original material, at day 10 to 14 post inoculation, somewhat later than CPE caused by other viruses such as hRSV or hPIV-1.
  • hRSV hRSV
  • hPIV-1 hPIV-1
  • the Paramyxoviridae form a family within the order of Mononegavirales (negative-sense single stranded RNA viruses), consisting of the sub-familys Paramyxovirinae and Pneumovirinae. The latter sub-family is at present taxonomically divided in the genera Pneumovirus and Metapneumovirus x .
  • Human respiratory syncytial virus (hRSV) the type species of the Pneumovirus genus, is the single most important cause of lower respiratory tract infections during infancy and early childhood worldwide 2 .
  • Other members of the Pneumovirus genus include the bovine and ovine respiratory syncytial viruses and pneumonia virus of mice (PVM).
  • Avian pneumovirus also known as turkey rhinotracheitis virus (TRTV)
  • TRTV turkey rhinotracheitis virus
  • Serological subgroups of APV can be differentiated on the basis of nucleotide or amino acid sequences of the G glycoprotein and neutralization tests using monoclonal antibodies that also recognize the G glycoprotein, Within subgroups A, B and D the G protein shows 98.5 to 99.7% aa sequence identity within subgroups while between the subgroups only 31.2- 38% aa identity is observed.
  • Colorado isolate of APV and compared it to known APV or TRT strains with in vitro serum neutrahzation tests.
  • the Colorado isolate was tested against monospecific polyclonal antisera to recognized TRT isolates.
  • the Colorado isolate was not neutrahzed by monospecific antisera to any of the TRT strains. It was, however, neutrahzed by a hyperimmune antiserum raised against a subgroup A strain. This antiserum neutrahzed the homologous virus to a titre of 1:400 and the Colorado isolate to a titer of 1: 80.
  • the Colorado isolate was then tested against TRT monoclonal antibodies. In each case, the reciprocal neutrahzation titer was ⁇ 10. Monospecific antiserum raised to the Colorado isolate was also tested against TRT strains of both subgroups. None of the TRT strains tested were neutrahzed by the antiserum to the Colorado isolate.
  • Colorado strain of APV does not protect SPF chicks against chaUenge with either a subgroup A or a subgroup B strain of TRT virus.
  • Colorado isolate may be the first example of a further serotype of avian pneumovirus, as also suggested by Bayon-Auboyer et al (J. Gen. Vir. 81:2723-2733 (2000).
  • the invention provides an isolated MPV taxonomically corresponding to a (hereto unknown mammalian) metapneumovirus comprising a gene order distinct from that of the pneumoviruses within the sub- family Pneumovirinae of the family Paramyxoviridae.
  • the classification of the two genera is based primarily on their gene constellation; metapneumoviruses generally lack non-structural proteins such NSl or NS2 ( see also Randhawa et al., J. Vir.
  • MPV or virus isolates phylogenetically corresponding or taxonomically corresponding therewith are sensitive to treatment with chloroform; are cultured optimally on tMK cells or cells functionally equivalent thereto and are essentially trypsine dependent in most ceU cultures.
  • the typical CPE and lack of haemagglutinating activity with most classically used red blood cells suggested that a virus as provided herein is, albeit only distantly, related to classical pneumoviruses such as RSV.
  • An MPV according to the invention also contains a second overlapping ORF (M2-2) in the nucleic acid fragment encoding the M2 protein, as in general most other pneumoviruses such as for example also demonstrated in Ahmadian et al., J. Gen. Vir. 80:2011-2016 (1999)
  • a virus isolate phylogenetically corresponding and thus taxonomically corresponding with MPV may be found by cross-hybridisation experiments using nucleic acid from a here provided MPV isolate, or in classical cross-serology experiments using monoclonal antibodies specifically directed against and/or antigens and/or immunogens specifically derived from an MPV isolate.
  • Newly isolated viruses are phylogenetically corresponding to and thus taxonomically corresponding to MPV when comprising a gene order and/or amino acid sequence sufficiently similar to our prototypic MPV isolate(s), or are structurally corresponding therewith, and show close relatedness to the genus Metapneumovirus within the subfamily Pneumovirinae.
  • the highest amino sequence homology, and defining the structural correspondence on the individual protein level, between MPV and any of the known other viruses of the same family to date (APV subtype C) is for matrix 87%, for nucleoprotein 88%, for phosphoprotein 68%, for fusionprotein 81% and for parts of the polymerase protein 56-64%, as can be deduced when comparing the sequences given in figure 6 with sequences of other viruses, in particular of AVP- C.
  • Individual proteins or whole virus isolates with, respectively, higher homology to these mentioned maximum values are considered phylogenetically corresponding and thus taxonomically corresponding to MPV, and comprise a nucleic acid sequence structurally corresponding with a sequence as shown in figure 6.
  • the invention provides a virus phylogenetically corresponding to the deposited virus. It should be noted that, similar to other viruses, a certain degree of variation is found between different isolated essentially mammalian negative-sense single stranded
  • RNA virus isolates as provided herein.
  • phylogenetic trees we have identified at least 2 genetic clusters of virus isolates based on comparitive sequence analyses of parts of the L, M, N and F genes. Based on nucleotide and amino-acid differences in the viral nucleic acid or amino acid sequences (the viral sequences), and in analogy to other pneumoviruses such as RSV, these MPV genotypes represent subtypes of MPV.
  • the percentage identity at the nucleotide level was found to be 94-100 for L, 91-100 for M, 90-100 for N and 93-100 for F and at the amino acid level the percentage identity was found to be 91-100 for L, 98-100 for M, 96-100 for N and 98-100 for F.
  • the minimum percentage identity at the nucleotide level for the entire group of isolated essentially mammahan negative-sense single stranded RNA virus as provided herein (MPV isolates) identified so far was 81 for L and M, 83 for N and 82 for F.
  • the viral sequence of a MPV isolate or an isolated MPV F gene as provided herein for example shows less than 81%nucleotide sequence identity or less than 82%(amino acid sequence identity with the respective nucleotide or amino acid sequence of an APV-C fusion (F) gene as for example provided by Seal et al., Vir. Res. 66:139147 (2000).
  • the viral sequence of a MPV isolate or an an isolated MPV L gene as provided herein shows less than 61% nucleotide sequence identity or less than 63% amino acid sequence identity with the respective nucleotide or amino acid sequence of an APV- A polymerase gene as for example provided by Randhawa et al.,., J. Gen. Vir. 77:3047-3051 (1996).
  • Sequence divergence of MPV strains around the world may be somewhat higher, in analogy with other viruses. Consequently, two potential genetic clusters are identified by analyses of partial nucleotide sequences in the N, M, F and L ORFs of 9 virus isolates. 90-100% nucleotide identity was observed within a cluster, and 81- 88% identity was observed between the clusters. Sequence information obtained on more virus isolates confirmed the existence of two genotypes. Virus isolate nedV00/01 as prototype of cluster A, and virus isolate ned/99/01 as prototype of cluster B have been used in cross neutrahzation assays to test whether the genotypes are related to different serotypes or subgroups.
  • essentially mammalian virus isolates displaying percentage amino acid homology higher than 64 for L, 87 for M, 88 for N, 68 for P, 81 for F 84 for M2-1 or 58 for M2-2 to isolate 1-2614 may be classified as an isolated essentially mammalian negative-sense single stranded RNA virus as provided herein.
  • virus isolates in general that have a minimum percentage identity at the nucleotide sequence level with a prototype MPV isolate as provided herein of 81 for L and M, 83 for N and/or 82 for F are members of the group of MPV isolates as provided herein .
  • these percentage are 91 for L and N, 94 for M, and/or 95 for F.
  • the virus isolate When the percentage amino acid sequence homology for a given virus isolate is higher than 90 for L and N, 93 for M, or 94 for F, the virus isolate is similar to the group of MPV isolates displayed in figure 5. When the percentage amino acid sequence homology for a given virus isolate is higher than 94 for L, 95 for N or 97 for M and F the virus isolate can be identified to belong to one of the genotype clusters represented in figure 5. It should be noted that these percentages of homology, by which genetic clusters are defined, are similar to the degree of homology found among genetic clusters in the corresponding genes of RSV.
  • the invention provides an isolated essentiaUy mammalian negative- sense single stranded RNA virus (MPV) belonging to the sub-family Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus by determining a nucleic acid sequence of a suitable fragment of the genome of said virus and testing it in phylogenetic tree analyses wherein maximum likelihood trees are generated using 100 bootstraps and 3 jumbles and finding it to be more closely phylogenetically corresponding to a virus isolate deposited as 1-2614 with CNCM, Paris than it is corresponding to a virus isolate of avian pneumovirus (APV) also known as turkey rhinotracheitis virus (TRTV), the aetiological agent of avian rhinotracheitis.
  • AMV avian pneumovirus
  • TRTV turkey rhinotracheitis virus
  • Suitable nucleic acid genome fragments each useful for such phylogenetic tree analyses are for example any of the RAP-PCR fragments 1 to 10 as disclosed herein in the detailed description, leading to the various phylogenetic tree analyses as disclosed herein in figures 4 or 5.
  • the invention provides an isolated essentially mammahan negative-sense single stranded RNA virus (MPV) belonging to the subfamily Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus by determining a nucleic acid sequence of a suitable fragment of the genome of said virus and testing it in phylogenetic tree analyses wherein maximum likelihood trees are generated using 100 bootstraps and 3 jumbles and finding it to be more closely phylogenetically corresponding to a virus isolate deposited as 1-2614 with CNCM, Paris than it is corresponding to a virus isolate of avian pneumovirus (APV) also known
  • MPV essentially mammahan negative-sense single stranded RNA virus
  • a suitable open reading frame comprises the ORF encoding the N protein.
  • the analysed virus isolate comprises a preferred MPV isolate according to the invention.
  • the first gene in the genomic map of MPV codes for a 394 amino acid (aa) protein and shows extensive homology with the N protein of other pneumoviruses.
  • the length of the N ORF is identical to the length of the N ORF of APV-C (Table 5) and is smaller than those of other paramyxoviruses (Barr et al., 1991). Analysis of the amino acid sequence revealed the highest homology with APV-C (88%), and only 7- 11% with other paramyxoviruses (Table 6).
  • Another suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the P protein.
  • the analysed virus isolate comprises a preferred MPV isolate according to the invention.
  • the second ORF in the genome map codes for a 294 aa protein which shares 68% aa sequence homology with the P protein of APV-C, and only 22-26% with the P protein of RSV (Table 6).
  • the P gene of MPV contains one substantial ORF and in that respect is similar to P from many other paramyxoviruses
  • the MPV P ORF lacks cysteine residues.
  • Ling (1995) suggested that a region of high similarity between all pneumoviruses (aa 185-241) plays a role in either the RNA synthesis process or in maintaining the structural integrity of the nucleocapsid complex. This region of high similarity is also found in MPV ( Figure 9) especifically when conservative substitutions are taken in account, showing 100% similarity with APV-C, 93 % with APV-A and B, and approximately 81% with RSV.
  • the C-terminus of the MPV P protein is rich in glutamate residues as has been described for APVs (Ling et al., 1995).
  • Another suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the M protein.
  • the analysed virus isolate comprises a preferred MPV isolate according to the invention.
  • the third ORF of the MPV genome encodes a 254 aa protein, which resembles the M ORFs of other pneumoviruses.
  • the M ORF of MPV has exactly the same size as the M ORFs of other metapneumoviruses (Table 5) and shows high aa sequence homology with the matrix proteins of APV (76-87%) lower homology with those of RSV and PVM (37-38%) and 10% or less homology with those of other paramyxoviruses (Table 6).
  • Easton (1997) compared the sequences of matrix proteins of all pneumoviruses and found a conservedhexapeptide at residue 14 to 19 that is also conserved in MPV ( Figure 10).
  • ORFs in the M ORF of MPV One small ORF of 54 aa residues was found within the major M ORF , starting at nucleotide 2281 and one small ORF of 33 aa residues was found overlapping with the major ORF of M starting at nucleotide 2893 (data not shown). Similar to the secondary ORFs of RSV and APV there is no significant homology between these secondary ORFs and secondary ORFs of the other pneumoviruses, and apparent start or stop signals are lacking. In addition, evidence for the synthesis of proteins corresponding to these secondary ORFs of APV and RSV has not been reported.
  • Another suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the F protein. When an overall amino acid identity of at least 95%, preferably of at least 97% of the analysed F-protein with the F-protein of isolate I-
  • the analysed virus isolate comprises a preferred MPV isolate according to the invention.
  • the F ORF of MPV is located adjacent to the M ORF, which is characteristic for members of the Metapneumovirus genus.
  • the F gene of MPV encodes a 539 aa protein, which is two aa residues longer than F of APV-C (Table 5).
  • Analysis of the aa sequence revealed 81% homology with APV-C, 67% with APV-A and B, 33-39% with pneumovirus F proteins and only 10-18% with other paramyxoviruses (Table 6).
  • One of the conserved features among F proteins of paramyxoviruses, and also seen in MPV is the distribution of cysteine residues
  • F protein of MPV revealed typical fusion protein characteristics consistent with those described for the F proteins of other Paramyxoviridae family members (Morrison, 1988).
  • F proteins of Paramyxoviridae members are synthesized as inactive precursors (F0) that are cleaved by host cell proteases which generate amino terminal F2 subunits and large carboxy terminal Fl subunits.
  • the proposed cleavage site (Collins et al., 1996) is conserved among all members of the Paramyxoviridae family.
  • the cleavage site of MPV contains the residues RQSR.
  • arginine (R) residues are shared with APV and RSN but the glutamine (Q) and serine (S) residues are shared with other paramyxoviruses such as human parainfluenza virus type 1, Sendai virus and morbilhviruses (data not shown).
  • the hydrophobic region at the amino terminus of Fl is thought to function as the membrane fusion domain and shows high sequence similarity among paramyxoviruses and morbilhviruses and to a lesser extent the pneumoviruses (Morrison, 1988).
  • the signal peptide of MPV (aa 10- 35, Figure 11) at the amino terminus of F2 exhibits some sequence similarity with APV-C (18 out of 26 aa residues are similar) and less conservation with other APVs or RSV. Much more variability is seen in the membrane anchor domain at the carboxy terminus of Fl, although some homology is still seen with APV-C.
  • Another suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the M2 protein.
  • the analysed virus isolate comprises a preferred MPV isolate according to the invention.
  • M2 gene is unique to the Pneumovirinae and two overlapping ORFs have been observed in all pneumoviruses.
  • the first major ORF represents the M2-1 protein which enhances the processivity of the viral polymerase (Collins et al., 1995; Collins, 1996) and its readthrough of intergenic regions (Hardy et al, 1998; Fearns et al, 1999).
  • the M2-1 gene for MPV located adjacent to the F gene, encodes a 187 aa protein (Table 5), and reveals the highest (84%) homology with M2-1 of APV-C (Table 6).
  • Comparison of all pneumovirus M2-1 proteins revealed the highest conservation in the amino-terminal half of the protein (Collins et al, 1990; Zamora et al, 1992; Ahmadian et al, 1999), which is in agreement with the observation that MPV displays 100% similarity with APV-C in the first 80 aa residues of the protein ( Figure 12A).
  • the MPV M2-1 protein contains 3 cysteine residues located within the first 30 aa residues that are conserved among all pneumoviruses. Such a concentration of cysteines is frequently found in zinc-binding proteins (Ahmadian et al, 1991; Cuesta et al., 2000).
  • the secondary ORFs (M2-2) that overlap with the M2-1 ORFs of pneumoviruses are conserved in location but not in sequence and are thought to be involved in the control of the switch between virus RNA replication and transcription (Collins et al, 1985; Elango et al, 1985; Baybutt et al, 1987; Collins et al., 1990; Ling et al, 1992; Zamora et al, 1992; Alansari et al, 1994; Ahmadian et al, 1999; Bermingham et al, 1999).
  • the M2-2 ORF starts at nucleotide 512 in the M2-1 ORF ( Figure 7), which is exactly the same start position as for APV-C.
  • the length of the M2-2 ORFs are the same for APV-C and MPV, 71 aa residues (Table 5). Sequence comparison of the M2-2 ORF ( Figure 12B) revealed 56% aa sequence homology between MPV and APV-C and only 26-27%aa sequence homology between MPV and APV-A and B (Table 6).
  • Another suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the L protein.
  • the analysed virus isolate comprises a preferred MPV isolate according to the invention.
  • the last ORF of the MPV genome is the RNA-dependent RNA polymerase component of the rephcation and transcription complexes.
  • the L gene of MPV encodes a 2005 aa protein, which is 1 residue longer than the APV-A protein (Table 5).
  • the L protein of MPV shares 64% homology with APV-A, 42-44% with RSV, and approximately 13% with other paramyxoviruses (Table 6).
  • Poch et al (1989; 1990) identified six conserved domains within the L proteins of non-segmented negative strand RNA viruses, from which domain III contained the four core polymerase motifs that are thought to be essential for polymerase function.
  • motifs are well conserved in the MPV L protein: in motifs A, B and C: MPV shares 100% similarity with all pneumoviruses and in motif D MPV shares 100 % similarity with APV and 92% with RSVs. For the entire domain III (aa 625- 847 in the L ORF), MPV shares 83% identity with APV, 67- 68% with RSV and 26-30% with other paramyxoviruses ( Figure 15).
  • the pneumovirus L proteins contain a sequence which conforms to a consensus ATP binding motif K(X) 2 ⁇ GEGAGN(X) 2 oK (Stec, 1991).
  • the MPV L ORF contains a similar motif as APV, in which the spacing of the intermediate residues is off by one: K(x) 22 GEGAGN(X) ⁇ 9 K.
  • a much preferred suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the SH protein.
  • the analysed virus isolate comprises a preferred MPV isolate according to the invention.
  • the gene located adjacent to M2 of MPV encodes a 183 aa protein ( Figure 7).
  • Analysis of the nucleotide sequence and its deduced amino acid sequence revealed no discernible homology with other RNA virus genes or gene products.
  • the SH ORF of MPV is the longest SH ORF known to date (Table 5).
  • composition of the aa residues of the SH ORF is relatively similar to that of APV, RSV and PVM, with a high percentage of threonine and serine (22%, 18%, 19%, 20.0%, 21% and 28% serine/threonine content for MPV, APV, RSV A, RSV B, bRSV and PVM respectively).
  • the SH ORF of MPV contains 10 cysteine residues, whereas APV SH contains 16 cysteine residues. All pneumoviruses have similar numbers of potential N- lycosylation sites (MPV 2, APY 1, RSV 2, bRSV 3, PVM 4).
  • the hydrophobicity profiles for the MPV SH protein and SH of APV and RSV revealed similar structural characteristics ( Figure 13B).
  • the SH ORFs of APV and MPV have a hydrophylic N-terminus (aa 1-30), a central hydrophobic domain (aa 30- 53) which can serve as a potential membrane spanning domain, a second hydrophobic domain around residue 160 and a hydrophilic C-terminus.
  • RSV SH appears to lack the C-terminal half of the APV and MPV ORFs.
  • the hydrophobic domain is flanked by basic amino acids, which are also found in the SH ORF for MPV (aa 29 and 54).
  • Another much preferred suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the G protein.
  • the analysed virus isolate comprises a preferred MPV isolate according to the invention.
  • the G ORF of MPV is located adjacent to the SH gene and encodes a 236 amino acid protein.
  • a secondary small ORF is found immediately fohowing this ORF, potentially coding for 68 aa residues (pos. 6973-7179,), but lacking a start codon.
  • a third major ORF, in a different reading frame, of 194 aa residues is overlapping with both of these ORFs, but also lacks a startcodon (nucleotide 6416-7000).
  • This major ORF is followed by a fourth ORF in the same reading frame (nt 7001-7198), possibly coding for 65 aa residues but again lacking a start codon.
  • ORF of 97 aa residues is found in the third reading frame (nt 6444-6737, Figure 1). Unlike the first ORF, the other ORFs do not have apparent gene start or gene end sequences (see below). Although the 236 aa residue G ORF probably represents at least a part of the MPV attachment protein it can not be excluded that the additional coding sequences are expressed as separate proteins or as part of the attachment protein through some RNA editing event. It should be noted that for APV and RSV no secondary ORFs after the primary G ORF have been identified but that both APV and RSV have secondary ORFs within the major ORF of G. However, evidence for expression of these ORFs is lacking and there is no homology between the predicted aa sequences for different viruses (Ling et al., 1992).
  • the aa sequence revealed a serine and threonine content of 34%, which is even higher than the 32% for RSV and 24% for APV.
  • the G ORF also contains 8.5% proline residues, which is higher than the 8% for RSV and 7% for APV.
  • the unusual abundance of prohne residues in the G proteins of APV, RSV and MPV has also been observed in glycoproteins of mucinous origin where it is a major determinant of the proteins three dimensional structure (Collins et al, 1983; Wertz et al., 1985; Jentoft, 1990).
  • the number of potential N-hnked glycosylation sites in G of MPV is similar to other pneumoviruses: MPV has 5, whereas hRSV has 7, bRSV has 5, and APV has 3 to 5.
  • the predicted hydrophobicity profile of MPV G revealed characteristics similar to the other pneumoviruses.
  • the amino-terminus contains a hydrophylic region followed by a short hydrophobic area (aa 33-53) and a mainly hydrophihc carboxy terminus (Figure 14B).
  • This overall organisation is consistent with that of an anchored type II transmembrane protein and corresponds well with these regions in the G protein of APV and RSV.
  • the G ORF of MPV contains only 1 cysteine residue in contrast to RSV and APV (5 and 20 respectively).
  • an MPV isolate is also identifiable as belonging to a serotype as provided herein, being defined on the basis of its immunological distinctiveness, as determined by quantitative neutrahzation with animal antisera (obtained from for example ferrets or guinnea pigs as provided in the detailed description).
  • Such a serotype has either no cross-reaction with others or shows a homologous-to heterologous titer ratio >16 in both directions. If neutrahzation shows a certain degree of cross-reaction between two viruses in either or both directions (homologous-to-heterologous tier ration of eight or 16), distinctiveness of serotype is assumed if substantial biophysical/biochemical differences of DNA's exist. If neutrahzation shows a distinct degree of cross-reaction between two viruses in either or both directions (homologous-to-heterologous tier ration of smaller than eight), identity of serotype of the isolates under study is assumed.
  • useful prototype isolates such as isolate 1-2614, herein also known as MPV isolate 00-1, are provided herein.
  • a further classification of a virus as an isolated essentially mammalian negative-sense single stranded RNA virus as provided herein can be made on the basis of homology to the G and/or SH proteins.
  • N, P, M, F, M2 and L ORFs was 64 to 88 percent, and nucleotide sequence homology was also found between the non-coding regions of the APV and MPV genomes, essentially no discernable amino acid sequence homology was found between two of the ORFs of the human isolate (MPV) and any of the ORFs of other paramyxoviruses.
  • MPV human isolate
  • the amino acid content, hydrophobicity profiles and location of these ORFs in the viral genome show that they represent G and SH protein analogues.
  • the sequence homology between APV and MPV, their similar genomic organization (3'-N-P-M-F-M2-SH-G-L-5') as weU as phylogenetic analyses provide further evidence for the proposed classification of MPV as the first mammahan metapneumovirus.
  • New MPV isolates are for thus example identified as such by virus isolation and characterisation on tMK or other cells, by RT-PCR and/or sequence analysis followed by phylogenetic tree analyses, and by serologic techniques such as virus neutralisation assays, indirect immunofluorescence assays, direct immunofluorescence assays, FACs analyses or other immunological techniques. Preferably these techniques are directed at the SH and/or G protein analogues.
  • the invention provides herein a method to identify further isolates of MPV as provided herein, the method comprising inoculating a essentially
  • MPV-uninfected or specific-pathogen-free guinea pig or ferret in the detailed description the animal is inoculated intranasally but other ways of inoculation such as intramuscular or intradermal inoculation, and using an other experimental animal, is also feasible) with the prototype isolate 1-2614 or related isolates. Sera are collected from the animal at day zero, two weeks and three weeks post inoculation.
  • the animal specifically seroconverted as measured in virus neutrahsation (VN) assay and indirect IFA against the respective isolate 1-2614 and the sera from the seroconverted animal are used in the immunological detection of said further isolates.
  • the invention provides the characterisation of a new member in the family of Paramyxoviridae, a human metapneumovirus or metapneumovirus- like virus (since its final taxonomy awaits discussion by a viral taxonomy committee the MPV is herein for example described as taxonomically corresponding to APV) (MPV) which may cause severe RTI in humans.
  • the clinical signs of the disease caused by MPV are essentially similar to those caused by hRSV, such as cough, myalgia, vomiting, fever, broncheohtis or pneumonia, possible conjunctivitis, or combinations thereof.
  • hRSV infected children especifically very young children may require hospitahsation.
  • an MPV which was deposited January 19, 2001 as 1-2614 with CNCM, Institute Pasteur, Paris or a virus isolate phylogenetically corresponding therewith is herewith provided.
  • the invention provides a virus comprising a nucleic acid or functional fragment phylogenetically corresponding to a nucleic acid sequence shown in figure 6a, 6b, 6c, or structurally corresponding therewith.
  • the invention provides a virus characterised in that after testing it in phylogenetic tree analyses wherein maximum likelihood trees are generated using 100 bootstraps and 3 jumbles it is found to be more closely phylogenetically corresponding to a virus isolate deposited as 1-2614 with CNCM, Paris than it is related to a virus isolate of avian pneumovirus (APV) also known as turkey rhinotracheitis virus (TRTN), the aetiological agent of avian rhinotracheitis.
  • AAV avian pneumovirus
  • TRTN turkey rhinotracheitis virus
  • the new human virus was named human metapneumovirus or metapneumovirus-like virus (MPV) based on several observations. EM analysis revealed paramyxovirus-like particles. Consistent with the classification, MPV appeared to be sensitive to treatment with chloroform. MPV is cultured optimal on tMK ceUs and is trypsine dependent. The chnical symptoms caused by MPV as well as the typical CPE and lack of haemagglutinating activity suggested that this virus is closely related to hRSV. Although most paramyxoviruses have haemaglutinating acitivity, most of the pneumoviruses do not 13 -
  • the invention provides a not previously identified paramyxovirus from nasopharyngeal aspirate samples taken from 28 children suffering from severe RTI.
  • the chnical symptoms of these children were largely similar to those caused by hRSV. Twenty-seven of the patients were children below the age of five years and half of these were between 1 and 12 months old. The other patient was 18 years old.
  • the virus isolates from these patients had the paramyxovirus morphology in negative contrast electron microscopy but did not react with specific antisera against known human and animal paramyxoviruses. They were all closely related to one another as determined by indirect immunofluorescence assays (IF A) with sera raised against two of the isolates. Sequence analyses of nine of these isolates revealed that the virus is somewhat related to APV. Based on virological data, sequence homology as well as the genomic organisation we propose that the virus is a member of Metapneumovirus genus. Serological surveys showed that this virus is a relatively common pathogen since the seroprevalence in the Netherlands approaches 100% of humans by the age of five years.
  • the seroprevelance was found to be equally high in sera collected from humans in 1958, indicating this virus has been circulating in the human population for more than 40 years.
  • the identification of this proposed new member of the Metapneumovirus genus now also provides for the development of means and methods for diagnostic assays or test kits and vaccines or serum or antibody compositions for viral respiratory tract infections, and for methods to test or screen for antiviral agents useful in the treatment of MPV infections.
  • the invention provides among others an isolated or recombinant nucleic acid or virus-specific functional fragment thereof obtainable from a virus according to the invention.
  • the invention provides primers and/or probes suitable for identifying an MPV nucleic acid.
  • the invention provides a vector comprising a nucleic acid according to the invention.
  • vectors such as plasmid vectors containing (parts of) the genome of MPV, virus vectors containing (parts of) the genome of MPV. (For example, but not hmited to other paramyxoviruses, vaccinia virus, retroviruses, baculovirus), or MPV containing (parts of) the genome of other viruse or other pathogens are provided.
  • plasmid vectors containing (parts of) the genome of MPV virus vectors containing (parts of) the genome of MPV.
  • MPV containing (parts of) the genome of other viruse or other pathogens.
  • a number of reverse genetics techniques have been described for the generation of recombinant negative strand viruses, based on two critical parameters.
  • vRNA negative sense viral RNA
  • cRNA complementary copy thereof
  • vRNA or cRNA can be isolated from infectious virus, produced upon in- vitro transcription, or produced in cells upon transfection of nucleic acids.
  • the production of recombinant negative strand virus rehes on a functional polymerase complex.
  • the polymerase complex of pneumoviruses consists of N, P, L and possibly M2 proteins, but is not necessarily hmited thereto.
  • Polymerase complexes or components thereof can be isolated from virus particles, isolated from cells expressing one or more of the components, or produced upon transfection of specific expression vectors.
  • Infectious copies of MPV can be obtained when the above mentioned vRNA, cRNA, or vectors expressing these RNAs are rephcated by the above mentioned polymerase complex 16 , 17 , 18 , 19 , 20 , 21 , 22 j p or ⁇ generation of minirephcons or, a reverse genetics system for generating a full-length copy comprising most or all of the genome of MPV it suffices to use 3'end and/or 5'end nucleic acid sequences obtainable from for example APV (Randhawa et al., 1997) or MPV itself.
  • the invention provides a host cell comprising a nucleic acid or a vector according to the invention.
  • Plasmid or viral vectors containing the polymerase components of MPV are generated in prokaryotic cells for the expression of the components in relevant cell types (bacteria, insect cells, eukaryotic cells). Plasmid or viral vectors containing full-length or partial copies of the MPV genome will be generated in prokaryotic cells for the expression of viral nucleic acids in- vitro or in- vivo.
  • the latter vectors may contain other viral sequences for the generation of chimeric viruses or chimeric virus proteins, may lack parts of the viral genome for the generation of replication defective virus, and may contain mutations, deletions or insertions for the generation of attenuated viruses.
  • Infectious copies of MPV (being wild type, attenuated, replication-defective or chimeric) can be produced upon co-expression of the polymerase components according to the state-of-the-art technologies described above.
  • eukaryotic cells transiently or stably expressing one or more full-length or partial MPV proteins can be used.
  • Such cells can be made by transfection (proteins or nucleic acid vectors), infection (viral vectors) or transduction (viral vectors) and may be useful for complementation of mentioned wild type, attenuated, replication- defective or chimeric viruses.
  • a chimeric virus may be of particular use for the generation of recombinant vaccines protecting against two or more viruses 23 > 4 > 26 .
  • a MPV virus vector expressing one or more proteins of RSV or a RSV vector expressing one or more proteins of MPV will protect individuals vaccinated with such vector against both virus infections.
  • a similar approach can be envisaged for PI3 or other paramyxoviruses.
  • Attenuated and replication-defective viruses may be of use for vaccination purposes with hve vaccines as has been suggested for other viruses 25 ' 26 .
  • the invention provides a proteinaceous molecule or metapneumovirus-specific viral protein or functional fragment thereof encoded by a nucleic acid according to the invention.
  • useful proteinaceous molecules are for example derived from any of the genes or genomic fragments derivable from a virus according to the invention.
  • Such molecules, or antigenic fragments thereof, as provided herein, are for example useful in diagnostic methods or kits and in pharmaceutical compositions such as sub-unit vaccines.
  • Particularly useful are the F, SH and/or G protein or antigenic fragments thereof for inclusion as antigen or subunit immunogen, but inactivated whole virus can also be used.
  • Particulary useful are also those proteinaceous substances that are encoded by recombinant nucleic acid fragments that are identified for phylogenetic analyses, of course preferred are those that are within the preferred bounds and metes of ORFs useful in phylogenetic analyses, in particular for eliciting MPV specific antibodies, whether in vivo (e.g. for protective puposes or for providing diagnostic antibodies) or in vitro (e.g. by phage display technology or another technique useful for generating synthetic antibodies).
  • antibodies be it natural polyclonal or monoclonal, or synthetic (e.g. (phage) library-derived binding molecules) antibodies that specificallyreact with an antigen comprising a proteinaceous molecule or MPV- specific functional fragment thereof according to the invention.
  • Such antibodies are useful in a method for identifying a viral isolate as an MPV comprising reacting said viral isolate or a component thereof with an antibody as provided herein. This can for example be achieved by using purified or non-purified MPV or parts thereof (proteins, peptides) using ELISA, RIA, FACS or similar formats of antigen detection assays (Current Protocols in Immunology). Alternatively, infected cells or cell cultures may be used to identify viral antigens using classical immunofluorescence or immunohistochemical techniques.
  • identifying a viral isolate as a MPV comprise reacting said viral isolate or a component thereof with a virus specific nucleic acid according to the invention, in particular where said mammalian virus comprises a human virus.
  • the invention provides a viral isolate identifiable with a method according to the invention as a mammahan virus taxonomically corresponding to a negative-sense single stranded RNA virus identifiable as likely belonging to the genus Metapneumovirus within the sub-family Pneumovirinae of the family Paramyxoviridae.
  • the method is useful in a method for virologically diagnosing an MPV infection of a mammal, said method for example comprising determining in a sample of said mammal the presence of a viral isolate or component thereof by reacting said sample with a nucleic acid or an antibody according to the invention.
  • a method for virologically diagnosing an MPV infection of a mammal said method for example comprising determining in a sample of said mammal the presence of a viral isolate or component thereof by reacting said sample with a nucleic acid or an antibody according to the invention.
  • PCR or other amplification or hybridisation techniques well known in the art
  • immunofluorescence detection or other immunological techniques known in the art
  • the invention also provides a method for serologically diagnosing a MPV infection of a mammal comprising determining in a sample of said mammal the presence of an antibody specifically directed against a MPV or component thereof by reacting said sample with a proteinaceous molecule or fragment thereof or an antigen according to the invention
  • kits or assays may for example comprise a virus, a nucleic acid, a proteinaceous molecule or fragment thereof, an antigen and/or an antibody according to the invention.
  • Use of a virus, a nucleic acid, a proteinaceous molecule or fragment thereof, an antigen and/or an antibody according to the invention is also provided for the production of a pharmaceutical composition, for example for the treatment or prevention of MPV infections and/or for the treatment or prevention of respiratory tract illnesses, in particular in humans.
  • Attenuation of the virus can be achieved by estabhshed methods developed for this purpose, including but not hmited to the use of related viruses of other species, serial passages through laboratory animals or/and tissue/cell cultures, site directed mutagenesis of molecular clones and exchange of genes or gene fragments between related viruses.
  • a pharmaceutical composition comprising a virus, a nucleic acid, a proteinaceous molecule or fragment thereof, an antigen and/or an antibody according to the invention can for example be used in a method for the treatment or prevention of a MPV infection and/or a respiratory illness comprising providing an individual with a pharmaceutical composition according to the invention.
  • This is most useful when said individual comprises a human, especifically when said human is below 5 years of age, since such infants and young children are most likely to be infected by a human MPV as provided herein.
  • patients will suffer from upper respiratory symptoms predisposing for other respiratory and other diseases. Also lower respiratory illnesses may occur, predisposing for more and other serious conditions.
  • the invention also provides method to obtain an antiviral agent useful in the treatment of respiratory tract illness comprising estabhshing a cell culture or experimental animal comprising a virus according to the invention, treating said culture or animal with an candidate antiviral agent, and determining the effect of said agent on said virus or its infection of said culture or animal.
  • an antiviral agent comprises a MPV-neutrahsing antibody, or functional component thereof, as provided herein, but antiviral agents of other nature are obtained as well.
  • the invention also provides use of an antiviral agent according to the invention for the preparation of a pharmaceutical composition, in particular for the preparation of a pharmaceutical composition for the treatment of respiratory tract illness, especifically when caused by an MPV infection, and provides a pharmaceutical composition comprising an antiviral agent according to the invention, useful in a method for the treatment or prevention of an MPV infection or respiratory illness, said method comprising providing an individual with such a pharmaceutical composition.
  • an antiviral agent according to the invention for the preparation of a pharmaceutical composition, in particular for the preparation of a pharmaceutical composition for the treatment of respiratory tract illness, especifically when caused by an MPV infection
  • a pharmaceutical composition comprising an antiviral agent according to the invention, useful in a method for the treatment or prevention of an MPV infection or respiratory illness, said method comprising providing an individual with such a pharmaceutical composition.
  • Figure IA comprises table 1: Percentage homology found between the amino acid sequence of isolate 00-1 and other members of the Pneumovirinae. Percentages (xlOO) are given for the amino acid sequences of N, P, M, F and two RAP-PCR fragments in L (8 and 9/10). Accession numbers used for the analyses are described in the materials and methods section.
  • Fig IB comprises table 2: Seroprevalence of MPV in humans categorised by age group using immunofluorescence and virus neutrahsation assays..
  • Fig. 2 Schematic representation of the genome of APV with the location and size of the fragments obtained with RAP-PCR and RT-PCR on virus isolate 00-1. Fragments 1 to 10 were obtained using RAP-PCR. Fragment A was obtained with a primer in RAP-PCR fragment 1 and 2 and a primer designed based on ahgnment of leader and trailer sequences of APV and RSV 6 . Fragment B was obtained using primers designed in RAP-PCR fragment 1 and 2 and RAP-PCR fragment 3. Fragment C was obtained with primers designed in RAP-PCR fragment 3 and RAP-PCR fragment 4,5,6 and 7.
  • hRSV human RSV
  • bRSV bovine RSV
  • PVM pneumonia virus of mice
  • APV-A,B,and C avian pneumovirus typa A, B and C.
  • Fig. 3 Comparison of the N, P, M and F ORF's of members of the subfamily Pneumovirinae and virus isolate 00-1. The ahgnment shows the amino acid sequence of the complete N, P, M and F proteins and partial L proteins of virus isolate 00-1.
  • Amino acids that differ between isolate 00-1 and the other viruses are shown, identical amino acids are represented by periods, gaps are represented as dashes.
  • Avian Pneumovirus type A, B or C, b-or hRSV bovine or human respiratory syncytial virus
  • PVM pneumonia virus of mice.
  • L9/10 consensus of fragment 9 and 10 obtained with RAP-PCR, located in L.
  • Fig. 4 Phylogenetic analyses of the N, P, M, and F ORF's of members of the genus Pneumovirinae and virus isolate 00-1. Phylogenetic analysis was performed on viral sequences from the fohowing genes: F (panel A), N (panel B), M (panel C), and P (panel D). The phylogenetic trees are based on maximum likelyhood analyses using 100 bootstraps and 3 jumbles. The scale representing the number of nucleotide changes is shown for each tree.
  • Fig. 5 Phylogenetic relationship for parts of the F (panel A), N (panel B), M (panel C) and L (panel D) ORFs of nine of the primary MPV isolates with APV-C, it's closest relative genetically.
  • the phylogenetic trees are based on maximum likelyhood analyses. The scale representing the number of nucleotide changes is shown for each tree. Accesion numbers for APV-C: panel A: D00850; panel B: U39295; panel C: X58639; and panel D: U65312.
  • Fig. 6A Nucleotide and amino acid sequence information from the 3'end of the genome of MPV isolate 00-l.ORF's are given.
  • N ORF for nucleoprotein
  • P ORF for phosphoprotein
  • M ORF for matrix protein
  • F ORF for fusion protein
  • GE gene end
  • GS gene start.
  • Fig. 6B and C Nucleotide and amino acid sequence information from obtained fragments in the polymerase gene (L) of MPV isolates 00-1. Positioning of the fragments in L is based on protein homologies with APV-C (accession number U65312). The translated fragment 8 (Fig. 6B.) is located at amino acid number 8 to 243, and the consensus of fragments 9 and 10 (Fig. 6C) is located at amino acid number 1358 to 1464 of the APV-C L ORF.
  • Genomic map of MPV isolate 00-1 The nucleotide positions of the start and stop codons are indicated under each ORF.
  • the double hnes which cross the L ORF indicate the shortened representation of the L gene.
  • the three reading frames below the map indicate the primary G ORF (nt 6262-6972) and overlapping potential secondary ORFs.
  • Figure 8 Ahgnment of the predicted amino acid sequence of the nucleoprotein of MPV with those of other pneumoviruses.
  • the conserved regions identified by Barr (1991) are represented by boxes and labeUed A, B, and C.
  • the conserved region among pneumoviruses (Li, 1996) is shown gray shaded.
  • Gaps are represented by dashes, periods indicate the positions of identical amino acid residues compared to MPV.
  • Domain III Comparison of the amino acid sequences of a conserved domain of the polymerase gene of MPV and other paramyxoviruses. Domain III is shown with the four conserved polymerase motifs (A, B, C, D) in domain III (Poch 1998, 1999) boxed. Gaps are represented by dashes and periods indicate the position of identical amino acid residues relative to MPV.
  • hPIV3 human parainfluenza virus type 3; SV: sendai virus; hPIV-2: human parainfluenza virus type 2; ⁇ DV: New castle disease virus; MV: measles virus;; nipah: Nipah virus.
  • Figure 16 Phylogenetic analyses of the M2-1 and L ORFs of MPV and selected paramyxoviruses.
  • the M2-1 ORF was ahgned with the M2-1 ORFs of other members of the genus Pneumovirinae (A) and the L ORF was ahgned with L ORFs members of the genus pneumovirinae and selected other paramyxoviruses as described in the legends of figure 15 (B).
  • Phylogenetic trees were generated by maximum likelihood analyses using 100 bootstraps and 3 jumbles. The scale representing the number of nucleotide changes is shown for each tree. Numbers in the trees represent bootstrap values based on the consensus trees.
  • Figure 17 Noncoding sequences of hMPV isolate 00-1.
  • A The noncoding sequences between the ORFs and at the genomic termini are shown in the positive sense. From left to right, stop codons of indicated ORFs are shown, followed by the noncoding sequences, the gene start signals and start codons of the indicated subsequent ORFs. Numbers indicate the first position of start and stop codons in the hMPV map. Sequences that display similarity to pubhshed gene end signals are underhned and sequences that display similarity to UAAAAAU/A/C are represented with a hne above the sequence.
  • Figure 19 Comparison of two prototypic hMPV isolates with APV-A and APV-C; protein similarity matrices for the various viral proteins.
  • Figure 29 Results of RT-PCR assays on throat and nose swabs of 12 guinea pigs inoculated with ned/00/01 and/or ned/99/01.
  • Figure 30A IgG response against ned/00/01 and ned/99/01 for guinea pigs infected with ned/00/01 and re-infected with ned 00/01 (GP 4, 5 and 6) or ned/99/01 (GP 1 and 3).
  • Figure 30B IgG response against ned/00/01 and ned/99/01 for guinea pigs infected with ned 99/01 and re-infected with either ned 00/01 (GP's 8 and 9) or with ned/99/01 (GP's 10, 11, 12).
  • Figure 31 Specificity of the ned/00/01 and ned/99/01 ELISA on sera taken from guinea pigs infected with either ned/00/01 or ned/99/01.
  • Figure 32 Mean IgG response against ned/00/01 and ned/99/01 ELISA of 3 homologous (00-1/00-1), 2 homologous (99-1/99-1), 2 heterologous (99-1/00-1) and 2 heterologous (00-1/99-1) infected guinea pigs.
  • Figure 33 Mean percentage of APV inhibition of hMPV infected guinea pigs.
  • Figure 34 Virus neutrahsation titers of ⁇ ed/00/01 and ned/99/01 infected guinea pigs against ned/00/01, ned/99/01 and APV-C.
  • Figure 35 Results of RT-PCR assays on throat swabs of cynomolgous macaques inoculated (twice) with ned/00/01.
  • Figure 37 Comparison of the use of the hMPV ELISA and the APV inhibition ELISA for the detection of IgG antibodies in human sera.
  • ceUs usually (sometimes later) displayed CPE after three passages of virus from original material, at day 10 to 14 post inoculation, somewhat later than CPE caused by other viruses such as hRSV or hPIV.
  • enveloped viruses such as the Paramyxoviridae, standard chloroform or ether treatment 8 resulted in >10 4 TCID50 reduction of infectivity for tMK cells.
  • Virus-infected tMK ceh culture supernatants did not display heamagglutinating activity with turkey, chicken and guinea pig erythrocytes. During culture, the virus rephcation appeared to be trypsine dependent on the cells tested. These combined virological data aUowed that the newly identified virus was taxonomically classified as a member of the Paramyxoviridae family.
  • RT-PCR assays were carried out at low stringency in order to detect potentially related viruses and RNA isolated from homologous virus stocks were used as controls.
  • virus-infected tMK ceh culture supernatants to inoculate guinea pigs and ferrets intranasaly.
  • Sera were collected from these animals at day zero, two weeks and three weeks post inoculation.
  • the animals displayed no chnical symptoms but aU seroconverted as measured in virus neutrahsation (VN) assays and indirect IFA against the homologous viruses.
  • the sera did not react in indirect IFA with any of the known paramyxoviruses described above and with PVM.
  • ORFs showed an average of 30-33% homology with members of the genus
  • the amino acid sequence for P showed about 25% homology with hRSV and about 66-68% with APV-C
  • M showed about 36-39% with hRSV and about 87-89% with APV-C
  • F showed about 40% homology with hRSV and about 81% with APV-C
  • M2- 1 showed about 34-36% homology with pneumoviruses and 84-86 % with APV-C
  • M2-2 showed 15-17% homology with pneumoviruses and 56% with APV-C and the fragments obtained in L showed an average of 44% with pneumoviruses and 64% with APV-C .
  • phylogenetic trees were constructed based on the N, P, M and F ORFs of these viruses. In aU four phylogenetic trees, the newly identified virus isolate was most closely related to APV (Fig.4). From the four serotypes of APV that have been described 11 , APV serotype C, the metapneumovirus found primarily in birds in the USA, showed the closest resemblance to the newly identified virus. It should be noted however, that only partial sequence information for APV serotype D is available.
  • Metapneumovirus genus of mammalian, in particular of human origin is a member of the group consisting of the group consisting of the group consisting of the group consisting of the group consisting of the group consisting of the group consisting of the group consisting of the group consisting of the group consisting of the group consisting of the group consisting of the group consisting of the group consisting of the group consisting of the group consisting of the group consisting of the group consisting of a virus, in particular of human origin.
  • nasopharyngeal aspirates from children suffering from RTI, which are routinely tested for the presence of viruses.
  • Ah nasopharyngeal aspirates were tested by direct immmunofluorescence assays (DIF) using fluorescence labeUed antibodies against influenza virus types A, and B, hRSV and human parainfluenza virus (hPrV) types 1 to 3.
  • DIF direct immmunofluorescence assays
  • nasopharyngeal aspirates were also processed for virus isolation using rapid sheU vial techniques 14 on various cellhnes including VERO ceUs, tertiary cynomolgous monkey kidney (tMK) ceUs, human endothelial lung (HEL) ceUs and marbin dock kidney (MDCK) ceUs.
  • CPE cytophatic effects
  • IFA indirect immunofluorescence assays
  • Nasopharyngeal aspirate samples from patients suffering from RTI were used for DIF and virus isolation as described 14 - 15 .
  • Samples were stored at -70 °C.
  • nasopharyngeal aspirates were diluted with 5 ml Dulbecco MEM (BioWhittaker, Walkersville, MD) and thoroughly mixed on a vortex mixer for one minute. The suspension was thus centrifuged for ten minutes at 840 x g. The sediment was spread on a multispot shde (Nutacon, Leimuiden, The Netherlands), the supernatant was used for virus isolation. After drying, the ceUs were fixed in aceton for 1 minute at room temperature.
  • the shdes were incubated for 15 minutes at 37 °C with commercial available FITC-labehed virus specific anti-sera such as influenza A and B, hRSV and hPTV 1 to 3 (Dako, Glostrup, Denmark). After three washings in PBS and one in tap water, the shdes were included in a glycerol/PBS solution (Citifluor, UKC, Canterbury, UK) and covered. The shdes were analysed using a Axioscop fluorescence microscope (Carl Zeiss B.V, Weesp, the Netherlands. Virus isolation
  • tMK ceUs were cultured in 24 weU plates containing glass shdes (Costar, Cambridge, UK), with the medium described below supplemented with 10% fetal bovine serum (BioWhittaker, Vervier, Belgium).
  • the plates were inoculated with supernatant of the nasopharyngeal aspirate samples, 0,2 ml per weU in triphcate, foUowed by centrifuging at 840x g for one hour. After inoculation the plates were incubated at 37 °C for a maximum of 14 days changing the medium once a week and cultures were checked daily for CPE. After 14 days ceUs were scraped from the second passage and incubated 14 days. This step was repeated for the third passage. The glass shdes were used to demonstrate the presence of the virus by indirect IFA as described below.
  • Ferret and guinea pig specific antisera for the newly discovered virus were generated by experimental intranasal infection of two specific pathogen free ferrets and two guinea pigs, housed in separate pressurised glove boxes. Two to three weeks later aU the animals were bled by cardiac puncture, and their sera were used as reference sera. The sera were tested for aU previous described viruses with indirect IFA as described below.
  • Antigen detection by indirect IFA We performed indirect IFA on shdes containing infected tMK ceUs. After washing with PBS the shdes were incubated for 30 minutes at 37 °C with virus specific antisera. We used monoclonal antibodies in DIF against influenza A, B and C, hPIV type 1 to 3 and hRSV as described above. For hPIV type 4, mumps virus, measles virus, sendai virus, simian virus type 5, New-Castle Disease virus polyclonal antibodies (RIVM) and ferret and guinea pig reference sera were used. After three washings with PBS and one wash with tap water, the shdes were stained with a secondary antibodies directed against the sera used in the first incubation.
  • RIVM New-Castle Disease virus polyclonal antibodies
  • infected tMK ceUs were fixed with cold acetone on covershps, washed with PBS and stained with serum samples at a 1 to 16 dilution. Subsequently, samples were stained with FITC-labeUed rabbit anti human antibodies 80 times diluted in PBS (Dako). Shdes were processed as described above.
  • Sub-confluent mono-layers of tMK ceUs in media as described above were inoculated with supernatants of samples that displayed CPE after two or three passages in the 24 weU plates. Cultures were checked for CPE daUy and the media was changed once a week. Since CPE differed for each isolate, aU cultures were tested at day 12 to 14 with indirect IFA using ferret antibodies against the new virus isolate. Positive cultures were freeze-thawed three times, after which the supernatants were clarified by low-speed centrifugation, aliquoted and stored frozen at -70 °C. The 50% tissue culture infectious doses (TCID50) of virus in the culture supernatants were determined as described 16 .
  • TCID50 tissue culture infectious doses
  • VN assays were performed with serial two-fold dilutions of human and animal sera starting at an eight-fold dilution. Diluted sera were incubated for one hour with 100 TCID50 of virus before inoculation of tMK ceUs grown in 96 weU plates, after which the plates were centrifuged at 840 x g. The media was changed after three and six days and IFA was conducted with ferret antibodies against MPV 8 days after inoculation. The VN titre was defined as the lowest dilution of the serum sample resulting in negative IFA and inhibition of CPE in ceU cultures. Virus characterisation
  • Haemagglutination assays and chloroform sensitivity tests were performed as described 8 - 14 .
  • virus was concentrated from infected ceU culture supernatants in a micro-centrifuge at 4 °C at 17000 x g, after which the peUet was resuspended in PBS and inspected by negative contrast EM.
  • virus was concentrated from infected tMK ceU supernatants by ultra-centrifugation on a 60% sucrose cussion (2 hours at 150000 x g, 4 °C).
  • the 60% sucrose interphase was subsequently diluted with PBS and layered on top of a 20-60% continuous sucrose gradient which was centrifuged for 16 hours at 275000 x g at 4 °C.
  • Sucrose gradient fractions were inspected for the presence of virus-like particles by EM and poly- acrylamide gel electrophoresis foUowed by sflver staining.
  • the approximately 50% sucrose fractions that appeared to contain nucleocapsids were used for RNA isolation and RAP-PCR.
  • Virus-specific ohgonucleotide sequences for RT-PCR assays on known paramyxoviruses are described in addenda 1.
  • a one-step RT-PCR was performed in 50 ⁇ l reactions containing 50 mM Tris.HCl pH 8.5, 50 mM NaCl, 4 mM MgCl 2 , 2 mM dithiotreitol, 200 ⁇ M each dNTP, 10 units recombinant RNAsin (Promega, Leiden, the Netherlands), 10 units AMV RT (Promega, Leiden, The Netherlands), 5 units Amplitaq Gold DNA polymerase (PE Biosystems, Nieuwerkerk aan de Ijssel, The Netherlands) and 5 ⁇ l RNA.
  • Cychng conditions were 45 min. at 42 °C and 7 min. at 95 °C once, 1 min at 95 °C, 2 min. at 42 °C and 3 min. at 72 °C repeated 40 times and 10 min.
  • RAP-PCR was performed essentiaUy as described 10 .
  • the ohgonucleotide sequences are described in addenda 2.
  • 2 ⁇ l RNA was used in a 10 ⁇ l reaction containing 10 ng/ ⁇ l ohgonucleotide, 10 mM dithiotreitol, 500 ⁇ m each dNTP,
  • RT enzyme (LifeTechnologies) were added. The incubation at 37 °C was continued for 55 min. and the reaction terminated by a 5 min. incubation at 72 °C. The RT mixture was diluted to give a 50 ⁇ l PCR reaction containing 8 ng/ ⁇ l ohgonucleotide, 300 ⁇ m each dNTP, 15 mM Tris-HCL pH 8.3, 65 mM KC1, 3.0 mM MgCL 2 and 5 units Taq
  • RAP-PCR products cloned in vector pCR2.1 were sequenced with M13- specific ohgonucleotides.
  • DNA fragments obtained by RT-PCR were purified from agarose gels using Qiaquick Gel Extraction kit (Qiagen, Leusden, The Netherlands), and sequenced directly with the same ohgonucleotides used for PCR. Sequence analyses were performed using a Dyenamic ET terminator sequencing kit (Amersham Pharmacia Biotech, Roosendaal, The Netherlands) and an ABI 373 automatic DNA sequencer (PE Biosystem). AU techniques were performed according to the instructions of the manufacturer.
  • N2 designed at the 5'end of the RAP-PCR fragments obtained in N: (5'-CATGCAAGCTTATGGGGC-3') and Ml designed at the 3'end of the RAP-PCR fragments obtained in M: (5'-CAGAGTGGTTATTGTCAGGGT-3').
  • fragment C M2 designed at the 5'end of the RAP-PCR fragment obtained in M: (5'-GTAGAACTAGGAGCATATG-3') and Fl designed at the 3'end of the RAP-PCR fragments obtained in F: (5'-TCCCCAATGTAGATACTGCTTC-3'). Fragments were purified from the gel, cloned and sequenced as described before.
  • N3 5'-GCACTCAAGAGATACCCTAG -3'
  • N4 5'-AGACTTTCTGCTTTGCTGCCTG-3'
  • M3 5'-CCCTGACAATAACCACTCTG-3'
  • M4 ⁇ '-GCCAACTGATTTGGCTGAGCTC- 3'
  • F7 5'- TGCACTATCTCCTCTTGGGGCTTTG-3'
  • F8 5'- TCAAAGCTGCTTGACACTGGCC-3'
  • L6 5'-CATGCCCACTATAAAAGGTCAG-3'
  • L7 5'-CACCCCAGTCTTTCTTGAAA-3'
  • Probe used in M 5'-TGC TTG TAC TTC CCA AAG-3' Probe used in N: 5'-TAT TTG AAC AAA AAG TGT-3' Probe used in L: 5'-TGGTGTGGGATATTAACAG-3' Phylogenetic analyses
  • DNA sequences were aUigned using the ClustalW software package and maximum likelihood trees were generated using the DNA-ML software package of the Phyhp 3.5 program using 100 bootstraps and 3 jumbles 15 .
  • Previously pubhshed sequences that were used for the generation of phylogenetic trees are avaflable from Genbank under accessions numbers :
  • F ORF PVM, D11128; APV-A, D00850; APV-B, Y14292; APV-C, AF187152;
  • hRSV human RSV
  • bRSV bovine RSV
  • PVM pneumonia virus of mice
  • APV-A, B,and C avian pneumovirus typ A, B and C.
  • broncheo alveolar lavages preferably from mammals such as humans, carnivores (dogs, cats, musteUits, seals etc.), horses, ruminants (cattle, sheep, goats etc.), pigs, rabbits, birds (poultry, ostriches, etc) should be examined. From birds cloaca swabs and droppings can be examined as weU. Sera should be coUected for immunological assays, such as ELISA and virus neutrahsation assays.
  • CoUected virus specimens were diluted with 5 ml Dulbecco MEM medium (BioWhittaker, WalkersviUe, MD) and thoroughly mixed on a vortex mixer for one minute. The suspension was thus centrifuged for ten minutes at 840 x g. The sediment was spread on a multispot shde (Nutacon, Leimuiden, The Netherlands) for immunofluorescence techniques, and the supernatant was used for virus isolation.
  • Virus isolation 5 ml Dulbecco MEM medium (BioWhittaker, WalkersviUe, MD) and thoroughly mixed on a vortex mixer for one minute. The suspension was thus centrifuged for ten minutes at 840 x g. The sediment was spread on a multispot shde (Nutacon, Leimuiden, The Netherlands) for immunofluorescence techniques, and the supernatant was used for virus isolation.
  • Virus isolation 5 ml Dulbecco MEM medium (BioWhittaker, Walkersvi
  • tMK ceUs were cultured in 24 weU plates containing glass shdes (Costar, Cambridge, UK), with the medium described below supplemented with 10% fetal bovine serum (BioWhittaker, Vervier, Belgium).
  • the plates were inoculated with supernatant of the nasopharyngeal aspirate samples, 0,2 ml per weU in triphcate, foUowed by centrifuging at 840x g for one hour. After inoculation the plates were incubated at 37 °C for a maximum of 14 days changing the medium once a week and cultures were checked dafly for CPE. After 14 days, ceUs were scraped from the second passage and incubated for another 14 days. This step was repeated for the third passage. The glass shdes were used to demonstrate the presence of the virus by indirect IFA as described below. CPE was generaUy observed after the third passage, at day 8 to 14 depending on the isolate.
  • the CPE was virtuaUy indistinghuisable from that caused by hRSV or hPIV in tMK or other ceU cultures.
  • hRSV induces CPE starting around day 4.
  • CPE was characterised by syncytia formation, after which the ceUs showed rapid internal disruption, foUowed by detachment of ceUs from the monolayer.
  • IFA was used to confirm the presence of the virus in these cultures.
  • Sub-confluent monolayers of tMK ceUs in media as described above were inoculated with supernatants of samples that displayed CPE after two or three passages in the 24 weU plates. Cultures were checked for CPE daily and the media was changed once a week. Since CPE differed for each isolate, aU cultures were tested at day 12 to 14 with indirect IFA using ferret antibodies against the new virus isolate. Positive cultures were freeze-thawed three times, after which the supernatants were clarified by low-speed centrifugation, ahquoted and stored frozen at -70 °C. The 50% tissue culture infectious doses (TCID50) of virus in the culture supernatants were determined fohowing estabhshed techniques used in the field 16 .
  • TCID50 tissue culture infectious doses
  • Haemagglutination assays and chloroform sensitivity tests were performed fohowing weU estabhshed and described techniques used in the field 1 .
  • virus was concentrated from infected ceU culture supernatants in a micro-centrifuge at 4 ° C at 17000 x g, after which the peUet was resuspended in PBS and inspected by negative contrast EM.
  • CoUected specimens were processed as described and sediment of the samples was spread on a multispot shde. After drying, the ceUs were fixed in aceton for 1 minute at room temperature.
  • virus was cultured on tMK ceUs in 24 weU slides containing glass shdes. These glass shdes were washed with PBS and fixed in aceton for 1 minute at room temperature. After washing with PBS the shdes were incubated for 30 minutes at 37 °C with polyclonal antibodies at a dilution of 1:50 to 1:100 in PBS.
  • the shdes were incubated at 37°C for 30 minutes with FITC labeled goat-anti- ferret antibodies (KPL, Guilford, UK, 40 fold chluted). After three washes in PBS and one in tap water, the shdes were included in a glycerol PBS solution (Citifluor, UKC, Canterbury, UK) and covered. The shdes were analysed using an Axioscop fluorescence microscope (Carl Zeiss B.V, Weesp, the Netherlands). Detection of antibodies in humans, mammals, ruminants or other animals by indirect IFA
  • infected tMK ceUs with MPV were fixed with acetone on covershps (as described above), washed with PBS and incubated 30 minutes at 37°C with serum samples at a 1 to 16 dilution. After two washes with PBS and one with tap water, the shdes were incubated 30 minutes at 37°C with FITC- labeUed secondary antibodies to the species used (Dako). Shdes were processed as described above.
  • Antibodies can be labeUed directly with a fluorescent dye, which wiU result in a direct immuno fluorescence assay.
  • FITC can be replaced with any fluorescent dye.
  • Ferret and guinea pig specific antisera for the newly discovered virus were generated by experimental intranasal infection of two specific pathogen free ferrets and two guinea pigs, housed in separate pressurised glove boxes. Two to three weeks later the animals were bled by cardiac puncture, and their sera were used as reference sera. The sera were tested for aU previous described viruses with indirect IFA as described below. Other animal species are also suitable for the generation of specific antibody preparations and other antigen preparations may be used.
  • VN assay Virus neutralisation assay
  • VN assays were performed with serial two-fold chlutions of human and animal sera starting at an eight-fold dhution. DUuted sera were incubated for one hour with 100 TCID50 of virus before inoculation of tMK ceUs grown in 96 well plates, after which the plates were centrifuged at 840 x g. The same culture media as described above was used. The media was changed after three and six days, and after 8 days IFA was performed (see above). The VN titre was defined as the lowest dilution of the serum sample resulting in negative IFA and inhibition of CPE in ceU cultures.
  • a one-step RT-PCR was performed in 50 ⁇ l reactions containing 50 mM Tris.HCl pH 8.5, 50 mM NaCl, 4 mM MgCl 2 , 2 mM dithiotreitol, 200 ⁇ M each dNTP, 10 units recombinant RNAsin (Promega, Leiden, the Netherlands), 10 units AMV RT (Promega, Leiden, The Netherlands), 5 units Amplitaq Gold DNA polymerase (PE Biosystems, Nieuwerkerk aan de Ijssel, The Netherlands) and 5 ⁇ l RNA. Cychng conditions were 45 min. at 42 °C and 7 min. at 95 °C once, 1 min at 95 °C, 2 min. at
  • N3 (5'-GCACTCAAGAGATACCCTAG -3') and N4 (5'- AGACTTTCTGCTTTGCTGCCTG-3'), amphfying a 151 nucleotide fragment.
  • M3 (5'-CCCTGACAATAACCACTCTG-3') and M4 (5'- GCCAACTGATTTGGCTGAGCTC-3') amplifying a 252 nucleotide fragment
  • L6 (5'-CATGCCCACTATAAAAGGTCAG-3') and L7 (5'- CACCCCAGTCTTTCTTGAAA-3') amphfying a 173 nucleotide fragment.
  • Other primers can be designed based on MPV sequences, and different buffers and assay conditions may be used for specific purposes.
  • PCR fragments were sequenced directly with the same ohgonucleotides used for PCR, or the fragments were purified from the gel with Qiaquick Gel Extraction kit (Qiagen, Leusden, The Netherlands) and cloned in pCR2.1 vector (Invitrogen, Groningen, The Netherlands) according to instructions from the manufacturer and subsequently sequenced with Ml3-specific ohgonucleotides.
  • Oligonucleotides used for analysing the 3'end of the genome (absence of NS1/NS2).
  • Primer TR1 (5'-AAAGAATTCACGAGAAAAAAACGC-3') was designed based on pubhshed sequences of the traUer and leader for hRSV and APV, pubhshed by Randhawa (1997) and primer Nl (5'-CTGTGGTCTCTAGTCCCACTTC-3') was designed based on obtained sequences in the N protein. The RT-PCR assay and sequencing was performed as described above.
  • the RT-PCR gave a product of approximately 500 base pairs which is to smaU to contain information for two ORFS, and translation of these sequences did not reveal an ORF.
  • the N protein is the most abundant protein, and the immune response to this protein occurs early in infection.
  • a recombinant source of the N proteins is preferably used for developing an ELISA assay for detection of antibodies to MPV.
  • Antigens suitable for antibody detection include any MPV protein that combines with any MPV-specific antibody of a patient exposed to or infected with MPV virus.
  • Preferred antigens of the invention include those that predominantly engender the immune response in patients exposed to MPV, which therefore, typicaUy are recognised most reachly by antibodies of a patient.
  • Particularly preferred antigens include the N, F and G proteins of MPV.
  • Antigens used for immunological techniques can be native antigens or can be modified versions thereof.
  • WeU known techniques of molecular biology can be used to alter the amino acid sequence of a MPV antigen to produce modified versions of the antigen that may be used in immunologic techniques.
  • Methods for cloning genes, for manipulating the genes to and from expression vectors, and for expressing the protein encoded by the gene in a heterologous host are weU-known, and these techniques can be used to provide the expression vectors, host ceUs, and the for expressing cloned genes encoding antigens in a host to produce recombinant antigens for use in diagnostic assays. See for instance: Molecular cloning, A laboratory manual and Current Protocols in Molecular Biology.
  • a variety of expression systems may be used to produce MPV antigens.
  • a variety of expression vectors suitable to produce proteins in E.Coli, B.subtilis, yeast, insect ceUs and mammahan ceUs have been described, any of which might be used to produce a MPV antigen suitable to detect anti-MPV antibodies in exposed patients.
  • the baculovirus expression system has the advantage of providing necessary processing of proteins, and is therefor preferred.
  • the system utilizes the polyhedrin promoter to direct expression of MPV antigens. (Matsuura et al. 1987, J.Gen.Virol. 68: 1233-1250).
  • Antigens produced by recombinant baculo-viruses can be used in a variety of immunological assays to detect anti-MPV antibodies in a patient. It is weU estabhshed, that recombinant antigens can be used in place of natural virus in practicaUy any immunological assay for detection of virus specific antibodies.
  • the assays include direct and indirect assays, sandwich assays, sohd phase assays such as those using plates or beads among others, and hquid phase assays.
  • Assays suitable include those that use primary and secondary antibodies, and those that use antibody binding reagents such as protein A.
  • detection methods can be used in the invention, including colorimetric, fluorescent, phosphorescent, chemfluminescent, luminescent and radioactive methods.
  • An indirect IgG EIA using a recombinant N protein (produced with recombinant baculo-virus in insect (Sf9) ceUs) as antigen can be performed.
  • Sf9 ceUs are infected with the recombinant baculovirus and harvested 3- 7 days post infection. The ceU suspension is washed twice in PBS, pH 7.2, adjusted to a ceU density of 5. OX 10 6 ceUs/ml, and freeze-thawed three times. Large cellular debris is peUeted by low speed centrifugation (500 x g for 15 min.) and the supernatant is coUected and stored at -70°C until use. Uninfected ceUs are processed simUarly for negative control antigen.
  • 100 ⁇ l of a freeze-thaw lysate is used to coat microtiter plates, at dilutions ranging from 1:50 to 1:1000.
  • An uninfected ceU lysate is run in duphcate weUs and serves as a negative control. After incubation overnight, plates are washed twice with
  • PBS/0.05%Tween.Test sera are diluted 1:50 to 1:200 in ELISA buffer (PBS, supplemented to 2% with normal goat sera, and with 0.5% bovine serum albumine and 0.1% milk), foUowed by incubation weUs for 1 hour at 37°C.
  • ELISA buffer PBS, supplemented to 2% with normal goat sera, and with 0.5% bovine serum albumine and 0.1% milk
  • Plates are washed two times with PBS/0.05%Tween. Horseradish peroxidase labeUed goat anti-human (or against other species) IgG, diluted 1:3000 to 1:5000 in ELISA buffer, added to weUs, and incubated for 1 hour at 37°. The plates are then washed two times with PBS/0.05%Twee ⁇ and once with tap water, incubated for 15 minutes at room temperature with the enzyme substrate TMB, 3, 3', 5,5' tetramethylbenzidine, such as that obtained from Sigma, and the reaction is stopped with 100 ⁇ l of 2 M phosphoric acid. Colorimetric readings are measured at 450 nm using an automated microtiter plate reader.
  • Example 2 Capture anti-MPV IgM EIA using a recombinant nucleoprotein
  • a capture IgM EIA using the recombinant nucleoprotein or any other recombinant protein as antigen can be performed by modification of assays as previously described by Erdman et al (1990) J.Chn.Microb. 29: 1466-1471.
  • Affinity purified anti-human IgM capture antibody (or against other species), such as that obtained from Dako, is added to weUs of a microtiter plate in a concentration of 250 ng per weU in 0.1 M carbonate buffer pH 9.6. After overnight incubation at room temperature, the plates are washed two times with PBS/0.05% Tween. 100 ⁇ l of test serum diluted 1:200 to_l: 1000 in ELISA buffer is added to triphcate weUs and incubated for 1 hour at 37°C. The plates are then washed two times with in PBS/0.05%Tween.
  • the freeze-thawed (infected with recombinant virus) Sf21 ceU lysate is diluted 1:100 to 1: 500 in ELISA buffer is added to the weUs and incubated for 2 hours at 37°C. Uninfected ceU lysate serves as a negative control and is run in duphcate weUs.
  • the plates are then washed three times in PBS/0.05% Tween and incubated for 1 hour at 37°C with 100 ⁇ l of a polyclonal antibody against MPV in a optimal dilution in ELISA buffer. After 2 washes with PBS/0.05% Tween , the plates are incubated with horseradish peroxide labeled secondary antibody (such as rabbit anti ferret), and the plates are incubated 20 minutes at 37°C.
  • horseradish peroxide labeled secondary antibody such as rabbit anti ferret
  • the plates are then washed five times in PBS/0/05% Tween, incubated for 15 minutes at room temperature with the enzyme substrate TMB, 3, 3', 5, 5' tetramethylbenzidine, as, for instance obtained from "Sigma", and the reaction is stopped with 100 ⁇ l of 2M phosphoric acid. Colormetric readings are measured at 450 nm using automated microtiter plate reader . .
  • the sensitivities of the capture IgM EIAs using the recombinant nucleoprotein (or other recombinant protein) and whole MPV virus are compared using acute-and convalescent-phase serum pairs form persons with chnical MPV virus infection.
  • the specificity of the recombinant nucleoprotein capture EIA is determined by testing serum specimens from healthy persons and persons with other paramyxovirus infections.
  • glycoproteins G and F are the two transmembraneous envelope glycoproteins of the MPV virion and represent the major neutrahsation and protective antigens.
  • glycoproteins in a vector virus system sych as a baculovirus system provides a source of recombinant antigens for use in assays for detection of MPV specific antibodies.
  • their use in combination with the nucleoprotein for instance, further enhances the sensitivity of enzyme immunoassays in the detection of antibodies against MPV.
  • broncheo alveolar lavages and throat swabs preferable from but not hmited to humans, carnivores (dogs, cats, seals etc.), horses, ruminants (cattle, sheep, goats etc.), pigs, rabbits, birds (poultry, ostridges, etc) can be examined. From birds, cloaca and intestinal swabs and droppings can be examined as weU. For aU samples, serology (antibody and antigen detection etc.), virus isolation and nucleic acid detection techniques can be performed for the detection of virus.
  • Monoclonal antibodies can be generated by immunising mice (or other animals) with purified MPV or parts thereof (proteins, peptides) and subsequently using estabhshed hybridoma technology (Current protocols in Immunology). Alternatively, phage display technology can be used for this purpose (Current protocols in Immunology). Simflarly, polyclonal antibodies can be obtained from infected humans or animals, or from immunised humans or animals (Current protocols in Immunology).
  • the detection of the presence or absence of NSl and NS2 proteins can be performed using western-blotting, IFA, immuno precipitation techniques using a variety of antibody preparations.
  • the detection of the presence or absence of NSl and NS2 genes or homologues thereof in virus isolates can be performed using PCR with primer sets designed on the basis of known NSl and/or NS2 genes as weU as with a variety of nucleic acid hybridisation techniques.
  • a PCR can be performed with primers specific for this 3' end of the genome. In our case, we used a primer specific for the 3' untranslated region of the viral genome and a primer in the N ORF.
  • primers may be designed for the same purpose.
  • the absence of the NS1/NS2 genes is revealed by the length and/or nucleotide sequence of the PCR product.
  • Primers specific for NSl and/or NS2 genes may be used in combination with primers specific for other parts of the 3' end of the viral genome (such as the untranslated region or N, M or F ORFs) to aUow a positive identification of the presence of NSl or NS2 genes.
  • a variety of techniques such as molecular cloning, nucleic acid hybridisation may be used for the same purpose.
  • Two potential genetic clusters are identified by analyses of partial nucleotide sequences in the N, M, F and L ORFs of 9 virus isolates. 90 -100% nucleotide identity was observed within a cluster, and 81-88% identity was observed between the clusters. Sequence information obtained on more virus isolates confirmed the existence of two genotypes. Virus isolate ned/00/01 as prototype of cluster A, and virus isolate ned/99/01 as prototype of cluster B have been used in cross neutrahzation assays to test whether the genotypes are related to different serotypes or subgroups.
  • Virus isolates ned/00/01 and ned/99/01 have been used to inoculate ferrets to raise virus-specific antisera. These antisera were used in virus neutrahzation assays with both viruses.
  • guinea pigs have been inoculated with either one of the viruses (ned/00/01 and ned/99/01).
  • RT-PCR assays on nasopharyngeal aspirate samples showed virus rephcation from day 2 till day 10 post infection.
  • the guinea pigs have been chaUenged with either the homologous or the heterologous virus, and for in aU four cases virus rephcation has been noticed.
  • Virus neutrahzation assays with anti sera after the first chaUenge showed essentiaUy the same results as in the VN assays performed with the ferrets (> 16-fold difference in VN titer).
  • N nucleoprotein
  • P phosphoprotein
  • M matrixprotein
  • F fusion protein
  • sequences presented here complete the genomic sequence of MPV with the exception of the extreme 12-15 nucleotides of the genomic termini and estabhsh the genomic organisation of MPV.
  • Side by side comparisons of the sequences of the MPV genome with those of APV subtype A, B and C, RSV subtype A and B, PVM and other paramyxoviruses provides strong evidence for the classification of MPV in the Metapneumovirus genus.
  • MPV isolate 00-1 (van den Hoogen et al., 2001) was propagated in tertiary monkey kidney (tMK) ceUs and RNA isolated from the supernatant 3 weeks after inoculation was used as template for RT-PCR analyses. Primers were designed on the basis of the partial sequence information available for MPV 00-1 (van den Hoogen et al, 2001) as weU as the leader and traUer sequences of APV and RSV (Randhawa et al, 1997; Mink et al, 1991). InitiaUy, fragments between the previously obtained products, ranging in size from 500 bp to 4 Kb in length, were generated by RT-PCR amplification and sequenced directly.
  • tMK tertiary monkey kidney
  • the genomic sequence was subsequently confirmed by generating a series of overlapping RT-PCR fragments ranging in size from 500 to 800 bp that represented the entire MPV genome. For aU PCR fragments, both strands were sequenced directly to minimize amplification and sequencing errors.
  • the nucleotide and amino acid sequences were used to search for homologies with sequences in the Genbank database using the BLAST software (www.ncbi.nlm.nih.gov/BLAST). protein names were assigned to open reading frames (ORFs) based on homology with known viral genes as weU as their location in the genome. Based on this information, a genomic map for MPV was constructed (Figure 7).
  • the MPV genome is 13378 nucleotides in length and its organization is simflar to the genomic organization of APV.
  • the nucleoprotein (N) gene The nucleoprotein (N) gene
  • the first gene in the genomic map of MPV codes for a 394 amino acid (aa) protein and shows extensive homology with the N protein of other pneumoviruses.
  • the length of the N ORF is identical to the length of the N ORF of APV-C (Table 5) and is smaUer than those of other paramyxoviruses (Barr et al., 1991).
  • Analysis of the amino acid sequence revealed the highest homology with APV-C (88%), and only 7- 11% with other paramyxoviruses (Table 6).
  • the phosphoprotein (P) gene The second ORF in the genome map codes for a 294 aa protein which shares 68% aa sequence homology with the P protein of APV-C, and only 22-26% with the P protein of RSV (Table 6).
  • the P gene of MPV contains one substantial ORF and in that respect is similar to P from many other paramyxoviruses (Reviewed in Lamb and Kolakofsky, 1996; Sedlmeier et al, 1998).
  • the MPV P ORF lacks cysteine residues.
  • Ling (1995) suggested that a region of high simUarity between aU pneumoviruses (aa 185-241) plays a role in either the RNA synthesis process or in maintaining the structural integrity of the nucleocapsid complex. This region of high simUarity is also found in MPV ( Figure 9) especificaUy when conservative substitutions are taken in account, showing 100% simUarity with APV- C, 93 % with APV-A and B, and approximately 81% with RSV.
  • the C-terminus of the MPV P protein is rich in glutamate residues as has been described for APVs (Ling et al, 1995).
  • the third ORF of the MPV genome encodes a 254 aa protein, which resembles the M ORFs of other pneumoviruses.
  • the M ORF of MPV has exactly the same size as the M ORFs of other metapneumoviruses (Table 5) and shows high aa sequence homology with the matrix proteins of APV (78-87%), lower homology with those of RSV and
  • the F ORF of MPV is located adjacent to the M ORF, which is characteristic for members of the Metapneumovirus genus.
  • the F gene of MPV encodes a 539 aa protein, which is two aa residues longer than F of APV-C (Table 5). Analysis of the aa sequence revealed 81% homology with APV-C, 67% with APV-A and B, 33-39% with pneumovirus F proteins and only 10-18% with other paramyxoviruses (Table 6).
  • One of the conserved features among F proteins of paramyxoviruses, and also seen in MPV is the distribution of cysteine residues (Morrison, 1988; Yu et al, 1991).
  • the metapneumoviruses share 12 cysteine residues in Fl (7 are conserved among aU paramyxoviruses), and two in F2 (1 is conserved among all paramyxoviruses).
  • Fl (7 are conserved among aU paramyxoviruses
  • F2 1 is conserved among all paramyxoviruses.
  • N-hnked glycosylation sites present in the F ORF of MPN none are shared with RSV and two (position 74 and 389) are shared with APV.
  • the third, unique, potential N-hnked glycosylation site for MPV is located at position 206 ( Figure 11).
  • F protein of MPV revealed typical fusion protein characteristics consistent with those described for the F proteins of other Paramyxoviridae famUy members (Morrison, 1988).
  • F proteins of Paramyxoviridae members are synthesized as inactive precursors (F0) that are cleaved by host ceU proteases which generate amino terminal F2 subunits and large carboxy terminal Fl subunits.
  • the proposed cleavage site (Collins et al, 1996) is conserved among aU members of the Paramyxoviridae famUy.
  • the cleavage site of MPV contains the residues RQSR.
  • arginine (R) residues are shared with APV and RSN but the glutamine (Q) and serine (S) residues are shared with other paramyxoviruses such as human parainfluenza virus type 1, Sendai virus and morbilhviruses (data not shown).
  • the hydrophobic region at the amino terminus of Fl is thought to function as the membrane fusion domain and shows high sequence simUarity among paramyxoviruses and morbilhviruses and to a lesser extent the pneumoviruses (Morrison, 1988).
  • the signal peptide and anchor domain were found to be conserved within subtypes and displayed high variability between subtypes (Plows et al, 1995; Naylor et al, 1998).
  • the signal peptide of MPV (aa 10-35, Figure 11) at the amino terminus of F2 exhibits some sequence simUarity with APV-C (18 out of 26 aa residues are simUar) . and less conservation with other APVs or RSV. Much more variability is seen in the membrane anchor domain at the carboxy terminus of Fl, although some homology is stiU seen with APV-C.
  • the M2 gene is unique to the Pneumovirinae and two overlapping ORFs have been observed in aU pneumoviruses.
  • the first major ORF represents the M2-1 protein which enhances the processivity of the viral polymerase (Colhns et al, 1995; Collins, 1996) and its readthrough of intergenic regions (Hardy et al, 1998; Fearns et al, 1999).
  • the M2-1 gene for MPV located adjacent to the F gene, encodes a 187 aa protein (Table 5), and reveals the highest (84%) homology with M2-1 of APV-C (Table 6).
  • the secondary ORFs (M2-2) that overlap with the M2-1 ORFs of pneumoviruses are conserved in location but not in sequence and are thought to be involved in the control of the switch between virus RNA rephcation and transcription (CoUins et al, 1985; Elango et al, 1985; Baybutt et al, 1987; Colhns et al., 1990; Ling et al, 1992; Zamora et al, 1992; Alansari et al, 1994; Ahmadian et al, 1999; Bermingham et al, 1999).
  • the M2-2 ORF starts at nucleotide 512 in the M2-1 ORF ( Figure 7), which is exactly the same start position as for APV-C.
  • the length of the M2-2 ORFs are the same for APV-C and MPV, 71 aa residues (Table 5). Sequence comparison of the M2-2 ORF ( Figure 12B) revealed 64% aa sequence homology between MPV and
  • the small hydrophobic protein (SH) ORF The small hydrophobic protein (SH) ORF
  • the gene located adjacent to M2 of hMPV probably encodes a 183 aa SH protein (Fig.
  • the putative SH ORF of hMPV is the longest SH ORF known to date (Table 1).
  • the aa composition of the SH ORF is relatively simUar to that of APV, RSV and PVM, with a high percentage of threonine and serine residues (22%, 18%, 19%, 20.0%, 21% and 28% for hMPV, APV, RSV A, RSV B, bRSV and PVM respectively).
  • the SH ORF of hMPV contains 10 cysteine residues, whereas APV SH contains 16 cysteine residues.
  • the SH ORF of hMPV contains two potential N-hnked glycosylation sites (aa 76 and 121), whereas APV has one, RSV has two or three and PVM has four.
  • the SH ORFs of APV and hMPV have a hydrophihc ⁇ -terminus, a central hydrophobic domain which can serve as a potential membrane spanning domain (aa 30-53 for hMPV), a second hydrophobic domain (aa 155-170) and a hydrophihc C-terminus.
  • RSN SH appears to lack the C-terminal part of the APV and hMPV ORFs.
  • the hydrophobic domain is flanked by basic aa residues, which are also found in the SH ORF for hMPV (aa 29 and 54).
  • the attachment glycoprotein (G) ORF The attachment glycoprotein (G) ORF
  • the putative G ORF of hMPV is located adjacent to the putative SH gene and encodes a 236 aa protein (nt 6262-6972, Fig. 1).
  • a secondary smaU ORF is found immediately foUowing this ORF, potentiaUy coding for 68 aa residues (nt 6973-7179) but lacking a start codon.
  • a third potential ORF in the second reading frame of 194 aa residues is overlapping with both of these ORFs but also lacks a start codon (nt 6416-7000).
  • This ORF is foUowed by a potential fourth ORF of 65 aa residues in the same reading frame (nt 7001-7198), again lacking a start codon.
  • FinaUy a potential ORF of 97 aa residues (but lacking a start codon) is found in the third reading frame (nt 6444-6737,
  • the other ORFs do not have apparent gene start or gene end sequences (see below).
  • the 236 aa G ORF probably represents at least a part of the hMPV attachment protein it can not be excluded that the additional coding sequences are expressed as separate proteins or as part of the attachment protein through some RNA editing event. It should be noted that for APV and RSV no secondary ORFs after the primary G ORF have been identified but that both APV and RSV have secondary ORFs within the major ORF of G. However, evidence for expression of these ORFs is lacking and there is no sequence identity between the predicted aa sequences for different viruses (Ling et al, 1992).
  • the secondary ORFs in hMPV G do not reveal characteristics of other G proteins and whether the additional ORFs are expressed requires further investigation.
  • BLAST analyses with aU ORFs revealed no discernible sequence identity at the nucleotide or aa sequence level with other known virus genes or gene products. This is in agreement with the low percentage sequence identity found for other G proteins such as those of hRSV A and B (53%) (Johnson et al, 1987) and APV A and B (38%) (Juhasz and Easton, 1994).
  • the putative G ORF of 236 aa residues of hMPV is considerably smaUer than the G ORF of APV (Table 1).
  • the aa sequence revealed a serine and threonine content of 34%, which is even higher than the 32% for RSV and 24% for APV.
  • the putative G ORF also contains 8.5% prohne residues, which is higher than the 8% for RSV and 7% for APV.
  • the ⁇ -terminus contains a hydrophilic region foUowed by a short hydrophobic area (aa 33-53 for hMPV) and a mainly hydrophihc C-terminus (Fig. 8B).
  • This overaU organization is consistent with that of an anchored type II transmembrane protein and corresponds weU with these regions in the G protein of APV and RSV.
  • the putative G ORF of hMPV contains only 1 cysteine residue in contrast to RSV and APV (5 and 20 respectively). Of note, only two of the four secondary ORFs in the G gene contained one additional cysteine residue and these four potential ORFs revealed 12-20% serine and threonine residues and 6-11% prohne residues.
  • RNA-dependent RNA polymerase component of the rephcation and transcription complexes The L gene of MPV encodes a 2005 aa protein, which is 1 residue longer than the APV-A protein (Table 5).
  • the L protein of MPV shares 64% homology with APV-A, 42-44% with RSV, and approximately 13% with other paramyxoviruses (Table 6).
  • Poch et al. (1989; 1990) identified six conserved domains within the L proteins of non-segmented negative strand RNA viruses, from which domain III contained the four core polymerase motifs that are thought to be essential for polymerase function.
  • motifs (A, B, C and D) are weU conserved in the MPV L protein: in motifs A, B and C: MPV shares 100% simUarity with aU pneumoviruses and in motif D MPV shares 100 % simUarity with APV and 92% with RSVs. For the entire domain III (aa 627- 903 in the L ORF), MPV shares 77% identity with APV, 61- 62% with RSV and 23-27% with other paramyxoviruses (Figure 15).
  • the pneumovirus L proteins contain a sequence which conforms to a consensus ATP binding motif K(X) 2 ⁇ GEGAGN(X) 2 oK (Stec, 1991).
  • the MPV L ORF contains a simUar motif as APV, in which the spacing of the intermediate residues is off by one: K(x) 22 GEGAGN(X)i9 K.
  • MPV non-coding sequences The gene junctions of the genomes of paramyxoviruses contain short and highly conserved nucleotide sequences at the beginning and end of each gene (gene start and gene end signals), possibly playing a role in initiation and termination of transcription (Curran et al, 1999). Comparing the intergenic sequences between aU genes of MPV revealed a consensus sequence for the gene start signal of the N, P, M, F, M2 and G: GGGACAAGU ( Figure 17A), which is identical to the consensus gene start signal of the metapneumoviruses (Ling et al, 1992; Yu et al, 1992; Li et al, 1996; Bayon-Auboyer et al, 2000).
  • the gene start signals for the SH and L genes of MPV were found to be slightly different from this consensus (SH: GGGAUAAAU, L: GAGACAAAU).
  • SH GGGAUAAAU
  • L GAGACAAAU
  • the gene start signal of L was also found to be different from the consensus: AGGACCAAT (APV-A) (Randhawa et al, 1996) and GGGACCAGT (APV-D) (Bayon-Auboyer et al, 2000).
  • the intergenic regions of MPV did not reveal homology with those of APV and RSV and range in size from 10 to 228 nucleotides (Figure 17B).
  • the intergenic region between the M and F ORFs of MPV contains part of a secondary ORF, which starts in the primary M ORF (see above).
  • the intergenic region between SH and G contains 192 nucleotides, and does not appear to have coding potential based on the presence of numerous stop-codons in aU three reading frames.
  • the intergenic region between G and L contains 241 nucleotides, which may include additional ORFs (see above). Interestingly, the start of the L ORF is located in these secondary ORFs.
  • the L gene of APV does not start in the preceding G ORF
  • the L ORF of RSV also starts in the preceding M2 gene.
  • leader and traUer sequences At the 3' and 5' extremities of the genome of paramyxoviruses short extragenic region are referred to as the leader and traUer sequences, and approximately the first
  • the length of the 5'traUer of MPV (188 nucleotides) resembles the size of the RSV 5'traUer (155 nucleotides), which is considerably longer than that of APV (40 nucleotides). Alignments of the extreme 40 nucleotides of the traUer of MPV and the traUer of APV revealed 21 out of 32 nucleotides homology, apart from the extreme 12 nucleotides which represent primer sequences based on the genomic sequence of APV.
  • Metapneumovirus genus that is isolatable from mammals. It should be noted that the found sequence variation between different virus isolates of MPV in the N, M, F and L genes revealed the possible existence of different genotypes (van den Hoogen et al, 2001). The close relationship between MPV and APV-C is not reflected in the host range, since APV infects birds in contrast to MPV (van den Hoogen et al, 2001). This difference in host range may be determined by the differences between the SH and G proteins of both viruses that are highly divergent. The SH and G proteins of MPV did not reveal significant aa sequence homology with SH and G proteins of any other virus. Although the amino acid content and hydrophobicity plots are in favour of defining these ORFs as SH and G, experimental data are required to assess their function. Such analyses will also shed hght on the role of the additional overlapping
  • Nucleotide sequences of the 3' leader and 5' traUer regions of human respiratory syncytial virus genomic RNA are Virology 185, 615-24 (1991).)
  • a homopolymer A taU is added to purified vRNA using poly-A-polymerase and the leader sequence subsequently amplified by PCR using a poly-T primer and a primer in the N gene.
  • a cDNA copy of the traUer sequence is made using reverse transcriptase and a primer in the L gene, foUowed by homopolymer dG tailing of the cDNA with terminal transferase.
  • vRNA is hgated to itself or synthetic hnkers, after which the leader and traUer regions are amplified using primers in the L and N genes and linker-specific primers.
  • dideoxynucleotide sequencing of purified vRNA is also feasible (Randhawa, 1997). Using these approaches, we can analyse the exact sequence of the ends of the hMPV genome.. The sequence information provided here is of importance for the generation of diagnostic tests, vaccines and antivirals for MPV and MPV infections. Materials and Methods Sequence analysis
  • Virus isolate 00-1 was propagated to high titers (approximately 10,000 TCID50/ml) on tertiary monkey kidney ceUs as described previously (van den Hoogen et al, 2001). Viral RNA was isolated from supernatants from infected ceUs using a High Pure RNA Isolating Kit according to instructions from the manufacturer (Roch Diagnostics, Almere, The Netherlands). Primers were designed based on sequences pubhshed previously (van den Hoogen et al, 2001) in addition to sequences pubhshed for the leader and traUer of APV/RSV (Randhawa et al, 1997; Mink et al, 1991) and are avaUable upon request.
  • RT-PCR assays were conducted with viral RNA, using a one- tube assay in a total volume of 50 ⁇ l with 50 mM Tris pH 8.5, 50 mM NaCl, 4.5 mM MgCl 2 , 2 mM DTT, 1 ⁇ M forward primer, l ⁇ M reverse primer, 0.6 mM dNTP's, 20 units RNAsin (Promega, Leiden, The Netherlands), 10 U AMV reverse transcriptase (Promega, Leiden, The Netherlands), and 5 units Taq Polymerase (PE Apphed Biosystems, Nieuwerkerk aan de IJssel, The Netherlands).
  • Reverse transcription was conducted at 42°C for 30 minutes, foUowed by 8 minutes inactivation at 95°C.
  • the cDNA was amphfied during 40 cycles of 95°C, 1 min.; 42°C, 2 min.72°C, 3 min. with a final extension at 72°C for 10 minutes.
  • the RT-PCR products were purified from the gel using a Qiaquick Gel Extraction kit (Qiagen, Leusden, The Netherlands) and sequenced directly using a Dyenamic ET terminator sequencing kit (Amersham Pharmacia Biotech, Roosendaal, the Netherlands) and an ABI 373 automatic DNA sequencer (PE Apphed Biosystem, Nieuwerkerk aan den IJssel, the Netherlands), according to the instructions of the manufacturer.
  • the MPV genomic sequence is avaUable from Genbank under accession number AF371337.
  • AU other sequences used here are avaUable from Genbank under accession numbers AB046218 (measles virus, aU ORFs), NC-001796 (human parainfluenza virus type 3, aU ORFs), NC-001552 (Sendai virus, aU ORFs), X57559 (human parainfluenza virus type 2, aU ORFs), NC-002617 (New Castle Disease virus, aU ORFs), NC-002728 (Nipah virus, aU ORFs), NC-001989 (bRSV, aU ORFs), M11486 (hRSV A, aU ORFs except L), NC-001803 (hRSV, L ORF), NC-001781 (hRSV B, aU ORFs), D 10331 (PVM, N ORF), U09649 (PVM, P ORF
  • the PVM M2 ORF was taken from Ahmadian (1999), AF176590 (APV-C, N ORF), U39295 (APV-A, N ORF), U39296 (APV-B, N ORF), AF262571 (APV-C, M ORF), U37586 (APV-B, M ORF), X58639 (APV-A, M ORF), AF176591 (APV-C, P ORF), AF325443 (APV-B, P
  • ORF U22110 (APV-A, P ORF), AF187152 (APV-C, F ORF), Y14292 (APV-B, F ORF), D00850 (APV-A, F ORF), AF176592 (APV-C, M2 ORF), AF35650 (APV-B, M2 ORF), X63408 (APV-A, M2 ORF), U65312 (APV-A, L ORF), S40185 (APV-A, SH ORF).
  • Table 5 Lengths of the ORFs of MPV and other paramyxoviruses.
  • Table 6 Amino acid sequence identity between the ORFs of MPV and those of other paramyxoviruses 1 .
  • PVM 45 26 37 39 33 12 .2 others 3 7-11 4-9 7-10 10- .4 .4 13-
  • AHMADIAN, G., CHAMBERS, P., and EASTON A. J. (1999). Detection and characterisation of proteins encoded by the second ORF of the M2 gene of pneumoviruses. J Gen Virol 80, 2011-6. ALANSARI, H., and POTGIETER, L. N. (1994). Molecular cloning and sequence analysis of the phosphoprotein, nucleocapsid protein, matrix protein and 22K (M2) protein of the ovine respiratory syncytial virus. J Gen Virol 75, 3597-601. BARR, J., CHAMBERS, P., PRINGLE, C R., and EASTON, A. J. (1991).
  • Sequence of the major nucleocapsid protein gene of pneumonia virus of mice sequence comparisons suggest structural homology between nucleocapsid proteins of pneumoviruses, paramyxoviruses, rhabdoviruses and filoviruses. J Gen Virol 72, 677-85. BAYBUTT, H. N., and PRINGLE, C. R. (1987). Molecular cloning and sequencing of the F and 22K membrane protein genes of the RSS-2 strain of respiratory syncytial virus. J Gen Virol 68, 2789-96. BAYON-AUBOYER, M. H., ARNAULD, C, TOQUIN, D., and ETERRADOSSI, N. (2000).
  • Nucleotide sequences of the F, L and G protein genes of two non-A non-B avian pneumoviruses reveal a novel APV subgroup. J Gen Virol 81, 2723-33. BERMINGHAM, A., and COLLINS, P. L. (1999).
  • the M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA rephcation and transcription. Proc Natl Acad Sci U SA 96, 11259-64.
  • COLLINS COLLINS, P. L., and WERTZ, G. W. (1983). cDNA cloning and transcriptional mapping of nine polyadenylylated RNAs encoded by the genome of human respiratory syncytial virus. Proc Natl Acad Sci U S A 80, 3208-12. COLLINS, P. L., and WERTZ, G. W. (1985).
  • the envelope-associated 22K protein of human respiratory syncytial virus nucleotide SEQUENCE of the mRNA and a related polytranscript. J Virol 54, 65-71. COLLINS, P.L., DICKENS, L.E., BUCKLER- WHITE, A., OLMSTED, R.A., SPRIGGS, M.K.,
  • COLLINS P. L., HILL, M. G., CAMARGO, E., GROSFELD, H., CHANOCK, R. M., and MURPHY
  • JOHNSON P. R., JR., OLMSTED, R. A., PRINCE, G. A., MURPHY, B. R., ALLING, D. W.,
  • MIYAHARA K. ; KITADA, S., YOSHIMOTO, M., MATSUMURA, H., KAWANO, M., KOMADA, H.,
  • SATAKE, M., and VENKATESAN S. (1984). Nucleotide sequence of the gene encoding respiratory syncytial virus matrix protein. J Virol 50, 92-9. SEAL, B. S., SELLERS, H. S., and MEINERSMANN, R. J. (2000). Fusion protein predicted amino acid sequence of the first US avian pneumovirus isolate and lack of heterogeneity among other US isolates. Virus Res 66, 139-47. SEDLMEIER, R., and NEUBERT, W. J. (1998). The rephcative complex of paramyxoviruses: structure and function. Adv Virus Res 50, 101-39.
  • VANDENHOOGEN B. G., DE JONG, J. C, GROEN, J., KUIKEN, T., DE GROOT, R.,
  • Deduced amino acid sequence of the fusion glycoprotein of turkey rhinotracheitis virus has greater identity with that of human respiratory syncytial virus, a pneumovirus, than that of paramyxoviruses and morbilhviruses.
  • Cloning and sequencing of the matrix protein (M) gene of turkey rhinotracheitis virus reveal a gene order different from that of respiratory syncytial virus. Virology 186, 426-34.
  • ZF1 5'-CCCACCACCAGAGAAA-3'
  • ZF4 5'-ACCACCAGAGAAACCC-3'
  • ZF7 5'-ACCAGAGAAACCCACC-3'
  • ZF10 5'-AGAGAGAAACCCACCACCACC-3'
  • ZF13 5'-GAGAAACCCACCACCAGA-3'
  • ZF16 5'-AAACCCACCACCAGAGAG-3'
  • CS1 5'-GGAGGCAAGCGAACGCAA-3'
  • CS4 5'-GGCAAGCGAACGCAAGGA-3'
  • CS7 5'-AAGCGAACGCAAGGAGGC-3'
  • 10 5'-CGAACGCAAGGAGGCAAG-3'
  • CS 13 5'-ACGCAAGGAGGCAAGCGA-3'
  • CS16 5'-CAAGGAGGCAAGCGAACG-3'
  • virus isolate 00-1 being the prototype of genotype A
  • isolate 99-1 the prototype of genotype B.
  • genotypes are related to subtypes and that re-infection with viruses from both subgroups occur in the presence of pre-existing immunity and the antigenic variation may not be strictly required to aUow re-infection.
  • hMPV appears to be closely related to avian pneumovirus, a virus primarUy found in poultry.
  • the nucleotide sequences of both viruses show high percentages of homology, with the exception of the SH and G proteins.
  • the viruses are cross-reacting in tests, which are based primarUy on the nucleoprotein and matrixprotein, but they respond differently in tests, which are based on the attachment proteins.
  • the differences in virus neutralisation titers provide further proof that the two genotypes of hMPV are two different serotypes of one virus, where APV is a different virus.
  • the indirect IgG EIA for hMPV was performed in microtitre plates essentiaUy as described previously (Rothbarth, P.H. et al., 1999; Influenza virus serology-a comparative study. J. of Vir. Methods 78 (1999) 163-169. Briefly, concentrated hMPV was solubUized by treatment with 1% Triton X-100 an coated for 16 hr at room temperature into microtitre plates in PBS after determination of the optimal working dilution by checkerboard titration. Subsequently, 100 ul volumes of 1:100 chluted human serum samples in EIA buffer were added to the weUs and incubated for 1 h at 37C.
  • Binding of human IgG was detected by adding a goat anti-human IgG peroxidase conjugate (Biosource, USA). Adding TMB as substrate developed plates and OD was measured at 450 nm. the results were expressed as the S(ignal)/N(egative) ratio of the OD. A serum was considered positive for IgG, if the S/N ratio was beyond the negative control plus three times the standard.
  • hMPV antibodies of the IgM and IgA classes were detected in sera by capture EIA essentiaUy as described previously (Rothbarth, P.H et al. 1999; Influenza virus serolgy-a comparative study. J. Vir. methods 78 (1999) 163-169.
  • IgA and IgM commerciaUy avaUable microtiter plates coated with anti human IgM or IgA specific monoclonal antibodies were used.
  • Sera were diluted 1:100 and after incubation of 1 hr at 37C, an optimal working dilution of hMPV is added at each well (100 ul). Incubated 1 hr 37C After washing polyclonal anti hMPV labeled with peroxidase was added, the plate was incubated 1 hr 37C Adding TMB as substrate developed plates and OD was measured at 450 nm. the results were expressed as the S(ignal)/N(egative) ratio of the OD. A serum was considered positive for IgG, if the S/N ratio was beyond the negative control plus three times the standard.
  • AVP antibodies were detected in an AVP inhibition assay. Protocol for APV inhibition test is included the APV-Ab SVANOVIR ® enzyme immunoassay which is manufactured by SVANOVA Biotech AB, Uppsal Science Park Glunten SE-751 83 Uppsala Sweden. The results were expressed as the S(ignal)/N(egative) ratio of the OD. A serum was considered positive for IgG, if the S/N ratio was beyond the negative control plus three times the standard.
  • Virus isolates ned 00/01 (subtype A) and ned/99/01 (subtype B) have been used to inoculate 6 guinea pigs per subtype (intratracheal, nose and eyes). 6 GP's infected with hMPV 00-1 (10e6,5 TCID50) 6 GP's infected with hMPV 99-1 (10e4,l TCID50) 54 Days after the primary infection, the guinea pigs have been inoculated with the homologous and heterologous subtypes (10e4 TCID50/ml):
  • Throat and nose swabs have been coUected for 12 days (1 st infection) or 8 days (2 nd infection) post infection, and have been tested for presence of the virus by RT-PCR assays.
  • guinea pigs inoculated with virus isolate ned/00/01 show infection of the upper respiratory tract day 1 to 10 post infection.
  • Guinea pigs inoculated with ned/99/01 show infection of the upper respiratory tract day 1 to 5 post infection. Infection with ned/99/01 appears to be less severe than infection with ned/00/01.
  • a second inoculation of the guinea pigs with the heterologous virus results in re-infection in 3 out of 4 guinea pigs and with the homologous virus in 2 out of 6 guinea pigs.
  • Figure 30 A and B IgG response against ned/00/01 and ned/99/01 for each individual guinea pig
  • Figure 31 Specificity of the ned/00/01 and ned/99/01 ELISA. Only data from homologous reinfected guinea pigs have been used.
  • Figure 32 Mean IgG response against ned/00/01 and ned/99/01 ELISA of 3 homologous (00-1/00-1), 2 homologous (99-1/99-1), 2 heterologous (99-1/00-1) and 2 heterologous (00-1/99-1) infected guinea pigs.
  • Figure 33 Mean percentage of APV inhibition of hMPV infected guinea pigs.
  • Sera raised against ned/99/01 reveal a lower percentage of inhibition in the APV inhibition ELISA than sera raised against ned/00/01.
  • Guinea pigs infected with ned/99/01 might have a lower titer (as is seen in the hMPV ELISA's) or the cross- reaction of ned/99/01 with APV is less than that of ned 00/01. Nevertheless, the APV- Ab inhibition ELISA can be used to detect hMPV antibodies in guinea pigs.
  • Sera coUected at day 0, day 52, 70 and 80 post infection were used in a virus (cross) neutrahsation assay with ned/00/01, ned/99/01 and APV-C. Starting dUution was 1 to
  • TCID50 virus 10 and 100 TCID50 virus per weU was used. After neutralisation, the virus was brought on tMK ceUs, 15 min. centrifuged at 3500 RPM, after which the media was refreshed.
  • the APV tests were grown for 4 days and the hMPV tests were grown for 7 days.
  • CeUs were fixed with 80% aceton, and IFA's were conducted with monkey-anti hMPV fitc labeled. WeUs that were negative in the staining were considered as the neutralising titer. For each virus a 10-log titration of the virus stock and 2 fold titration of the working solution was included.
  • Figure 34 Virus neutrahsation titers of ned 00/01 and ned/99/01 infected guinea pigs against ned/00/01, ned/99/01 and APV-C
  • Virus isolates ned/00/01 (subtype A) and ned/99/01 (subtype B) (l e 5 TCID50) have been used to inoculate 2 cynomologous macaques per subtype (intratracheal, nose and eyes).
  • the macaque Six months after the primary infection, the macaque have been inoculated for the second time with ned/00/01.
  • Throat swabs have been coUected for 14 days (1 st infection) or 8 days (2 nd infection) post infection, and have been tested for presence of the virus by RT-PCR assays.
  • Figure 35 Results of RT-PCR assays on throat swabs of cynomolgous macaques inoculated (twice) with ned/00/01.
  • Sera were used to test for the presence of IgG antibodies against either ned/00/01 or
  • the APV inhibition EIA is suitable for testing human samples for the presence of hMPV antibodies.
  • neutrahzation shows a certain degree of cross-reaction between two viruses in either or both directions (homologous-to-heterologous titer ration of eight or 16), distinctiveness of serotype is assumed if substantial biophysical/biochemical differences of DNA's exist. If neutrahzation shows a distinct degree of cross-reaction between two viruses in either or both directions (homologous-to-heterologous titer ration of smaUer than eight), identity of serotype of the isolates under study is assumed.”
  • the famUy oi Paramyxoviridae contains two subfamUys: the Paramyxovirinae and the Pneumovirinae.
  • the subfamUy Pneumovirinae consists of two genera: Pneumovirus and Metapneumovirus.
  • the genus Pneumovirus contains the human, bovine, ovine and caprine respiratory syncytial viruses and the pneumonia virus of mice (PVM).
  • the genus Metapneumovirus contains the avian pneumoviruses (APV, also referred to as TRTV).
  • the classification of the genera in the subfamUy Pneumovirinae is based on classical virus characteristics, gene order and gene consteUation.
  • Viruses of the genus Pneumovirus are unique in the famUy of Paramyxoviridae in having two nonstructural proteins at the 3'end of the genome (3'-NS 1-NS2-N-P-M-SH-G-F-M2-L- 5').
  • viruses in the genus Metapneumovirus lack the NSl and NS2 genes and the organisation of genes between the M and L coding regions is different: 3'-N-P- M-F-M2-SH-G-L-5'.
  • AU members of the subfamUy Paramyxovirinae have haemagluttinating activity, but this function is not a defining feature for the subfamUy Pneumovirinae, being absent in RSV and APV but present in PMV.
  • Neuraminidase activity is present in members of the genera Paramyxovirus and Rubulavirus (subfamUy Paramyxovirinae) but is absent in the genus Morbillivirus (subfamUy Paramyxovirinae) and the genera Pneumovirus and Metapneumovirus (subfamUy Pneumovirinae).
  • a second distinguishing feature of the subfamUy Pneumovirinae is the apparent hmited utilization of alternative ORFs within mRNA by RSN
  • several members of the subfamUy Paramyxovirinae such as Sendai and Measles viruses, access alternative ORFs within the mR ⁇ A encoding the phosphoprotein (P) to direct the synthesis of a novel protein.
  • the G protein of the Pneumovirinae does not have sequence relatedness or structural simUarity to the H ⁇ or H proteins oi Paramyxovirinae and is only approximately half the size of their chain length.
  • the ⁇ and P proteins are smaUer than their counterparts in the Paramyxovirinae and lack unambigous sequence homology.
  • Most nonsegmented negative stranded R ⁇ A viruses have a single matrix (M) protein.
  • M matrix
  • Members of the subfamUy Pneumovirinae are an exception in having two such proteins, M and M2.
  • the M protein is smaUer than its Paramyxovirinae counterparts and lacks sequence relatedness with Paramyxovirinae.
  • hRSV The subfamily Pneumovirinae, genus Pneumovirus hRSV is the type-species of the genus Pneumovirus and is a major and widespread cause of lower respiratory tract illness during infancy and early childhood (Selwyn, 1990). In addition, hRSV is increasingly recognised as an important pathogen in other patient groups, including immune compromised individuals and the elderly. RSV is also an important cause of community-acquired pneumonia among hospitahsed adults of all ages (Englund, 1991; Falsey, 2000; DoweU, 1996).
  • RSV-A and B Two major antigenic types for RSV (A and B) have been identified based on differences in their reactivity with monoclonal and polyclonal antibodies and by nucleic acid sequence analyses (Anderson, 1985; Johnson, 1987; SuUender, 2000). In particular the G protein is used in distinguishing the two subtypes. RSV-A and B share only 53% amino acid sequence homology in G, whereas the other proteins show higher homologies between the subtypes (table 1) (Colhns, 1996).
  • Detection of RSV infections has been described using monoclonal and polyclonal antibodies in immunofluorescence techniques (DIF, IFA), virus neutrahsation assays and ELISA or RT-PCR assays (Rothbarth, 1988; Van MUaan, 1994; Coggins, 1998).
  • DIF, IFA immunofluorescence techniques
  • oRSV ovine RSV
  • oRSV caprine RSV
  • Diagnosis of ruminant RSV infection and subtyping is based on the combined use of serology, antigen detection, virus isolation and RT-PCR assays (Uttenthal, 1996;Valarcher, 1999; Oberst, 1993; VUcek, 1994).
  • G and F proteins represent the major neutrahsation and protective antigens.
  • the G protein is highly variable between the hRSV subtypes and between hRSV and bRSV
  • the F proteins of hRSV and bRSV strains present comparable structural characteristics and antigenic relatedness.
  • the F protein of bRSV shows 80-81% homology with hRSV, whUe the two hRSV subtypes share 90% homology in F (Walravens, K. 1990).
  • RSV has also been isolated from naturaUy infected sheep (oRSV) (LeaMaster, 1983) and goats (cRSV) (Lehmkuhl, 1980). Both strains share 96% nucleotide sequence with the bovine RSV and are antigenicaUy crossre acting. Therefore, these viruses are also classified within the Pneumovirus genus.
  • oRSV naturaUy infected sheep
  • cRSV goats
  • Pneumkuhl A distinct member of the subfamUy Pneumovirinae, genus Pneumovirus is the Pneumonia virus of mice (PVM).
  • PVM is a common pathogen in laboratory animal colonies, particularly those containing atymic mice.
  • the naturaUy acquired infection is thought to be asymptomatic, though passage of virus in mouse lungs resulted in overt signs of disease ranging from an upper respiratory tract infection to a fatal pneumonia (Richter, 1988; Weir, 1988).
  • PVM has haemagglutinating activity with murine erythrocytes, for which the G protein appears to be responsible since a monoclonal antibody to this protein inhibits haemagglutination (Ling, 1989b).
  • the genome of PVM resembles that of hRSV, including two nonstructural proteins at its 3'end and a simUar genomic organisation (Chambers, 1990a; Chambers, 1990b).
  • the nucleotide sequences of the PVM NS1/NS2 genes are not detectably homologous with those of hRSV (Chambers, 1991).
  • Some proteins of PVM show strong homology with hRSV (N: 60%, and F: 38 to 40%) whUe G is distinctly different (the amino acid sequence is 31 % longer) (Barr, 1991; Barr, 1994; Chambers, 1992).
  • the PVM P gene but not that of RSV or APV, has been reported to encode a second ORF, representing a unique PVM protein (CoUins, 1996). New PVM isolates are identified by virus isolation, heamagglutination assays, virus neutrahsation assay and various immunofluorescence techniques.
  • Avian pneumoviruses has been identified as the aetiological agent of turkey rhinotracheitis (McDougaU, 1986; CoUins, 1988) and is therefore often referred to as turkey rhinotracheitis virus (TRTV).
  • the disease is an upper respiratory tract infection of turkeys, resulting in high morbidity and variable, but often high, mortahty.
  • the virus can also induce substantial reductions in egg production.
  • the same virus can also infect chickens, but in this species, the role of the virus as a primary pathogen is less clearly defined, although it is commonly associated with swoUen head syndrome (SHS) in breeder chicken (Cook, 2000).
  • SHS swoUen head syndrome
  • the virions are pleiomorphic, though mainly spherical, with sizes ranging from 70 to
  • nucleocapsid containing the hnear, non-segmented, negative-sense
  • RNA genome shows hehcal symmetry (Colhns, 1986; Giraud, 1986). This morphology resembles that of members of the famUy Paramyxoviridae. Analyses of the APV- encoded proteins and RNAs suggested that of the two subfamUys of this famUy (Paramyxovirinae and Pneumovirinae), APV most closely resembled the Pneumovirinae (CoUins, 1988; Ling, 1988; Cavanagh, 1988).
  • APV has no non-structural proteins (NSl and NS2) and the gene order (3'-N-P-M-F- M2-SH-G-L-5') is different from that of mammahan pneumoviruses such as RSV. APV has therefore recently been classified as the type species for the new genus Metapneumovirus (Pringle, 1999).
  • Diagnosis of APV infection can be achieved by virus isolation in chicken or turkey tracheal organ cultures (TOCs) or in Vero ceU cultures.
  • a cytopathic effect (CPE) is generaUy observed after one or two additional passages. This CPE is characterised by scattered focal areas of ceU rounding leading to synctyial formation (Buys, 1989).
  • a number of serology assays, including IF and virus neutrahsation assays have been developed. Detection of antibodies to APV by ELISA is the most commonly used method (O'Loan, 1989; Gulati, 2000). Recently, the polymerase chain reaction (PCR) has been used to diagnose APV infections. Swabs taken from the oesophagus can be used as the starting material (Bayon-Auboyer, 1999; Shin, 2000)
  • Sequence of the major nucleocapsid protein gene of pneumonia virus of mice sequence comparisons suggest structural homology between nucleocapsid proteins of pneumoviruses, paramyxoviruses, rhabdoviruses and filoviruses. J.Gen.Virol. 72: 677-685.
  • Matrix protein gene nucleotide and predicted amino acid sequence demonstrate that the first US avian pneumovirus isolate is distinct form European strans. Virus Res. 58, 45-52.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

The invention relates to the field of virology. The invention provides an isolated essentially mammalian negative-sense single stranded RNA virus (MPV) within the sub-family Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus and components thereof.

Description

A virus causing respiratory tract illness in susceptible mammals.
The invention relates to the field of virology.
In the past decades several etiological agents of mammalian disease, in particular of respiratory tract illnesses (RTI), in particular of humans, have been identified7. Classical etiological agents of RTI with mammals are respiratory syncytial viruses belonging to the genus Pneumovirus found with humans (hϊtSV) and ruminants such as cattle or sheep (bRSV and/or oRSV). In human RSV differences in reciprocal cross neutralization assays, reactivity of the G proteins in immunological assays and nucleotide sequences of the G gene are used to define 2 hRSV antigenic subgroups. Within the subgroups the aa sequences show 94 % (subgroup A) or 98% (subgroup B) identity, while only 53% aa sequence identity is found between the subgroups. Additional variability is observed within subgroups based on monoclonal antibodies, RT-PCR assays and RNAse protection assays. Viruses from both subgroups have a worldwide distribution and may occur during a single season. Infection may occur in presence of pre-existing immunity and the antigenic variation is not strictly required to allow re-infection. See for example Sullender, W.M., Respiratory Syncytial Virus Genetic and Antigenic Diversity. Clinical Microbiology Reviews, 2000. 13(1): p. 1-15; Collins, P.L., Mclntosh, K. and Chanock, R.M., Respiratory syncytial virus. Fields virology, ed. B.N. Knipe, Howley, P.M. 1996, Philadelphia: lippencott-raven. 1313-1351; Johnson, P.R, et al, The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci U S A, 1987. 84(16): p. 5625-9; Collins, P. ., The molecular Biology of Human Respiratory Syncytial Virus (RSV) of the Genus Pneumovirus, in The Paramyxoviruses, D.W. Kingsbury, Editor. 1991, Plenum Press: New York. p. 103-153. Another classical Pneumovirus is the pneumonia virus of mice (PVM), in general only found with laboratory mice. However, a proportion of the illnesses observed among mammals can still not be attributed to known pathogens. The invention provides an isolated essentially mammalian negative-sense single stranded RNA virus (MPV) belonging to the sub-family Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus. Said virus is identifiable as phylogenetically corresponding to the genus Metapneumovirus by determining a nucleic acid sequence of said virus and testing it in phylogenetic analyses, for example wherein maximum likelihood trees are generated using 100 bootstraps and 3 jumbles and finding it to be more closely phylogenetically corresponding to a virus isolate deposited as 1-2614 with CNCM, Paris than it is corresponding to a essentially avian virus isolate of avian pneumovirus (APV) also known as turkey rhinotracheitis virus (TRTV), the aetiological agent of avian rhinotracheitis. For said phylogenetic analyses it is most useful to obtain the nucleic acid sequence of a non-MPV as outgroup to be compared with, a very useful outgroup isolate can be obtained from avian pneumovirus serotype C (APV-C), as is for example demonstrated in figure 5 herein. Although phylogenetic analyses provides a convenient method of identifying a virus as an MPV several other possibly more straightforward albeit somewhat more course methods for identifying said virus or viral proteins or nucleic acids from said virus are herein also provided. As a rule of thumb an MPV can be identified by the percentages of a homology of the virus, proteins or nucleic acids to be identified in comparison with isolates, viral proteins, or nucleic acids identified herein by sequence or deposit. It is generally known that virus species, especially RNA virus species, often constitute a quasi species wherein a cluster of said viruses displays heterogeneity among its members. Thus it is expected that each isolate may have a somewhat different percentage relationship with one of the various isolates as provided herein.
When one wishes to compare with the deposited virus 1-2614, the invention provides an isolated essentially mammalian negative-sense single stranded RNA virus (MPV) belonging to the sub-family Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus by determining an amino acid sequence of said virus and determining that said amino acid sequence has a percentage amino acid homology to a virus isolate deposited as 1-2614 with CNCM, Paris which is essentially higher than the percentages provided herein for the L protein, the M protein, the N protein, the P protein, or the F protein, in comparison with APV-C or, likewise, an isolated essentially mammalian negative-sense single stranded RNA virus (MPV) belonging to the sub-family Pneumovirinae of the family Paramyxoviridae is provided as identifiable as phylogenetically corresponding to the genus Metapneumovirus by determining a nucleic acid sequence of said virus and determining that said nucleic acid sequence has a percentage nucleic acid identity to a virus isolate deposited as I-
2614 with CNCM, Paris which is essentially higher than the percentages identified herein for the nucleic acids encoding the L protein, the M protein, the N protein, the
P protein, or the F protein as identified herein below in comparison with APV-C.
Again as a rule of thumb one may consider an MPV as belonging to one of the two serological groups of MPV as identified herein when the isolates or the viral proteins or nuclear acids of the isolates that need to be identified have percentages homology that fall within the bounds and metes of the percentages of homology identified herein for both separate groups, taking isolates 00-1 or 99-1 as the respective isolates of comparison. However, when the percentages of homology are smaller or there is more need to distinguish the viral isolates from for example APV- C it is better advised to resort to the phylogenetic analyses as identified herein. Again one should keep in mind that said percentages can vary somewhat when other isolates are selected in the determination of the percentage of homology. With the provision of this MPN the invention provides diagnostic means and methods and therapeutic means and methods to be employed in the diagnosis and/or treatment of disease, in particular of respiratory disease, in particular of mammals, more in particular in humans. However, due to the , albeit distant, genetic relationship of the essentially mammalian MPV with the essentially avian APV, in particular with APV-C, the invention also provides means and methods to be employed in the diagnosis and treatment of avian disease. In virology, it is most advisory that diagnosis and/or treatment of a specific viral infection is performed with reagents that are most specific for said specific virus causing said infection. In this case this means that it is preferred that said diagnosis and/or treatment of an MPV infection is performed with reagents that are most specific for MPV. This by no means however excludes the possibility that less specific, but sufficiently cross- reactive reagents are used instead, for example because they are more easily available and sufficiently address the task at hand. Herein it is for example provided to perform virological and/or serological diagnosis of MPV infections in mammals with reagents derived from APV, in particular with reagents derived from APV-C, in the detailed description herein it is for example shown that sufficiently trustworthy serological diagnosis of MPV infections in mammals can be achieved by using an ELISA specifically designed to detect APV antibodies in birds. A particular useful test for this purpose is an ELISA test designed for the detection of APV antibodies (e.g in serum or egg yolk), one commercialy available version of which is known as APV-Ab SVANOVIR ® which is manufactured by SVANOVA Biotech AB, Uppsal Science Park Glunten SE-751 83 Uppsala Sweden. The reverse situation is also the case, herein it is for example provided to perform virological and/or serological diagnosis of APV infections in mammals with reagents derived from MPV, in the detailed description herein it is for example shown that sufficiently trustworthy serological diagnosis of APV infections in birds can be achieved by using an ELISA designed to detect MPV antibodies. Considering that antigens and antibodies have a lock-and-key relationship, detection of the various antigens can be achieved by selecting the appropriate antibody having sufficient cross-reactivity. Of course, for relying on such cross-reactivity, it is best to select the reagents (such as antigens or antibodies) under guidance of the amino acid homologies that exist between the various (glyco)proteins of the various viruses, whereby reagents relating to the most homologous proteins will be most useful to be used in tests relying on said cross- reactivity. For nucleic aciddetection, it is even more straightforward, instead of designing primers or probes based on heterologous nucleic acid sequences of the various viruses and thus that detect differences between the essentially mammalian or avian Metapneumoviruses, it suffices to design or select primers or probes based on those stretches of virus-specific nucleic acid sequences that show high homology. In general, for nucleic acid sequences, homology percentages of 90% or higher guarantee sufficient cross-reactivity to be relied upon in diagnostic tests utilizing stingent conditions of hybridisation.
The invention for example provides a method for virologically diagnosing a MPV infection of an animal, in particular of a mammal, more in particular of a human being, comprising determining in a sample of said animal the presence of a viral isolate or component thereof by reacting said sample with a MPV specific nucleic acid a or antibody according to the invention, and a method for serologically diagnosing an MPV infection of a mammal comprising determining in a sample of said mammal the presence of an antibody specifically directed against an MPV or component thereof by reacting said sample with a MPV-specific proteinaceous molecule or fragment thereof or an antigen according to the invention. The invention also provides a diagnostic kit for diagnosing an MPV infection comprising an MPV, an MPV-specific nucleic acid, proteinaceous molecule or fragment thereof, antigen and/or an antibody according to the invention, and preferably a means for detecting said MPV, MPV-specific nucleic acid, proteinaceous molecule or fragment thereof, antigen and/or an antibody, said means for example comprising an excitable group such as a fluorophore or enzymatic detection system used in the art (examples of suitable diagnostic kit format comprise IF, ELISA, neutrahzation assay, RT-PCR assay). To determine whether an as yet unidentified virus component or synthetic analogue thereof such as nucleic acid, proteinaceous molecule or fragment thereof can be identified as MPV-specific, it suffices to analyse the nucleic acid or amino acid sequence of said component, for example for a stretch of said nucleic acid or amino acid, preferably of at least 10, more preferably at least 25, more preferably at least 40 nucleotides or amino acids (respectively), by sequence homology comparison with known MPV sequences and with known non-MPV sequences APV-C is preferably used) using for example phylogenetic analyses as provided herein. Depending on the degree of relationship with said MPV or non-MPV sequences, the component or synthetic analogue can be identified. The invention also provides method for virologically diagnosing an MPV infection of a mammal comprising determining in a sample of said mammal the presence of a viral isolate or component thereof by reacting said sample with a cross- reactive nucleic acid derived from APV (preferably serotype C) or a cross-reactive antibody reactive with said APV, and a method for serologically diagnosing an MPV infection of a mammal comprising determining in a sample of said mammal the presence of a cross-reactive antibody that is also directed against an APV or component thereof by reacting said sample with a proteinaceous molecule or fragment thereof or an antigen derived from APV. Furthermore, the invention provides the use of a diagnostic kit initially designed for AVP or AVP-antibody detection for diagnosing an MPV infection, in particular for detecting said MPV infection in humans.
The invention also provides method for virologically diagnosing an APV infection in a bird comprising determining in a sample of said bird the presence of a viral isolate or component thereof by reacting said sample with a cross-reactive nucleic acid derived from MPV or a cross-reactive antibody reactive with said MPV, and a method for serologically diagnosing an APV infection of a bird comprising determining in a sample of said bird the presence of a cross-reactive antibody that is also directed against an MPV or component thereof by reacting said sample with a proteinaceous molecule or fragment thereof or an antigen derived from MPV.
Furthermore, the invention provides the use of a diagnostic kit initially designed for
MPV or MPV-antibody detection for diagnosing an APV infection, in particular for detecting said APV infection in poultry such as a chicken, duck or turkey.
As said, with treatment, similar use can be made of the cross-reactivity found, in particular when circumstances at hand make the use of the more homologous approach less straightforward. Vaccinations that can not wait, such as emergency vaccinations against MPV infections can for example be performed with vaccine preparations derived from APV(preferably type C) isolates when a more homologous MPV vaccine is not available, and, vice versa, vaccinations against APV infections can be contemplated with vaccine preparations derived from MPV. Also, reverse genetic techniques make it possible to generate chimeric APV-MPV virus constructs that are useful as a vaccine, being sufficiently dissimilar to field isolates of each of the respective strains to be attenuated to a desirable level. Similar reverse genetic techniques will make it also possible to generate chimeric paramyxovirus- metapneumovirus constructs, such as RSV-MPV or PI3-MPV constructs for us in a vaccine preparation. Such constructs are particularly useful as a combination vaccine to combat respiratory tract illnesses.
The invention thus provides a novel etiological agent, an isolated essentially mammalian negative-sense single stranded RNA virus (herein also called MPV) belonging to the subfamily Pneumovirinae of the family Paramyxoviridae but not identifiable as a classical pneumovirus, and belonging to the genus Metapneumovirus, and MPV-specific components or synthetic analogues thereof. Mammalian viruses resembling metapneumoviruses, i.e. metapneumoviruses isolatable from mammals that essentially function as natural host for said virus or cause disease in said mammals, have until now not been found. Metapneumoviruses, in general thought to be essentially restricted to poultry as natural host or aetiological agent of disease, are also known as avian pneumoviruses. Recently, an APV isolate of duck was described (FR 2 801 607), further demonstrating that APV infections are essentially restricted to birds as natural hosts. The invention provides an isolated mammalian pneumovirus (herein also called MPV) comprising a gene order and amino acid sequence distinct from that of the genus Pneumovirus and which is closely related and considering its phylogenetic relatedness likely belonging to the genus Metapneumovirus within the subfamily Pneumovirinae of the family Paramyxoviridae. Although until now, metapneumoviruses have only been isolated from birds, it is now shown that related, albeit materially distinct, viruses can be identified in other animal species such as mammals. Herein we show repeated isolation of MPV from humans, whereas no such reports exists for APV. Furthermore, unlike APN MPV essentially does not or only little replicates in chickens and turkeys where it easily does in cynomolgous macaques. No reports have been found on replication of APV in mammals. In addition, whereas specific anti-sera raised against MPV neutralize MPV, anti-sera raised against APV A, B or C do not neutralize MPV to the same extent, and this lack of full cross reactivity provides another proof for MPV being a different metapneumovirus. Furthermore, where APV and MPV share a similar gene order, the G and SH proteins of MPV are largely different from the ones known of APV in that they show no significant sequence homologies on both the amino acid or nucleic acid level. Diagnostic assays to discriminate between APV and MPV isolates or . antibodies directed against these different viruses can advantageously be developed based on one or both of these proteins (examples are IF, ELISA, neutrahzation assay, RT-PCR assay). However, also sequence and/or antigenic information obtained from the more related N, P, M, F and L proteins of MPV and analyses of sequence homologies with the respective proteins of APV, can also be used to discriminate between APV and MPV. For example, phylogenetic analyses of sequence information obtained from MPV revealed that MPV and APV are two different viruses. In particular, the phylogenetic trees show that APV and MPV are two different lineages of virus. We have also shown that MPV is circulating in the human population for at least 50 years, therefore interspecies transmission has probably taken place at least 50 years ago and is not an everyday event.Since MPV CPE was virtually indistinguishable from that caused by hRSV or hPIV-1 in tMK or other cell cultures, the MPV may have well gone unnoticed until now. tMK (tertiary mon ey kidney cells, i.e. MK cells in a third passage in cell culture) are preferably used due to their lower costs in comparison to primary or secondary culltures. The CPE is, as well as with some of the classical Paramyxoviridae, characterized by syncytium formation after which the cells showed rapid internal disruption, followed by detachment of the cells from the monolayer. The cells usually (but not always) displayed CPE after three passages of virus from original material, at day 10 to 14 post inoculation, somewhat later than CPE caused by other viruses such as hRSV or hPIV-1. Classically, as devastating agents of disease, paramyxoviruses account for many animal and human deaths worldwide each year. The Paramyxoviridae form a family within the order of Mononegavirales (negative-sense single stranded RNA viruses), consisting of the sub-familys Paramyxovirinae and Pneumovirinae. The latter sub-family is at present taxonomically divided in the genera Pneumovirus and Metapneumovirus x. Human respiratory syncytial virus (hRSV), the type species of the Pneumovirus genus, is the single most important cause of lower respiratory tract infections during infancy and early childhood worldwide2. Other members of the Pneumovirus genus include the bovine and ovine respiratory syncytial viruses and pneumonia virus of mice (PVM). Avian pneumovirus (APV) also known as turkey rhinotracheitis virus (TRTV), the aetiological agent of avian rhinotracheitis, an upper respiratory tract infection of turkeys3, is the sole member of the recently assigned Metapneumovirus genus, which, as said was until now not associated with infections, or what is more, with disease of mammals. Serological subgroups of APV can be differentiated on the basis of nucleotide or amino acid sequences of the G glycoprotein and neutralization tests using monoclonal antibodies that also recognize the G glycoprotein, Within subgroups A, B and D the G protein shows 98.5 to 99.7% aa sequence identity within subgroups while between the subgroups only 31.2- 38% aa identity is observed. See for example Collins, M.S., Gough, R.E. and Alexander, D.J., Antigenic differentiation of avian pneumovirus isolates using poly clonal antisera and mouse monoclonal antibodies. Avian Pathology, 1993. 22: p. 469-479.; Cook, J.K.A., Jones, B.V., Ellis, M.M., Antigenic differentiation of strains of turkey rhinotracheitis virus using monoclonal antibodies. Avian Pathology, 1993. 22: p. 257-273; Bayon-Auboyer, M.H., et al., Nucleotide sequences of the F, L and G protein genes of two non-A/non-B avian pneumoviruses (APV) reveal a novel APV subgroup. J Gen Virol, 2000. 81(Pt 11): p. 2723-33; Seal, B.S., Matrix protein gene nucleotide and predicted amino acid sequence demonstrate that the first US avian pneumovirus isolate is distinct from European strains. Virus Res, 1998. 58(1-2): p. 45-52; Bayon-Auboyer, M.H., et al., Comparison of F-, G- and N-based RT-PCR protocols with conventional virological procedures for the detection and typing of turkey rhinotracheitis virus. Arch Virol,
1999. 144(6): p. 1091-109; Juhasz, K. and A.J. Easton, Extensive sequence variation in the attachment (G) protein gene of avian pneumovirus: evidence for two distinct subgroups. J Gen Virol, 1994. 75(Pt 11): p. 2873-80. A further serotype of APV is provided in WO00/20600, which describes the
Colorado isolate of APV and compared it to known APV or TRT strains with in vitro serum neutrahzation tests. First, the Colorado isolate was tested against monospecific polyclonal antisera to recognized TRT isolates. The Colorado isolate was not neutrahzed by monospecific antisera to any of the TRT strains. It was, however, neutrahzed by a hyperimmune antiserum raised against a subgroup A strain. This antiserum neutrahzed the homologous virus to a titre of 1:400 and the Colorado isolate to a titer of 1: 80. Using the above method, the Colorado isolate was then tested against TRT monoclonal antibodies. In each case, the reciprocal neutrahzation titer was <10. Monospecific antiserum raised to the Colorado isolate was also tested against TRT strains of both subgroups. None of the TRT strains tested were neutrahzed by the antiserum to the Colorado isolate.
The Colorado strain of APV does not protect SPF chicks against chaUenge with either a subgroup A or a subgroup B strain of TRT virus. These results suggest that the Colorado isolate may be the first example of a further serotype of avian pneumovirus, as also suggested by Bayon-Auboyer et al (J. Gen. Vir. 81:2723-2733 (2000).
In a preferred embodiment, the invention provides an isolated MPV taxonomically corresponding to a (hereto unknown mammalian) metapneumovirus comprising a gene order distinct from that of the pneumoviruses within the sub- family Pneumovirinae of the family Paramyxoviridae. The classification of the two genera is based primarily on their gene constellation; metapneumoviruses generally lack non-structural proteins such NSl or NS2 ( see also Randhawa et al., J. Vir. 71:9849-9854 (1997) and the gene order is different from that of pneumoviruses (RSV: '3-NS1-NS2-N-P-M-SH-G-F-M2-L-5', APV: '3-N-P-M-F-M2-SH-G-L-5') 4^s. MPV as provided by the invention or a virus isolate taxonomically corresponding therewith is upon EM analysis revealed by paramyxovirus-like particles. Consistent with the classification, MPV or virus isolates phylogenetically corresponding or taxonomically corresponding therewith are sensitive to treatment with chloroform; are cultured optimally on tMK cells or cells functionally equivalent thereto and are essentially trypsine dependent in most ceU cultures. Furthermore, the typical CPE and lack of haemagglutinating activity with most classically used red blood cells suggested that a virus as provided herein is, albeit only distantly, related to classical pneumoviruses such as RSV. Although most paramyxoviruses have haemagglutinating acitivity, most of the pneumoviruses do not 13- An MPV according to the invention also contains a second overlapping ORF (M2-2) in the nucleic acid fragment encoding the M2 protein, as in general most other pneumoviruses such as for example also demonstrated in Ahmadian et al., J. Gen. Vir. 80:2011-2016 (1999)
To find further viral isolates as provided by the invention it suffices to test a sample, optionally obtained from a diseased animal or human, for the presence of a virus of the sub-family Pneumovirinae, and test a thus obtained virus for the presence of genes encoding (functional) NS1 or NS2 or essentially demonstrate a gene order that is different from that of pneumoviruses such as RSV as already discussed above. Furthermore, a virus isolate phylogenetically corresponding and thus taxonomically corresponding with MPV may be found by cross-hybridisation experiments using nucleic acid from a here provided MPV isolate, or in classical cross-serology experiments using monoclonal antibodies specifically directed against and/or antigens and/or immunogens specifically derived from an MPV isolate. Newly isolated viruses are phylogenetically corresponding to and thus taxonomically corresponding to MPV when comprising a gene order and/or amino acid sequence sufficiently similar to our prototypic MPV isolate(s), or are structurally corresponding therewith, and show close relatedness to the genus Metapneumovirus within the subfamily Pneumovirinae. The highest amino sequence homology, and defining the structural correspondence on the individual protein level, between MPV and any of the known other viruses of the same family to date (APV subtype C) is for matrix 87%, for nucleoprotein 88%, for phosphoprotein 68%, for fusionprotein 81% and for parts of the polymerase protein 56-64%, as can be deduced when comparing the sequences given in figure 6 with sequences of other viruses, in particular of AVP- C. Individual proteins or whole virus isolates with, respectively, higher homology to these mentioned maximum values are considered phylogenetically corresponding and thus taxonomically corresponding to MPV, and comprise a nucleic acid sequence structurally corresponding with a sequence as shown in figure 6. Herewith the invention provides a virus phylogenetically corresponding to the deposited virus. It should be noted that, similar to other viruses, a certain degree of variation is found between different isolated essentially mammalian negative-sense single stranded
RNA virus isolates as provided herein. In phylogenetic trees, we have identified at least 2 genetic clusters of virus isolates based on comparitive sequence analyses of parts of the L, M, N and F genes. Based on nucleotide and amino-acid differences in the viral nucleic acid or amino acid sequences (the viral sequences), and in analogy to other pneumoviruses such as RSV, these MPV genotypes represent subtypes of MPV.
Within each of the genetic clusters of MPV isolates, the percentage identity at the nucleotide level was found to be 94-100 for L, 91-100 for M, 90-100 for N and 93-100 for F and at the amino acid level the percentage identity was found to be 91-100 for L, 98-100 for M, 96-100 for N and 98-100 for F. A further comparison can be found in figures 18 to 28. The minimum percentage identity at the nucleotide level for the entire group of isolated essentially mammahan negative-sense single stranded RNA virus as provided herein (MPV isolates) identified so far was 81 for L and M, 83 for N and 82 for F. At the amino acid level, this percentage was 91 for L and N, 94 for M, and 95 for F. The viral sequence of a MPV isolate or an isolated MPV F gene as provided herein for example shows less than 81%nucleotide sequence identity or less than 82%(amino acid sequence identity with the respective nucleotide or amino acid sequence of an APV-C fusion (F) gene as for example provided by Seal et al., Vir. Res. 66:139147 (2000).
Also, the viral sequence of a MPV isolate or an an isolated MPV L gene as provided herein for example shows less than 61% nucleotide sequence identity or less than 63% amino acid sequence identity with the respective nucleotide or amino acid sequence of an APV- A polymerase gene as for example provided by Randhawa et al.,., J. Gen. Vir. 77:3047-3051 (1996).
Sequence divergence of MPV strains around the world may be somewhat higher, in analogy with other viruses. Consequently, two potential genetic clusters are identified by analyses of partial nucleotide sequences in the N, M, F and L ORFs of 9 virus isolates. 90-100% nucleotide identity was observed within a cluster, and 81- 88% identity was observed between the clusters. Sequence information obtained on more virus isolates confirmed the existence of two genotypes. Virus isolate nedV00/01 as prototype of cluster A, and virus isolate ned/99/01 as prototype of cluster B have been used in cross neutrahzation assays to test whether the genotypes are related to different serotypes or subgroups. From these data we conclude that essentially mammalian virus isolates displaying percentage amino acid homology higher than 64 for L, 87 for M, 88 for N, 68 for P, 81 for F 84 for M2-1 or 58 for M2-2 to isolate 1-2614 may be classified as an isolated essentially mammalian negative-sense single stranded RNA virus as provided herein. In particular those virus isolates in general that have a minimum percentage identity at the nucleotide sequence level with a prototype MPV isolate as provided herein of 81 for L and M, 83 for N and/or 82 for F are members of the group of MPV isolates as provided herein . At the amino acid level, these percentage are 91 for L and N, 94 for M, and/or 95 for F. When the percentage amino acid sequence homology for a given virus isolate is higher than 90 for L and N, 93 for M, or 94 for F, the virus isolate is similar to the group of MPV isolates displayed in figure 5. When the percentage amino acid sequence homology for a given virus isolate is higher than 94 for L, 95 for N or 97 for M and F the virus isolate can be identified to belong to one of the genotype clusters represented in figure 5. It should be noted that these percentages of homology, by which genetic clusters are defined, are similar to the degree of homology found among genetic clusters in the corresponding genes of RSV.
In short, the invention provides an isolated essentiaUy mammalian negative- sense single stranded RNA virus (MPV) belonging to the sub-family Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus by determining a nucleic acid sequence of a suitable fragment of the genome of said virus and testing it in phylogenetic tree analyses wherein maximum likelihood trees are generated using 100 bootstraps and 3 jumbles and finding it to be more closely phylogenetically corresponding to a virus isolate deposited as 1-2614 with CNCM, Paris than it is corresponding to a virus isolate of avian pneumovirus (APV) also known as turkey rhinotracheitis virus (TRTV), the aetiological agent of avian rhinotracheitis.
Suitable nucleic acid genome fragments each useful for such phylogenetic tree analyses are for example any of the RAP-PCR fragments 1 to 10 as disclosed herein in the detailed description, leading to the various phylogenetic tree analyses as disclosed herein in figures 4 or 5. Phylogenetic tree analyses of the nucleoprotein (N), phosphoprotein (P), matrixprotein (M) and fusion protein (F) genes of MPV revealed the highest degree of sequence homology with APV serotype C, the avian pneumovirus found primarily in birds in the United States In a preferred embodiment, the invention provides an isolated essentially mammahan negative-sense single stranded RNA virus (MPV) belonging to the subfamily Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus by determining a nucleic acid sequence of a suitable fragment of the genome of said virus and testing it in phylogenetic tree analyses wherein maximum likelihood trees are generated using 100 bootstraps and 3 jumbles and finding it to be more closely phylogenetically corresponding to a virus isolate deposited as 1-2614 with CNCM, Paris than it is corresponding to a virus isolate of avian pneumovirus (APV) also known as turkey rhinotracheitis virus (TRTV), the aetiological agent of avian rhinotracheitis, wherein said suitable fragment comprises an open reading frame encoding a viral protein of said virus.
A suitable open reading frame (ORF) comprises the ORF encoding the N protein. When an overall amino acid identity of at least 91%, preferably of at least 95% of the analysed N-protein with the N-protein of isolate 1-2614 is found, the analysed virus isolate comprises a preferred MPV isolate according to the invention. As shown, the first gene in the genomic map of MPV codes for a 394 amino acid (aa) protein and shows extensive homology with the N protein of other pneumoviruses. The length of the N ORF is identical to the length of the N ORF of APV-C (Table 5) and is smaller than those of other paramyxoviruses (Barr et al., 1991). Analysis of the amino acid sequence revealed the highest homology with APV-C (88%), and only 7- 11% with other paramyxoviruses (Table 6).
Barr et al (1991) identified 3 regions of similarity between viruses belonging to the order Mononegavirales: A, B and C (Figure 8). Although similarities are highest within a virus family, these regions are highly conserved between virus familys. In all three regions MPV revealed 97% aa sequence identity with APV-C, 89% with APV-B, 92 with APV-A, and 66-73% with RSV and PVM. The region between aa residues 160 and 340 appears to be highly conserved among metapneumoviruses and to a somewhat lesser extent the Pneumovirinae (Miyahara et al., 1992; Li et al., 1996; Barr et al., 1991). This is in agreement with MPV being a metapneumovirus, this particular region showing 99% similarity with APV C.
Another suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the P protein. When an overall amino acid identity of at least 70%, preferably of at least 85% of the analysed P-protein with the P-protein of isolate 1-2614 is found, the analysed virus isolate comprises a preferred MPV isolate according to the invention. The second ORF in the genome map codes for a 294 aa protein which shares 68% aa sequence homology with the P protein of APV-C, and only 22-26% with the P protein of RSV (Table 6). The P gene of MPV contains one substantial ORF and in that respect is similar to P from many other paramyxoviruses
(Reviewed in Lamb and Kolakofsky, 1996; Sedlmeier et al., 1998). In contrast to APV
A and B and PVM and similar to RSV and APV-C the MPV P ORF lacks cysteine residues. Ling (1995) suggested that a region of high similarity between all pneumoviruses (aa 185-241) plays a role in either the RNA synthesis process or in maintaining the structural integrity of the nucleocapsid complex. This region of high similarity is also found in MPV (Figure 9) especifically when conservative substitutions are taken in account, showing 100% similarity with APV-C, 93 % with APV-A and B, and approximately 81% with RSV. The C-terminus of the MPV P protein is rich in glutamate residues as has been described for APVs (Ling et al., 1995).
Another suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the M protein. When an overall amino acid identity of at least 94%, preferably of at least 97% of the analysed M-protein with the M-protein of isolate 1-2614 is found, the analysed virus isolate comprises a preferred MPV isolate according to the invention. The third ORF of the MPV genome encodes a 254 aa protein, which resembles the M ORFs of other pneumoviruses. The M ORF of MPV has exactly the same size as the M ORFs of other metapneumoviruses (Table 5) and shows high aa sequence homology with the matrix proteins of APV (76-87%) lower homology with those of RSV and PVM (37-38%) and 10% or less homology with those of other paramyxoviruses (Table 6). Easton (1997) compared the sequences of matrix proteins of all pneumoviruses and found a conservedhexapeptide at residue 14 to 19 that is also conserved in MPV (Figure 10). For RSV, PVM and APV small secondary ORFs within or overlapping with the major ORF of M have been identified (52 aa and 51 aa in bRSV, 75 aa in RSN 46 aa in PVM and 51 aa in APV) (Yu et al, 1992; Easton et al., 1997; Samal et al., 1991; Satake et al., 1984). We noticed two small
ORFs in the M ORF of MPV. One small ORF of 54 aa residues was found within the major M ORF , starting at nucleotide 2281 and one small ORF of 33 aa residues was found overlapping with the major ORF of M starting at nucleotide 2893 (data not shown). Similar to the secondary ORFs of RSV and APV there is no significant homology between these secondary ORFs and secondary ORFs of the other pneumoviruses, and apparent start or stop signals are lacking. In addition, evidence for the synthesis of proteins corresponding to these secondary ORFs of APV and RSV has not been reported. Another suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the F protein. When an overall amino acid identity of at least 95%, preferably of at least 97% of the analysed F-protein with the F-protein of isolate I-
2614 is found, the analysed virus isolate comprises a preferred MPV isolate according to the invention. The F ORF of MPV is located adjacent to the M ORF, which is characteristic for members of the Metapneumovirus genus. The F gene of MPV encodes a 539 aa protein, which is two aa residues longer than F of APV-C (Table 5). Analysis of the aa sequence revealed 81% homology with APV-C, 67% with APV-A and B, 33-39% with pneumovirus F proteins and only 10-18% with other paramyxoviruses (Table 6). One of the conserved features among F proteins of paramyxoviruses, and also seen in MPV is the distribution of cysteine residues
(Morrison, 1988; Yu et al., 1991). The metapneumoviruses share 12 cysteine residues in Fl (7 are conserved among all paramyxoviruses), and two in F2 (1 is conserved among all paramyxoviruses). Of the 3 potential N-hnked glycosylation sites present in the F ORF of MPV, none are shared with RSV and two (position 66 and 389) are shared with APV. The third, unique, potential N-hnked glycosylation site for MPV is located at position 206 (Figure 11). Despite the low sequence homology with other paramyxoviruses, the F protein of MPV revealed typical fusion protein characteristics consistent with those described for the F proteins of other Paramyxoviridae family members (Morrison, 1988). F proteins of Paramyxoviridae members are synthesized as inactive precursors (F0) that are cleaved by host cell proteases which generate amino terminal F2 subunits and large carboxy terminal Fl subunits. The proposed cleavage site (Collins et al., 1996) is conserved among all members of the Paramyxoviridae family. The cleavage site of MPV contains the residues RQSR. Both arginine (R) residues are shared with APV and RSN but the glutamine (Q) and serine (S) residues are shared with other paramyxoviruses such as human parainfluenza virus type 1, Sendai virus and morbilhviruses (data not shown). The hydrophobic region at the amino terminus of Fl is thought to function as the membrane fusion domain and shows high sequence similarity among paramyxoviruses and morbilhviruses and to a lesser extent the pneumoviruses (Morrison, 1988). These 26 residues (position 137-163, Figure 11) are conserved between MPV and APV-C, which is in agreement with this region being highly conserved among the metapneumoviruses (Naylor et al., 1998; Seal et al., 2000). As is seen for the F2 subunits of APV and other paramyxoviruses, MPV revealed a deletion of 22 aa residues compared with RSV (position 107-128, Figure 11). Furthermore, for RSV and APV, the signal peptide and anchor domain were found to be conserved within subtypes and displayed high variability between subtypes (Plows et al, 1995; Naylor et al, 1998). The signal peptide of MPV (aa 10- 35, Figure 11) at the amino terminus of F2 exhibits some sequence similarity with APV-C (18 out of 26 aa residues are similar) and less conservation with other APVs or RSV. Much more variability is seen in the membrane anchor domain at the carboxy terminus of Fl, although some homology is still seen with APV-C.
Another suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the M2 protein. When an overall amino acid identity of at least 85%, preferably of at least 90% of the analysed M2-protein with the M2- protein of isolate 1-2614 is found, the analysed virus isolate comprises a preferred MPV isolate according to the invention. M2 gene is unique to the Pneumovirinae and two overlapping ORFs have been observed in all pneumoviruses. The first major ORF represents the M2-1 protein which enhances the processivity of the viral polymerase (Collins et al., 1995; Collins, 1996) and its readthrough of intergenic regions (Hardy et al, 1998; Fearns et al, 1999). The M2-1 gene for MPV, located adjacent to the F gene, encodes a 187 aa protein (Table 5), and reveals the highest (84%) homology with M2-1 of APV-C (Table 6). Comparison of all pneumovirus M2-1 proteins revealed the highest conservation in the amino-terminal half of the protein (Collins et al, 1990; Zamora et al, 1992; Ahmadian et al, 1999), which is in agreement with the observation that MPV displays 100% similarity with APV-C in the first 80 aa residues of the protein (Figure 12A). The MPV M2-1 protein contains 3 cysteine residues located within the first 30 aa residues that are conserved among all pneumoviruses. Such a concentration of cysteines is frequently found in zinc-binding proteins (Ahmadian et al, 1991; Cuesta et al., 2000).
The secondary ORFs (M2-2) that overlap with the M2-1 ORFs of pneumoviruses are conserved in location but not in sequence and are thought to be involved in the control of the switch between virus RNA replication and transcription (Collins et al, 1985; Elango et al, 1985; Baybutt et al, 1987; Collins et al., 1990; Ling et al, 1992; Zamora et al, 1992; Alansari et al, 1994; Ahmadian et al, 1999; Bermingham et al, 1999). For MPV, the M2-2 ORF starts at nucleotide 512 in the M2-1 ORF (Figure 7), which is exactly the same start position as for APV-C. The length of the M2-2 ORFs are the same for APV-C and MPV, 71 aa residues (Table 5). Sequence comparison of the M2-2 ORF (Figure 12B) revealed 56% aa sequence homology between MPV and APV-C and only 26-27%aa sequence homology between MPV and APV-A and B (Table 6). Another suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the L protein. When an overall amino acid identity of at least 91%, preferably of at least 95% of the analysed L-protein with the L-protein of isolate I- 2614 is found, the analysed virus isolate comprises a preferred MPV isolate according to the invention. In analogy to other negative strand viruses, the last ORF of the MPV genome is the RNA-dependent RNA polymerase component of the rephcation and transcription complexes. The L gene of MPV encodes a 2005 aa protein, which is 1 residue longer than the APV-A protein (Table 5). The L protein of MPV shares 64% homology with APV-A, 42-44% with RSV, and approximately 13% with other paramyxoviruses (Table 6). Poch et al (1989; 1990) identified six conserved domains within the L proteins of non-segmented negative strand RNA viruses, from which domain III contained the four core polymerase motifs that are thought to be essential for polymerase function. These motifs (A, B, C and D) are well conserved in the MPV L protein: in motifs A, B and C: MPV shares 100% similarity with all pneumoviruses and in motif D MPV shares 100 % similarity with APV and 92% with RSVs. For the entire domain III (aa 625- 847 in the L ORF), MPV shares 83% identity with APV, 67- 68% with RSV and 26-30% with other paramyxoviruses (Figure 15). In addition to the polymerase motifs the pneumovirus L proteins contain a sequence which conforms to a consensus ATP binding motif K(X)2ιGEGAGN(X)2oK (Stec, 1991).The MPV L ORF contains a similar motif as APV, in which the spacing of the intermediate residues is off by one: K(x)22GEGAGN(X)ι9 K. A much preferred suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the SH protein. When an overall amino acid identity of at least 30%, preferably of at least 50%, more preferably of at least 75% of the analysed SH-protein with the SH-protein of isolate 1-2614 is found, the analysed virus isolate comprises a preferred MPV isolate according to the invention. The gene located adjacent to M2 of MPV encodes a 183 aa protein (Figure 7). Analysis of the nucleotide sequence and its deduced amino acid sequence revealed no discernible homology with other RNA virus genes or gene products. The SH ORF of MPV is the longest SH ORF known to date (Table 5). The composition of the aa residues of the SH ORF is relatively similar to that of APV, RSV and PVM, with a high percentage of threonine and serine (22%, 18%, 19%, 20.0%, 21% and 28% serine/threonine content for MPV, APV, RSV A, RSV B, bRSV and PVM respectively). The SH ORF of MPV contains 10 cysteine residues, whereas APV SH contains 16 cysteine residues. All pneumoviruses have similar numbers of potential N- lycosylation sites (MPV 2, APY 1, RSV 2, bRSV 3, PVM 4).
The hydrophobicity profiles for the MPV SH protein and SH of APV and RSV revealed similar structural characteristics (Figure 13B). The SH ORFs of APV and MPV have a hydrophylic N-terminus (aa 1-30), a central hydrophobic domain (aa 30- 53) which can serve as a potential membrane spanning domain, a second hydrophobic domain around residue 160 and a hydrophilic C-terminus. In contrast, RSV SH appears to lack the C-terminal half of the APV and MPV ORFs. In all pneumovirus SH proteins the hydrophobic domain is flanked by basic amino acids, which are also found in the SH ORF for MPV (aa 29 and 54). Another much preferred suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the G protein. When an overall amino acid identity of at least 30%, preferably of at least 50%, more preferably of at least 75% of the analysed G-protein with the G-protein of isolate 1-2614 is found, the analysed virus isolate comprises a preferred MPV isolate according to the invention. The G ORF of MPV is located adjacent to the SH gene and encodes a 236 amino acid protein. A secondary small ORF is found immediately fohowing this ORF, potentially coding for 68 aa residues (pos. 6973-7179,), but lacking a start codon. A third major ORF, in a different reading frame, of 194 aa residues (fragment 4, Figure 7) is overlapping with both of these ORFs, but also lacks a startcodon (nucleotide 6416-7000). This major ORF is followed by a fourth ORF in the same reading frame (nt 7001-7198), possibly coding for 65 aa residues but again lacking a start codon. Finally, a potential
ORF of 97 aa residues (but lacking a startcodon) is found in the third reading frame (nt 6444-6737, Figure 1). Unlike the first ORF, the other ORFs do not have apparent gene start or gene end sequences (see below). Although the 236 aa residue G ORF probably represents at least a part of the MPV attachment protein it can not be excluded that the additional coding sequences are expressed as separate proteins or as part of the attachment protein through some RNA editing event. It should be noted that for APV and RSV no secondary ORFs after the primary G ORF have been identified but that both APV and RSV have secondary ORFs within the major ORF of G. However, evidence for expression of these ORFs is lacking and there is no homology between the predicted aa sequences for different viruses (Ling et al., 1992).
The secondary ORFs in MPV G do not reveal characteristics of other G proteins and whether the additional ORFs are expressed requires further investigation. BLAST analyses with aU four ORFs revealed no discernible homology at the nucleotide or aa sequence level with other known virus genes or gene products. This is in agreement with the low sequence homologies found for other G proteins such as hRSV A and B (53%) (Johnson et al, 1987) and APV A and B (38%) (Juhasz et al, 1994). Whereas most of the MPV ORFs resemble those of APV both in length and sequence, the G ORF of MPV is considerably smaller than the G ORF of APV (Table 5). The aa sequence revealed a serine and threonine content of 34%, which is even higher than the 32% for RSV and 24% for APV. The G ORF also contains 8.5% proline residues, which is higher than the 8% for RSV and 7% for APV. The unusual abundance of prohne residues in the G proteins of APV, RSV and MPV has also been observed in glycoproteins of mucinous origin where it is a major determinant of the proteins three dimensional structure (Collins et al, 1983; Wertz et al., 1985; Jentoft, 1990).
The number of potential N-hnked glycosylation sites in G of MPV is similar to other pneumoviruses: MPV has 5, whereas hRSV has 7, bRSV has 5, and APV has 3 to 5.
The predicted hydrophobicity profile of MPV G revealed characteristics similar to the other pneumoviruses. The amino-terminus contains a hydrophylic region followed by a short hydrophobic area (aa 33-53) and a mainly hydrophihc carboxy terminus (Figure 14B). This overall organisation is consistent with that of an anchored type II transmembrane protein and corresponds well with these regions in the G protein of APV and RSV. The G ORF of MPV contains only 1 cysteine residue in contrast to RSV and APV (5 and 20 respectively).
According to classical serological analyses as for example known from Francki, R.I.B., Fauquet, CM., Knudson, D.L., and Brown, F., Classification and nomenclature of viruses. Fifth report of the international Committee on Taxonomy of Viruses. Arch Virol, 1991. Supplement 2: p. 140-144. an MPV isolate is also identifiable as belonging to a serotype as provided herein, being defined on the basis of its immunological distinctiveness, as determined by quantitative neutrahzation with animal antisera (obtained from for example ferrets or guinnea pigs as provided in the detailed description). Such a serotype has either no cross-reaction with others or shows a homologous-to heterologous titer ratio >16 in both directions. If neutrahzation shows a certain degree of cross-reaction between two viruses in either or both directions (homologous-to-heterologous tier ration of eight or 16), distinctiveness of serotype is assumed if substantial biophysical/biochemical differences of DNA's exist. If neutrahzation shows a distinct degree of cross-reaction between two viruses in either or both directions (homologous-to-heterologous tier ration of smaller than eight), identity of serotype of the isolates under study is assumed. As said, useful prototype isolates, such as isolate 1-2614, herein also known as MPV isolate 00-1, are provided herein. A further classification of a virus as an isolated essentially mammalian negative-sense single stranded RNA virus as provided herein can be made on the basis of homology to the G and/or SH proteins. Where in general the overall amino acid sequence identity between APV (isolated from birds) and MPV (isolated from humans) N, P, M, F, M2 and L ORFs was 64 to 88 percent, and nucleotide sequence homology was also found between the non-coding regions of the APV and MPV genomes, essentially no discernable amino acid sequence homology was found between two of the ORFs of the human isolate (MPV) and any of the ORFs of other paramyxoviruses. The amino acid content, hydrophobicity profiles and location of these ORFs in the viral genome show that they represent G and SH protein analogues. The sequence homology between APV and MPV, their similar genomic organization (3'-N-P-M-F-M2-SH-G-L-5') as weU as phylogenetic analyses provide further evidence for the proposed classification of MPV as the first mammahan metapneumovirus.New MPV isolates are for thus example identified as such by virus isolation and characterisation on tMK or other cells, by RT-PCR and/or sequence analysis followed by phylogenetic tree analyses, and by serologic techniques such as virus neutralisation assays, indirect immunofluorescence assays, direct immunofluorescence assays, FACs analyses or other immunological techniques. Preferably these techniques are directed at the SH and/or G protein analogues. For example the invention provides herein a method to identify further isolates of MPV as provided herein, the method comprising inoculating a essentially
MPV-uninfected or specific-pathogen-free guinea pig or ferret (in the detailed description the animal is inoculated intranasally but other ways of inoculation such as intramuscular or intradermal inoculation, and using an other experimental animal, is also feasible) with the prototype isolate 1-2614 or related isolates. Sera are collected from the animal at day zero, two weeks and three weeks post inoculation.
The animal specifically seroconverted as measured in virus neutrahsation (VN) assay and indirect IFA against the respective isolate 1-2614 and the sera from the seroconverted animal are used in the immunological detection of said further isolates. As an example, the invention provides the characterisation of a new member in the family of Paramyxoviridae, a human metapneumovirus or metapneumovirus- like virus (since its final taxonomy awaits discussion by a viral taxonomy committee the MPV is herein for example described as taxonomically corresponding to APV) (MPV) which may cause severe RTI in humans. The clinical signs of the disease caused by MPV are essentially similar to those caused by hRSV, such as cough, myalgia, vomiting, fever, broncheohtis or pneumonia, possible conjunctivitis, or combinations thereof. As is seen with hRSV infected children, especifically very young children may require hospitahsation. As an example an MPV which was deposited January 19, 2001 as 1-2614 with CNCM, Institute Pasteur, Paris or a virus isolate phylogenetically corresponding therewith is herewith provided. Therewith, the invention provides a virus comprising a nucleic acid or functional fragment phylogenetically corresponding to a nucleic acid sequence shown in figure 6a, 6b, 6c, or structurally corresponding therewith. In particular the invention provides a virus characterised in that after testing it in phylogenetic tree analyses wherein maximum likelihood trees are generated using 100 bootstraps and 3 jumbles it is found to be more closely phylogenetically corresponding to a virus isolate deposited as 1-2614 with CNCM, Paris than it is related to a virus isolate of avian pneumovirus (APV) also known as turkey rhinotracheitis virus (TRTN), the aetiological agent of avian rhinotracheitis. It is particularly useful to use an AVP-C virus isolate as outgroup in said phylogenetic tree analyses, it being the closest relative, albeit being an essentially non-mammalian virus.
We propose the new human virus to be named human metapneumovirus or metapneumovirus-like virus (MPV) based on several observations. EM analysis revealed paramyxovirus-like particles. Consistent with the classification, MPV appeared to be sensitive to treatment with chloroform. MPV is cultured optimal on tMK ceUs and is trypsine dependent. The chnical symptoms caused by MPV as well as the typical CPE and lack of haemagglutinating activity suggested that this virus is closely related to hRSV. Although most paramyxoviruses have haemaglutinating acitivity, most of the pneumoviruses do not 13-
As an example, the invention provides a not previously identified paramyxovirus from nasopharyngeal aspirate samples taken from 28 children suffering from severe RTI. The chnical symptoms of these children were largely similar to those caused by hRSV. Twenty-seven of the patients were children below the age of five years and half of these were between 1 and 12 months old. The other patient was 18 years old. AU individuals suffered from upper RTI, with symptoms ranging from cough, myalgia, vomiting and fever to broncheohtis and severe pneumonia. The majority of these patients were hospitalised for one to two weeks. The virus isolates from these patients had the paramyxovirus morphology in negative contrast electron microscopy but did not react with specific antisera against known human and animal paramyxoviruses. They were all closely related to one another as determined by indirect immunofluorescence assays (IF A) with sera raised against two of the isolates. Sequence analyses of nine of these isolates revealed that the virus is somewhat related to APV. Based on virological data, sequence homology as well as the genomic organisation we propose that the virus is a member of Metapneumovirus genus. Serological surveys showed that this virus is a relatively common pathogen since the seroprevalence in the Netherlands approaches 100% of humans by the age of five years. Moreover, the seroprevelance was found to be equally high in sera collected from humans in 1958, indicating this virus has been circulating in the human population for more than 40 years. The identification of this proposed new member of the Metapneumovirus genus now also provides for the development of means and methods for diagnostic assays or test kits and vaccines or serum or antibody compositions for viral respiratory tract infections, and for methods to test or screen for antiviral agents useful in the treatment of MPV infections. To this extent, the invention provides among others an isolated or recombinant nucleic acid or virus-specific functional fragment thereof obtainable from a virus according to the invention. In particular, the invention provides primers and/or probes suitable for identifying an MPV nucleic acid. Furthermore, the invention provides a vector comprising a nucleic acid according to the invention. To begin with, vectors such as plasmid vectors containing (parts of) the genome of MPV, virus vectors containing (parts of) the genome of MPV. (For example, but not hmited to other paramyxoviruses, vaccinia virus, retroviruses, baculovirus), or MPV containing (parts of) the genome of other viruse or other pathogens are provided. Furthermore, a number of reverse genetics techniques have been described for the generation of recombinant negative strand viruses, based on two critical parameters. First, the production of such virus relies on the replication of a partial or full-length copy of the negative sense viral RNA (vRNA) genome or a complementary copy thereof (cRNA). This vRNA or cRNA can be isolated from infectious virus, produced upon in- vitro transcription, or produced in cells upon transfection of nucleic acids. Second, the production of recombinant negative strand virus rehes on a functional polymerase complex. Typically, the polymerase complex of pneumoviruses consists of N, P, L and possibly M2 proteins, but is not necessarily hmited thereto. Polymerase complexes or components thereof can be isolated from virus particles, isolated from cells expressing one or more of the components, or produced upon transfection of specific expression vectors.
Infectious copies of MPV can be obtained when the above mentioned vRNA, cRNA, or vectors expressing these RNAs are rephcated by the above mentioned polymerase complex 16,17,18,19,20,21,22 jp or ^^ generation of minirephcons or, a reverse genetics system for generating a full-length copy comprising most or all of the genome of MPV it suffices to use 3'end and/or 5'end nucleic acid sequences obtainable from for example APV (Randhawa et al., 1997) or MPV itself. Also, the invention provides a host cell comprising a nucleic acid or a vector according to the invention. Plasmid or viral vectors containing the polymerase components of MPV (presumably N, P, L and M2, but not necessarily hmited thereto) are generated in prokaryotic cells for the expression of the components in relevant cell types (bacteria, insect cells, eukaryotic cells). Plasmid or viral vectors containing full-length or partial copies of the MPV genome will be generated in prokaryotic cells for the expression of viral nucleic acids in- vitro or in- vivo. The latter vectors may contain other viral sequences for the generation of chimeric viruses or chimeric virus proteins, may lack parts of the viral genome for the generation of replication defective virus, and may contain mutations, deletions or insertions for the generation of attenuated viruses. Infectious copies of MPV (being wild type, attenuated, replication-defective or chimeric) can be produced upon co-expression of the polymerase components according to the state-of-the-art technologies described above.
In addition, eukaryotic cells, transiently or stably expressing one or more full-length or partial MPV proteins can be used. Such cells can be made by transfection (proteins or nucleic acid vectors), infection (viral vectors) or transduction (viral vectors) and may be useful for complementation of mentioned wild type, attenuated, replication- defective or chimeric viruses.
A chimeric virus may be of particular use for the generation of recombinant vaccines protecting against two or more viruses 23> 4>26 . For example, it can be envisaged that a MPV virus vector expressing one or more proteins of RSV or a RSV vector expressing one or more proteins of MPV will protect individuals vaccinated with such vector against both virus infections. A similar approach can be envisaged for PI3 or other paramyxoviruses. Attenuated and replication-defective viruses may be of use for vaccination purposes with hve vaccines as has been suggested for other viruses 25'26 .
In a preferred embodiment, the invention provides a proteinaceous molecule or metapneumovirus-specific viral protein or functional fragment thereof encoded by a nucleic acid according to the invention. Useful proteinaceous molecules are for example derived from any of the genes or genomic fragments derivable from a virus according to the invention. Such molecules, or antigenic fragments thereof, as provided herein, are for example useful in diagnostic methods or kits and in pharmaceutical compositions such as sub-unit vaccines. Particularly useful are the F, SH and/or G protein or antigenic fragments thereof for inclusion as antigen or subunit immunogen, but inactivated whole virus can also be used. Particulary useful are also those proteinaceous substances that are encoded by recombinant nucleic acid fragments that are identified for phylogenetic analyses, of course preferred are those that are within the preferred bounds and metes of ORFs useful in phylogenetic analyses, in particular for eliciting MPV specific antibodies, whether in vivo (e.g. for protective puposes or for providing diagnostic antibodies) or in vitro (e.g. by phage display technology or another technique useful for generating synthetic antibodies).
Also provided herein are antibodies, be it natural polyclonal or monoclonal, or synthetic (e.g. (phage) library-derived binding molecules) antibodies that specificallyreact with an antigen comprising a proteinaceous molecule or MPV- specific functional fragment thereof according to the invention. Such antibodies are useful in a method for identifying a viral isolate as an MPV comprising reacting said viral isolate or a component thereof with an antibody as provided herein. This can for example be achieved by using purified or non-purified MPV or parts thereof (proteins, peptides) using ELISA, RIA, FACS or similar formats of antigen detection assays (Current Protocols in Immunology). Alternatively, infected cells or cell cultures may be used to identify viral antigens using classical immunofluorescence or immunohistochemical techniques.
Other methods for identifying a viral isolate as a MPV comprise reacting said viral isolate or a component thereof with a virus specific nucleic acid according to the invention, in particular where said mammalian virus comprises a human virus.
In this way the invention provides a viral isolate identifiable with a method according to the invention as a mammahan virus taxonomically corresponding to a negative-sense single stranded RNA virus identifiable as likely belonging to the genus Metapneumovirus within the sub-family Pneumovirinae of the family Paramyxoviridae.
The method is useful in a method for virologically diagnosing an MPV infection of a mammal, said method for example comprising determining in a sample of said mammal the presence of a viral isolate or component thereof by reacting said sample with a nucleic acid or an antibody according to the invention. Examples are further given in the detailed description, such as the use of PCR (or other amplification or hybridisation techniques well known in the art) or the use of immunofluorescence detection (or other immunological techniques known in the art)
The invention also provides a method for serologically diagnosing a MPV infection of a mammal comprising determining in a sample of said mammal the presence of an antibody specifically directed against a MPV or component thereof by reacting said sample with a proteinaceous molecule or fragment thereof or an antigen according to the invention
Methods and means provided herein are particularly useful in a diagnostic kit for diagnosing a MPV infection, be it by virological or serological diagnosis. Such kits or assays may for example comprise a virus, a nucleic acid, a proteinaceous molecule or fragment thereof, an antigen and/or an antibody according to the invention. Use of a virus, a nucleic acid, a proteinaceous molecule or fragment thereof, an antigen and/or an antibody according to the invention is also provided for the production of a pharmaceutical composition, for example for the treatment or prevention of MPV infections and/or for the treatment or prevention of respiratory tract illnesses, in particular in humans. Attenuation of the virus can be achieved by estabhshed methods developed for this purpose, including but not hmited to the use of related viruses of other species, serial passages through laboratory animals or/and tissue/cell cultures, site directed mutagenesis of molecular clones and exchange of genes or gene fragments between related viruses.
A pharmaceutical composition comprising a virus, a nucleic acid, a proteinaceous molecule or fragment thereof, an antigen and/or an antibody according to the invention can for example be used in a method for the treatment or prevention of a MPV infection and/or a respiratory illness comprising providing an individual with a pharmaceutical composition according to the invention. This is most useful when said individual comprises a human, especifically when said human is below 5 years of age, since such infants and young children are most likely to be infected by a human MPV as provided herein. Generally, in the acute phase patients will suffer from upper respiratory symptoms predisposing for other respiratory and other diseases. Also lower respiratory illnesses may occur, predisposing for more and other serious conditions. The invention also provides method to obtain an antiviral agent useful in the treatment of respiratory tract illness comprising estabhshing a cell culture or experimental animal comprising a virus according to the invention, treating said culture or animal with an candidate antiviral agent, and determining the effect of said agent on said virus or its infection of said culture or animal. An example of such an antiviral agent comprises a MPV-neutrahsing antibody, or functional component thereof, as provided herein, but antiviral agents of other nature are obtained as well.
The invention also provides use of an antiviral agent according to the invention for the preparation of a pharmaceutical composition, in particular for the preparation of a pharmaceutical composition for the treatment of respiratory tract illness, especifically when caused by an MPV infection, and provides a pharmaceutical composition comprising an antiviral agent according to the invention, useful in a method for the treatment or prevention of an MPV infection or respiratory illness, said method comprising providing an individual with such a pharmaceutical composition. The invention is further explained in the detailed description without hmiting to.
Figure legends
Figure IA comprises table 1: Percentage homology found between the amino acid sequence of isolate 00-1 and other members of the Pneumovirinae. Percentages (xlOO) are given for the amino acid sequences of N, P, M, F and two RAP-PCR fragments in L (8 and 9/10). Accession numbers used for the analyses are described in the materials and methods section.
Fig IB comprises table 2: Seroprevalence of MPV in humans categorised by age group using immunofluorescence and virus neutrahsation assays..
Fig. 2: Schematic representation of the genome of APV with the location and size of the fragments obtained with RAP-PCR and RT-PCR on virus isolate 00-1. Fragments 1 to 10 were obtained using RAP-PCR. Fragment A was obtained with a primer in RAP-PCR fragment 1 and 2 and a primer designed based on ahgnment of leader and trailer sequences of APV and RSV6. Fragment B was obtained using primers designed in RAP-PCR fragment 1 and 2 and RAP-PCR fragment 3. Fragment C was obtained with primers designed in RAP-PCR fragment 3 and RAP-PCR fragment 4,5,6 and 7.
For all phylogenetic trees, (figures 3-5) DNA sequences were aligned using the
ClustalW software package and maximum likelihood trees were generated using the DNA-ML software package of the Phyhp 3.5 program using 100 bootstraps and 3 jumbles1 . Previously pubhshed sequences that were used for the generation of phylogenetic trees are available from Genbank under accessions numbers : For aU ORFs: hRSV: NC001781; bRSV: NC001989; For the F ORF: PVM, D11128; APV-A, D00850; APV-B, Y14292; APV-C, AF187152; For the N ORF: PVM, D10331; APV-A, U39295; APV-B, U39296; APV-C, AF176590; For the M ORF: PMV,U66893; APV-A, X58639; APV-B, U37586; APV-C, AF262571; For the P ORF: PVM, 09649; APV-A, U22110, APV-C, AF176591. Phylogenetic analyses for the nine different virus isolates of MPV were performed with APV strain C as outgroup.
Abbreviations used in figures: hRSV: human RSV; bRSV: bovine RSV; PVM: pneumonia virus of mice; APV-A,B,and C: avian pneumovirus typa A, B and C. Fig. 3 Comparison of the N, P, M and F ORF's of members of the subfamily Pneumovirinae and virus isolate 00-1. The ahgnment shows the amino acid sequence of the complete N, P, M and F proteins and partial L proteins of virus isolate 00-1.
Amino acids that differ between isolate 00-1 and the other viruses are shown, identical amino acids are represented by periods, gaps are represented as dashes.
Numbers correspond to amino acid positions in the proteins. Accession numbers used for the analyses are described in the materials and methods section. APV-A, B or C:
Avian Pneumovirus type A, B or C, b-or hRSV: bovine or human respiratory syncytial virus, PVM: pneumonia virus of mice. L8: fragment 8 obtained with RAP-PCR located in L, L9/10: consensus of fragment 9 and 10 obtained with RAP-PCR, located in L.
For the P allignment, no APV-B sequence was available from the Genebank, For the L allignment only bRSV, hRSV and APV-A sequences were available.
Fig. 4: Phylogenetic analyses of the N, P, M, and F ORF's of members of the genus Pneumovirinae and virus isolate 00-1. Phylogenetic analysis was performed on viral sequences from the fohowing genes: F (panel A), N (panel B), M (panel C), and P (panel D). The phylogenetic trees are based on maximum likelyhood analyses using 100 bootstraps and 3 jumbles. The scale representing the number of nucleotide changes is shown for each tree.
Fig. 5: Phylogenetic relationship for parts of the F (panel A), N (panel B), M (panel C) and L (panel D) ORFs of nine of the primary MPV isolates with APV-C, it's closest relative genetically. The phylogenetic trees are based on maximum likelyhood analyses. The scale representing the number of nucleotide changes is shown for each tree. Accesion numbers for APV-C: panel A: D00850; panel B: U39295; panel C: X58639; and panel D: U65312.
Fig. 6A: Nucleotide and amino acid sequence information from the 3'end of the genome of MPV isolate 00-l.ORF's are given. N: ORF for nucleoprotein; P: ORF for phosphoprotein; M: ORF for matrix protein; F: ORF for fusion protein; GE: gene end; GS: gene start.
Fig. 6B and C: Nucleotide and amino acid sequence information from obtained fragments in the polymerase gene (L) of MPV isolates 00-1. Positioning of the fragments in L is based on protein homologies with APV-C (accession number U65312). The translated fragment 8 (Fig. 6B.) is located at amino acid number 8 to 243, and the consensus of fragments 9 and 10 (Fig. 6C) is located at amino acid number 1358 to 1464 of the APV-C L ORF.
Figure 7
Genomic map of MPV isolate 00-1. The nucleotide positions of the start and stop codons are indicated under each ORF.. The double hnes which cross the L ORF indicate the shortened representation of the L gene. The three reading frames below the map indicate the primary G ORF (nt 6262-6972) and overlapping potential secondary ORFs.
Figure 8: Ahgnment of the predicted amino acid sequence of the nucleoprotein of MPV with those of other pneumoviruses. The conserved regions identified by Barr (1991) are represented by boxes and labeUed A, B, and C. The conserved region among pneumoviruses (Li, 1996) is shown gray shaded. Gaps are represented by dashes, periods indicate the positions of identical amino acid residues compared to MPV.
Figure 9:
Amino acid sequence comparison of the phosphoprotein of MPV with those of other pneumoviruses. The region of high similarity (Ling, 1995) is boxed, and the glutamate rich region is grey shaded. Gaps are represented by dashes and periods indicate the position of identical amino acid residues compared to MPV. Figure 10:
Comparison of the deduced amino acid sequence of the matrix protein of MPV with those of other pneumoviruses. The conserved hexapeptidesequence (Easton, 1997) is grey shaded. Gaps are represented by dashes and periods indicate the position of identical amino acid residues relative to MPV.
Figure 11:
Allignment of the predicted amino acid sequence of the fusion protein of MPV with those of other pneumoviruses. The conserved cysteine residues are boxed, N-hnked glycosylation sites are underhned, the cleavage site of FO is double underhned, the fusion peptide, signal peptide and membrane anchor domain are shown grey shaded. Gaps are represented by dashes and periods indicate the position of identical amino acids relative to MPV.
Figure 12
Comparison of amino acid sequence of the M2 ORFs of MPV with those of other pneumoviruses. The ahgnment of M2-1 ORFs is shown in panel A, with the conserved amino terminus (Collins, 1990; Zamora, 1999) shown grey shaded. The three conserved cysteine residues are printed bold face and indicated by #. The ahgnment of M2-2 ORFs is shown in panel B. Gaps are represented by dashes and periods indicate the position of identical amino acids relative to MPV.
Figure 13
Amino acid sequence analyses of the SH ORF of MPV. (A) Amino acid sequence of the SH ORFof MPV, with the serine and threonine residues grey shaded, cysteine residues in bold face and the hydrophobic region double underhned. Potential N- hnked glycosylation sites are single underhned. Numbers indicate the positions of the basic amino acids flanking the hydrophobic domain. (B) Ahgnment of the hydrophobicity plots of the SH proteins of MPV, APV-A and hRSV-B. The procedure of Kyte and Doohttle (1982) was used with a window of 17 amino acids. Arrows indicate a strong hydrophobic domain. Positions within the ORF are given on the X-axis. Figure 14
Amino acid sequence analyses of the G ORF of MPV. (A) Amino acid sequence of the G
ORF of MPV, with serine, threonine and prohne residues grey shaded, the cysteine residue is in bold face and the hydrophobic region double underhned. The potential N- hnked glycosylation sites are single underhned. (B) Alingment of the hydrophobicity plots of the G proteins of MPV, APV-A and hRSV-B. The procedure of Kyte and Doohttle
(1982) was used with a window of 17 amino acids. Arrows indicate the hydrophobic region, and positions within the ORF are given at the X-axis.
Figure 15
Comparison of the amino acid sequences of a conserved domain of the polymerase gene of MPV and other paramyxoviruses. Domain III is shown with the four conserved polymerase motifs (A, B, C, D) in domain III (Poch 1998, 1999) boxed. Gaps are represented by dashes and periods indicate the position of identical amino acid residues relative to MPV. hPIV3: human parainfluenza virus type 3; SV: sendai virus; hPIV-2: human parainfluenza virus type 2; ΝDV: New castle disease virus; MV: measles virus;; nipah: Nipah virus.
Figure 16: Phylogenetic analyses of the M2-1 and L ORFs of MPV and selected paramyxoviruses. The M2-1 ORF was ahgned with the M2-1 ORFs of other members of the genus Pneumovirinae (A) and the L ORF was ahgned with L ORFs members of the genus pneumovirinae and selected other paramyxoviruses as described in the legends of figure 15 (B). Phylogenetic trees were generated by maximum likelihood analyses using 100 bootstraps and 3 jumbles. The scale representing the number of nucleotide changes is shown for each tree. Numbers in the trees represent bootstrap values based on the consensus trees.
Figure 17: Noncoding sequences of hMPV isolate 00-1. (A) The noncoding sequences between the ORFs and at the genomic termini are shown in the positive sense. From left to right, stop codons of indicated ORFs are shown, followed by the noncoding sequences, the gene start signals and start codons of the indicated subsequent ORFs. Numbers indicate the first position of start and stop codons in the hMPV map. Sequences that display similarity to pubhshed gene end signals are underhned and sequences that display similarity to UAAAAAU/A/C are represented with a hne above the sequence.
(B) Nucleotide sequences of the genomic termini of hMPV. The genomic termini of hMPV are ahgned with each other and with those of APV. Underhned regions represent the primer sequences used in RT-PCR assays which are based on the 3' and
5' end sequences of APV and RSV (Randhawa et al, 1997; Mink et al, 1991). Bold itahcahzed nucleotides are part of the gene start signal of the N gene. Le: leader, Tr: trailer.
Figure 18:
Comparison of two prototypic hMPV isolates with APV-A and APV-C; DNA similarity matrices for nucleic acids encoding the various viral proteins.
Figure 19: Comparison of two prototypic hMPV isolates with APV-A and APV-C; protein similarity matrices for the various viral proteins.
Figure 20:
Amino acid ahgnment of the nucleoprotein of two prototype hMPV'isolates
Figure 21:
Amino acid ahgnment of the phosphoprotein of two prototype hMPV isolates
Figure 22: Amino acid ahgnment of the matrix protein of two prototype hMPV isolates
Figure 23:
Amino acid ahgnment of the fusion protein of two prototype hMPV isolates
Figure 24:
Amino acid ahgnment of the M2-1 protein of two prototype hMPV isolates
Figure 25:
Amino acid ahgnment of the M2-2 protein of two prototype hMPV isolates Figure 26:
Amino acid ahgnment of the short hydrophobic protein of two prototype hMPV isolates
Figure 27:
Amino acid ahgnment of the attachement glycoprotein of two prototype hMPV isolates
Figure 28:
Amino acid ahgnment of the N-terminus of the polymerase protein of two prototype hMPV isolates
Figure 29: Results of RT-PCR assays on throat and nose swabs of 12 guinea pigs inoculated with ned/00/01 and/or ned/99/01.
Figure 30A: IgG response against ned/00/01 and ned/99/01 for guinea pigs infected with ned/00/01 and re-infected with ned 00/01 (GP 4, 5 and 6) or ned/99/01 (GP 1 and 3).
Figure 30B: IgG response against ned/00/01 and ned/99/01 for guinea pigs infected with ned 99/01 and re-infected with either ned 00/01 (GP's 8 and 9) or with ned/99/01 (GP's 10, 11, 12).
Figure 31: Specificity of the ned/00/01 and ned/99/01 ELISA on sera taken from guinea pigs infected with either ned/00/01 or ned/99/01.
Figure 32: Mean IgG response against ned/00/01 and ned/99/01 ELISA of 3 homologous (00-1/00-1), 2 homologous (99-1/99-1), 2 heterologous (99-1/00-1) and 2 heterologous (00-1/99-1) infected guinea pigs.
Figure 33: Mean percentage of APV inhibition of hMPV infected guinea pigs. Figure 34: Virus neutrahsation titers of ήed/00/01 and ned/99/01 infected guinea pigs against ned/00/01, ned/99/01 and APV-C.
Figure 35: Results of RT-PCR assays on throat swabs of cynomolgous macaques inoculated (twice) with ned/00/01.
Figure 36 A (top two panels):
IgA, IgM and IgG response against ned/00/01 of 2 cynomologous macaques (re)infected with ned/00/01.
Figure 36B (bottom panels)
IgG response against APV of 2 cynbomologous macaques infected with ned/00/01.
Figure 37: Comparison of the use of the hMPV ELISA and the APV inhibition ELISA for the detection of IgG antibodies in human sera.
Detailed description
Virus isolation and characterisation
From 1980 till 2000 we found 28 unidentified virus isolates from patients with severe respiratory disease. These 28 unidentified virus isolates grew slowly in tMK cells, poorly in VERO cells and A549 cells and could not or only httle be propagated in MDCK or chicken embryonated fibroblast cells. Most of these virus isolates induced CPE after three passages on tMK cells, between day ten and fourteen. The CPE was virtually indistinguishable from that caused by hRSV or hPIV in tMK or other cell cultures, characterised by syncytium formation after which the cells showed rapid internal disruption, followed by detachment of the cells from the monolayer. The ceUs usually (sometimes later) displayed CPE after three passages of virus from original material, at day 10 to 14 post inoculation, somewhat later than CPE caused by other viruses such as hRSV or hPIV. We used the supernatants of infected tMK cells for EM analysis which revealed the presence of paramyxovirus-like virus particles ranging from 150 to 600 nanometer, with short envelope projections ranging from 13 to 17 nanaometer. Consistent with the biochemical properties of enveloped viruses such as the Paramyxoviridae, standard chloroform or ether treatment8 resulted in >104 TCID50 reduction of infectivity for tMK cells. Virus-infected tMK ceh culture supernatants did not display heamagglutinating activity with turkey, chicken and guinea pig erythrocytes. During culture, the virus rephcation appeared to be trypsine dependent on the cells tested. These combined virological data aUowed that the newly identified virus was taxonomically classified as a member of the Paramyxoviridae family. We isolated RNA from tMK cells infected with 15 of the unidentified virus isolates for reverse transcription and polymerase chain reaction (RT-PCR) analyses using primer-sets specific for Paramyxovirinae9, hETV 1-4, sendai virus, simian virus type 5, New-Castle disease virus, hRSV, morbilh, mumps, Nipah, Hendra, Tupaia and Mapuera viruses. RT-PCR assays were carried out at low stringency in order to detect potentially related viruses and RNA isolated from homologous virus stocks were used as controls. Whereas the available controls reacted positive with the respective virus-specific primers, the newly identified virus isolates did not react with any primer set, indicating the virus was not closely related to the viruses tested. We used two of the virus-infected tMK ceh culture supernatants to inoculate guinea pigs and ferrets intranasaly. Sera were collected from these animals at day zero, two weeks and three weeks post inoculation. The animals displayed no chnical symptoms but aU seroconverted as measured in virus neutrahsation (VN) assays and indirect IFA against the homologous viruses. The sera did not react in indirect IFA with any of the known paramyxoviruses described above and with PVM. Next, we screened the so far unidentified virus isolates using the guinea pig and ferret pre- and post-infection sera, of which 28 were clearly positive by indirect IFA with the post-infection sera suggesting they were serological closely related or identical.
RAP PCR
To obtain sequence information on the unknown virus isolates, we used a random PCR amplification strategy known as RAP-PCR10. To this end, tMK cells were infected with one of the virus isolates (isolate 00-1) as weU as with hPIV-1 which served as a control. After both cultures displayed similar levels of CPE, virus in the culture supernatants was purified on continuous 20-60% sucrose gradients. The gradient fractions were inspected for virus-like particles by EM, and RNA was isolated from the fraction containing approximately 50% sucrose, in which nucleocapsids were observed. Equivalent amounts of RNA isolated from both virus fractions were used for RAP-PCR, after which samples were run side by side on a 3% NuSieve agarose gel. Twenty differentially displayed bands specific for the unidentified virus were subsequently purified from the gel, cloned in plasmid pCR2.1 (Invitrogen) and sequenced with vector-specific primers. When we used these sequences to search for homologies against sequences in the Genbank database using the BLAST software (www.ncbi.nlm.nih.gov/BLAST/) 10 out of 20 fragments displayed resemblance to APV/TRTV sequences.
These 10 fragments were located in the genes coding for the nucleoprotein (N; fragment 1 and 2), the matrix protein (M; fragment 3), the fusion protein (F; fragment 4, 5, 6, 7,) and the polymerase protein (L; fragment 8,9,10) (Fig.2). We next designed PCR primers to complete the sequence information for the 3' end of the viral genome based on our RAP PCR fragments as well as published leader and trailer sequences for the Pneumovirinae 6. Three fragments were amplified, of wliich fragment A spanned the extreme 3' end of the N open reading frame (ORF), fragment B spanned the phosphoprotein (P) ORF and fragment C closed the gap between the M and F ORFs (Fig. 2). Sequence analyses of these three fragments revealed the absence of NS1 and NS2 ORFs at the extreme 3' end of the viral genome and positioning of the F ORF immediately adjacent to the M ORF. This genomic organisation resembles that of the metapneumovirus APV, which is also consistent with the sequence homology. OveraU the translated sequences for the N, P, M and F
ORFs showed an average of 30-33% homology with members of the genus
Pneumovirus and 66-68% with members of the genus Metapneumovirus. For the SH and G ORF's no discernable homology was found with members of either of the genera. The amino acid homologies found for N showed about 40% homology with hRSV and 88% with APV-C, its closest relative geneticahy, as for example can be deduced by comparing the amino acid sequence of figure 3 with the amino acid sequence of the respective N proteins of other viruses. The amino acid sequence for P showed about 25% homology with hRSV and about 66-68% with APV-C, M showed about 36-39% with hRSV and about 87-89% with APV-C, F showed about 40% homology with hRSV and about 81% with APV-C, M2- 1 showed about 34-36% homology with pneumoviruses and 84-86 % with APV-C, M2-2 showed 15-17% homology with pneumoviruses and 56% with APV-C and the fragments obtained in L showed an average of 44% with pneumoviruses and 64% with APV-C .
Phylogeny
Although BLAST searches using nucleotide sequences obtained from the unidentified virus isolate revealed homologies primarily with members of the Pneumovirinae, homologies based on protein sequences revealed some resemblance with other paramyxoviruses as weU (data not shown). As an indication for the relation between the newly identified virus isolate and members of the
Pneumovirinae, phylogenetic trees were constructed based on the N, P, M and F ORFs of these viruses. In aU four phylogenetic trees, the newly identified virus isolate was most closely related to APV (Fig.4). From the four serotypes of APV that have been described11, APV serotype C, the metapneumovirus found primarily in birds in the USA, showed the closest resemblance to the newly identified virus. It should be noted however, that only partial sequence information for APV serotype D is available.
To determine the relationship of our various newly identified virus isolates, we constructed phylogenetic trees based on sequence information obtained from eight to nine isolates (8 for F, 9 for N, M and L). To this end, we used RT-PCR with primers designed to amplify short fragments in the N, M, F and L ORFs, that were subsequently sequenced directly. The nine virus isolates that were previously found to be related in serological terms (see above) were also found to be closely related genetically. In fact, all nine isolates were more closely related to one another than to
APV. Although the sequence information used for these phylogenetic trees was hmited, it appears that the nine isolates can be divided in two groups, with isolate
94-1, 99-1 and 99-2 clustering in one group and the other six isolates (94-2; 93-1; 93-2;
93-3; 93-4; 00-1) in the other (Fig.5).
Seroprevalence
To study the seroprevalence of this virus in the human population, we tested sera from humans in different age categories by indirect IFA using tMK cells infected with one of the unidentified virus isolates. This analysis revealed that 25% of the children between six and twelve months had antibodies to the virus, and by the age of five nearly 100% of the children were seropositive. In total 56 serum samples tested by indirect IFA were tested by VN assay. For 51 (91%) of the samples the results of the VN assay (titre >8) coincided with the results obtained with indirect IFA (titre>32). Four samples that were found positive in IFA, were negative by VN test (titre <8) whereas one serum reacted negative in IFA (titre<32) and positive in the VN test (titre 16) (table 2).
IFA conducted with 72 sera taken from humans in 1958 (ages ranging from 8-99 years)12'27 revealed a 100% seroprevalence, indicating the virus has been circulating in the human population for more than 40 years. In addition a number of these sera were used in VN assays to confirm the IFA data (table 2).
Genetic analyses of the N, M, P and F genes revealed that MPV has higher sequence homology to the recently proposed genus Metapneumovirinae (average of 63 %) as compared to the genus Pneumovirinae (average of 30 %) and thus demonstrates a genomic organisation similar to and resembhng that of APV/TRTV. In contrast to the genomic organisation of the RSVs ('3-NS1-NS2-N-P-M-SH-G-F-M2-L-5'), metapneumoviruses lack NSl and NS2 genes and have a different positioning of the genes between M and L ('3-N-P-M-F-M2-SH-G-L-5'). The lack of ORFs between the M and F genes in our virus isolates and the lack of NSl and NS2 adjacent to to N, and the high amino acid sequence homology found with APV are reasons to propose the classification of MPV isolated from humans as a first member of the
Metapneumovirus genus of mammalian, in particular of human origin.
Phylogenetic analyses revealed that the nine MPV isolates from which sequence information was obtained are closely related. Although sequence information was hmited, they were in fact more closely related to one another than to any of the avian metapneumoviruses. Of the four serotypes of APV that have been described, serotype C was most closely related to MPV based on the N, P, M and F genes. It should be noted however that for serotype D only partial sequences for the F gene were available from Genbank and for serotype B only M, N and F sequences were available. Our MPV isolates formed two clusters in phylogenetic trees. For both hRSV and APV different genetic and serological subtypes have been described. Whether the two genetic clusters of MPV isolates represent serogical subgroups that are also functionally different remains unknown at presentOur serological surveys showed that MPV is a common human pathogen. The repeated isolation of this virus from clinical samples from children with severe RTI indicates that the chnical and economical impact of MPV may be high. New diagnostic assays based on virus detection and serology will allow a more detailed analysis of the incidence and chnical and economical impact of this viral pathogen. The shght differences between the IFA and VN results (5 samples) maybe due to the fact that in the IFA only IgG serum antibodies were detected whereas the VN assay detects both classes and sub-classes of antibodies or differences may be due to the differences in sensitivity between both assays. For IFA a cut off value of 16 is used, whereas for VN a cut off value of 8 is used. On the other hand, differences between IFA versus VN assay may also indicate possible differences between different serotypes of this newly identified virus. Since MPV seems most closely related to APV, we speculate that the human virus may have originated from birds. Analysis of serum samples taken from humans in 1958 revealed that MPV has been widespread in the human population for more then 40 years indicating that a tentative zoonosis event must have taken place long before
1958. Materials and Methods
Specimen collection
Over the past decades our laboratory has coUected nasopharyngeal aspirates from children suffering from RTI, which are routinely tested for the presence of viruses. Ah nasopharyngeal aspirates were tested by direct immmunofluorescence assays (DIF) using fluorescence labeUed antibodies against influenza virus types A, and B, hRSV and human parainfluenza virus (hPrV) types 1 to 3. The nasopharyngeal aspirates were also processed for virus isolation using rapid sheU vial techniques14 on various cellhnes including VERO ceUs, tertiary cynomolgous monkey kidney (tMK) ceUs, human endothelial lung (HEL) ceUs and marbin dock kidney (MDCK) ceUs. Samples showing cytophatic effects (CPE) after two to three passages, and which were negative in DIF, were tested by indirect immunofluorescence assays (IFA) using virus specific antibodies against influenza virus types A, B and C, hRSV types A and B, measles virus, mumps virus, human parainfluenza virus (hPIV) types 1 to 4, sendai virus, simian virus type 5, and New-Castle disease virus. Although for many cases the aetiological agent could be identified, some specimens were negative for aU these viruses tested.
Direct Immunofluorescence Assay (DIF)
Nasopharyngeal aspirate samples from patients suffering from RTI were used for DIF and virus isolation as described14-15. Samples were stored at -70 °C. In brief, nasopharyngeal aspirates were diluted with 5 ml Dulbecco MEM (BioWhittaker, Walkersville, MD) and thoroughly mixed on a vortex mixer for one minute. The suspension was thus centrifuged for ten minutes at 840 x g. The sediment was spread on a multispot shde (Nutacon, Leimuiden, The Netherlands), the supernatant was used for virus isolation. After drying, the ceUs were fixed in aceton for 1 minute at room temperature. After washing the shdes were incubated for 15 minutes at 37 °C with commercial available FITC-labehed virus specific anti-sera such as influenza A and B, hRSV and hPTV 1 to 3 (Dako, Glostrup, Denmark). After three washings in PBS and one in tap water, the shdes were included in a glycerol/PBS solution (Citifluor, UKC, Canterbury, UK) and covered. The shdes were analysed using a Axioscop fluorescence microscope (Carl Zeiss B.V, Weesp, the Netherlands. Virus isolation
For virus isolation tMK ceUs (RIVM, BUthoven, The Netherlands) were cultured in 24 weU plates containing glass shdes (Costar, Cambridge, UK), with the medium described below supplemented with 10% fetal bovine serum (BioWhittaker, Vervier, Belgium). Before inoculation the plates were washed with PBS and supplied with Eagle's MEM with Hanks' salt (ICN, Costa mesa, CA) of which half a litre was supplemented with 0.26 gram HaHC03 , 0.025 M Hepes (Biowhittaker), 2 mM L- glutamine (Biowhittaker), 100 units penicilhne, 100 μg streptomycine (Biowhittaker), 0.5 gram lactalbumine (Sigma-Aldrich, Zwijndrecht, The Netherlands), 1.0 gram D- glucose (Merck, Amsterdam, The Netherlands), 5.0 gram peptone (Oxoid, Haarlem, The Netherlands) and 0.02% trypsine (Life Technologies, Bethesda, MD). The plates were inoculated with supernatant of the nasopharyngeal aspirate samples, 0,2 ml per weU in triphcate, foUowed by centrifuging at 840x g for one hour. After inoculation the plates were incubated at 37 °C for a maximum of 14 days changing the medium once a week and cultures were checked daily for CPE. After 14 days ceUs were scraped from the second passage and incubated 14 days. This step was repeated for the third passage. The glass shdes were used to demonstrate the presence of the virus by indirect IFA as described below.
Animal immunisation
Ferret and guinea pig specific antisera for the newly discovered virus were generated by experimental intranasal infection of two specific pathogen free ferrets and two guinea pigs, housed in separate pressurised glove boxes. Two to three weeks later aU the animals were bled by cardiac puncture, and their sera were used as reference sera. The sera were tested for aU previous described viruses with indirect IFA as described below.
Antigen detection by indirect IFA We performed indirect IFA on shdes containing infected tMK ceUs. After washing with PBS the shdes were incubated for 30 minutes at 37 °C with virus specific antisera. We used monoclonal antibodies in DIF against influenza A, B and C, hPIV type 1 to 3 and hRSV as described above. For hPIV type 4, mumps virus, measles virus, sendai virus, simian virus type 5, New-Castle Disease virus polyclonal antibodies (RIVM) and ferret and guinea pig reference sera were used. After three washings with PBS and one wash with tap water, the shdes were stained with a secondary antibodies directed against the sera used in the first incubation. Secondary antibodies for the polyclonal anti sera were goat-anti-ferret (KPL, GuUford, UK, 40 fold diluted), mouse-anti-rabbit (Dako, Glostrup, Denmark, 20 fold diluted), rabbit- anti-chicken (KPL, 20 fold dilution) and mouse-anti-guinea pig (Dako, 20 fold diluted). Shdes were processed as described for DIF.
Detection of antibodies in humans by indirect IFA For the detection of virus specific antibodies, infected tMK ceUs were fixed with cold acetone on covershps, washed with PBS and stained with serum samples at a 1 to 16 dilution. Subsequently, samples were stained with FITC-labeUed rabbit anti human antibodies 80 times diluted in PBS (Dako). Shdes were processed as described above.
Virus culture of MPV
Sub-confluent mono-layers of tMK ceUs in media as described above were inoculated with supernatants of samples that displayed CPE after two or three passages in the 24 weU plates. Cultures were checked for CPE daUy and the media was changed once a week. Since CPE differed for each isolate, aU cultures were tested at day 12 to 14 with indirect IFA using ferret antibodies against the new virus isolate. Positive cultures were freeze-thawed three times, after which the supernatants were clarified by low-speed centrifugation, aliquoted and stored frozen at -70 °C. The 50% tissue culture infectious doses (TCID50) of virus in the culture supernatants were determined as described16.
Virus neutralisation assay
VN assays were performed with serial two-fold dilutions of human and animal sera starting at an eight-fold dilution. Diluted sera were incubated for one hour with 100 TCID50 of virus before inoculation of tMK ceUs grown in 96 weU plates, after which the plates were centrifuged at 840 x g. The media was changed after three and six days and IFA was conducted with ferret antibodies against MPV 8 days after inoculation. The VN titre was defined as the lowest dilution of the serum sample resulting in negative IFA and inhibition of CPE in ceU cultures. Virus characterisation
Haemagglutination assays and chloroform sensitivity tests were performed as described8-14. For EM analyses, virus was concentrated from infected ceU culture supernatants in a micro-centrifuge at 4 °C at 17000 x g, after which the peUet was resuspended in PBS and inspected by negative contrast EM. For RAP-PCR, virus was concentrated from infected tMK ceU supernatants by ultra-centrifugation on a 60% sucrose cussion (2 hours at 150000 x g, 4 °C). The 60% sucrose interphase was subsequently diluted with PBS and layered on top of a 20-60% continuous sucrose gradient which was centrifuged for 16 hours at 275000 x g at 4 °C. Sucrose gradient fractions were inspected for the presence of virus-like particles by EM and poly- acrylamide gel electrophoresis foUowed by sflver staining. The approximately 50% sucrose fractions that appeared to contain nucleocapsids were used for RNA isolation and RAP-PCR.
RNA isolation
RNA was isolated from the supernatant of infected ceU cultures or sucrose gradient fractions using a High Pure RNA Isolation kit according to instructions from the manufacturer (Roche Diagnostics, Almere, The Netherlands).
RT-PCR
Virus-specific ohgonucleotide sequences for RT-PCR assays on known paramyxoviruses are described in addenda 1. A one-step RT-PCR was performed in 50 μl reactions containing 50 mM Tris.HCl pH 8.5, 50 mM NaCl, 4 mM MgCl2, 2 mM dithiotreitol, 200 μM each dNTP, 10 units recombinant RNAsin (Promega, Leiden, the Netherlands), 10 units AMV RT (Promega, Leiden, The Netherlands), 5 units Amplitaq Gold DNA polymerase (PE Biosystems, Nieuwerkerk aan de Ijssel, The Netherlands) and 5 μl RNA. Cychng conditions were 45 min. at 42 °C and 7 min. at 95 °C once, 1 min at 95 °C, 2 min. at 42 °C and 3 min. at 72 °C repeated 40 times and 10 min. at 72 °C once.
RAP-PCR
RAP-PCR was performed essentiaUy as described10. The ohgonucleotide sequences are described in addenda 2. For the RT reaction, 2 μl RNA was used in a 10 μl reaction containing 10 ng/μl ohgonucleotide, 10 mM dithiotreitol, 500 μm each dNTP,
25 mM Tris-HCl pH 8.3, 75 mM KC1 and 3 mM MgCL. The reaction mixture was incubated for 5 min. at 70 °C and 5 min. at 37 °C, after which 200 units Superscript
RT enzyme (LifeTechnologies) were added. The incubation at 37 °C was continued for 55 min. and the reaction terminated by a 5 min. incubation at 72 °C. The RT mixture was diluted to give a 50 μl PCR reaction containing 8 ng/μl ohgonucleotide, 300 μm each dNTP, 15 mM Tris-HCL pH 8.3, 65 mM KC1, 3.0 mM MgCL2 and 5 units Taq
DNA polymerase (PE Biosystems). Cychng conditions were 5 min. at 94 °C, 5 min. at
40 °C and 1 min. at 72 °C once, foUowed by 1 min. at 94 °C, 2 min. at 56 °C and 1 min. at 72 °C repeated 40 times and 5 min. at 72°C once. After RAP-PCR, 15 μl the RT-PCR products were run side by side on a 3% NuSieve agarose gel (FMC BioProducts, Heerhugowaard, The Netherlands). DifferentiaUy displayed fragments specific for MPV were purified from the gel with Qiaquick Gel Extraction kit (Qiagen, Leusden, The Netherlands) and cloned in pCR2.1 vector (Invitrogen, Groningen, The Netherlands) according to instructions from the manufacterer.
Sequence analysis
RAP-PCR products cloned in vector pCR2.1 (Invitrogen) were sequenced with M13- specific ohgonucleotides. DNA fragments obtained by RT-PCR were purified from agarose gels using Qiaquick Gel Extraction kit (Qiagen, Leusden, The Netherlands), and sequenced directly with the same ohgonucleotides used for PCR. Sequence analyses were performed using a Dyenamic ET terminator sequencing kit (Amersham Pharmacia Biotech, Roosendaal, The Netherlands) and an ABI 373 automatic DNA sequencer (PE Biosystem). AU techniques were performed according to the instructions of the manufacturer.
Generating genomic fragments of MPV by RT-PCR
To generate PCR fragments spanning gaps A, B and C between the RAP-PCR fragments (Fig.2) we used RT-PCR assays as described before on RNA isolated from virus isolate 00-1. The fohowing primers were used: For fragment A: TR1 designed in the leader: (5'-
AAAGAATTCACGAGAAAAAAACGC-3') and Nl designed at the 3'end of the RAP- PCR fragments obtained in N (5'-CTGTGGTCTCTAGTCCCACTTC-3') For fragment B: N2 designed at the 5'end of the RAP-PCR fragments obtained in N: (5'-CATGCAAGCTTATGGGGC-3') and Ml designed at the 3'end of the RAP-PCR fragments obtained in M: (5'-CAGAGTGGTTATTGTCAGGGT-3'). For fragment C: M2 designed at the 5'end of the RAP-PCR fragment obtained in M: (5'-GTAGAACTAGGAGCATATG-3') and Fl designed at the 3'end of the RAP-PCR fragments obtained in F: (5'-TCCCCAATGTAGATACTGCTTC-3'). Fragments were purified from the gel, cloned and sequenced as described before.
RT-PCR for diagnosing MPV.
For the amplification and sequencing of parts of the N, M, F and L ORFs of nine of the MPV isolates, we used primers N3 (5'-GCACTCAAGAGATACCCTAG -3') and N4 (5'-AGACTTTCTGCTTTGCTGCCTG-3'), amphfying a 151 nucleotide fragments, M3 (5'-CCCTGACAATAACCACTCTG-3') and M4 (δ'-GCCAACTGATTTGGCTGAGCTC- 3') amphfying a 252 nucleotide fragment, F7 (5'- TGCACTATCTCCTCTTGGGGCTTTG-3') and F8 (5'- TCAAAGCTGCTTGACACTGGCC-3') amplifying a 221 nucleotide fragment and L6 (5'-CATGCCCACTATAAAAGGTCAG-3') and L7 (5'-CACCCCAGTCTTTCTTGAAA-3') amphfying a 173 nucleotide fragment respectively. RT-PCR, gel purification and direct sequencing were performed as described above. Furthermore, probes used were:
Probe used in M: 5'-TGC TTG TAC TTC CCA AAG-3' Probe used in N: 5'-TAT TTG AAC AAA AAG TGT-3' Probe used in L: 5'-TGGTGTGGGATATTAACAG-3' Phylogenetic analyses
For aU phylogenetic trees, DNA sequences were aUigned using the ClustalW software package and maximum likelihood trees were generated using the DNA-ML software package of the Phyhp 3.5 program using 100 bootstraps and 3 jumbles15. Previously pubhshed sequences that were used for the generation of phylogenetic trees are avaflable from Genbank under accessions numbers : For aU ORFs: hRSV: NC001781; bRSV: NC001989; For the F ORF: PVM, D11128; APV-A, D00850; APV-B, Y14292; APV-C, AF187152; For the N ORF: PVM, D10331; APV-A, U39295; APV-B, U39296; APV-C, AF176590; For the M ORF: PMV,U66893; APV-A, X58639; APV-B, U37586; APV-C, AF262571; For the P ORF: PVM, 09649; APV-A, U22110, APV-C, AF176591. Phylogenetic analyses for the nine different virus isolates of MPV were performed with APV strain C as outgroup.
Abbreviations used in figures: hRSV: human RSV; bRSV: bovine RSV; PVM: pneumonia virus of mice; APV-A, B,and C: avian pneumovirus typ A, B and C.
Examples of methods to identify MPV
Specimen collection
In order to find virus isolates nasopharyngeal aspirates, throat and nasal swabs, broncheo alveolar lavages preferably from mammals such as humans, carnivores (dogs, cats, musteUits, seals etc.), horses, ruminants (cattle, sheep, goats etc.), pigs, rabbits, birds (poultry, ostriches, etc) should be examined. From birds cloaca swabs and droppings can be examined as weU. Sera should be coUected for immunological assays, such as ELISA and virus neutrahsation assays. CoUected virus specimens were diluted with 5 ml Dulbecco MEM medium (BioWhittaker, WalkersviUe, MD) and thoroughly mixed on a vortex mixer for one minute. The suspension was thus centrifuged for ten minutes at 840 x g. The sediment was spread on a multispot shde (Nutacon, Leimuiden, The Netherlands) for immunofluorescence techniques, and the supernatant was used for virus isolation. Virus isolation
For virus isolation tMK ceUs (RIVM, BUthoven, The Netherlands) were cultured in 24 weU plates containing glass shdes (Costar, Cambridge, UK), with the medium described below supplemented with 10% fetal bovine serum (BioWhittaker, Vervier, Belgium). Before inoculation the plates were washed with PBS and supphed with Eagle's MEM with Hanks' salt (ICN, Costa mesa, CA) supplemented with 0.52/hter gram NaHCθ3 , 0.025 M Hepes (Biowhittaker), 2 mM L-glutamine (Biowhittaker), 200 units/liter penicilhne, 200 μg/liter streptomycine (Biowhittaker), lgram/hter lactalbumine (Sigma-Aldrich, Zwijndrecht, The Netherlands), 2.0 gram/liter D- glucose (Merck, Amsterdam, The Netherlands), 10 gram/liter peptone (Oxoid, Haarlem, The Netherlands) and 0.02% trypsine (Life Technologies, Bethesda, MD). The plates were inoculated with supernatant of the nasopharyngeal aspirate samples, 0,2 ml per weU in triphcate, foUowed by centrifuging at 840x g for one hour. After inoculation the plates were incubated at 37 °C for a maximum of 14 days changing the medium once a week and cultures were checked dafly for CPE. After 14 days, ceUs were scraped from the second passage and incubated for another 14 days. This step was repeated for the third passage. The glass shdes were used to demonstrate the presence of the virus by indirect IFA as described below. CPE was generaUy observed after the third passage, at day 8 to 14 depending on the isolate. The CPE was virtuaUy indistinghuisable from that caused by hRSV or hPIV in tMK or other ceU cultures. However, hRSV induces CPE starting around day 4. CPE was characterised by syncytia formation, after which the ceUs showed rapid internal disruption, foUowed by detachment of ceUs from the monolayer. For some isolates CPE was difficult to observe, and IFA was used to confirm the presence of the virus in these cultures.
Virus culture of MPV
Sub-confluent monolayers of tMK ceUs in media as described above were inoculated with supernatants of samples that displayed CPE after two or three passages in the 24 weU plates. Cultures were checked for CPE daily and the media was changed once a week. Since CPE differed for each isolate, aU cultures were tested at day 12 to 14 with indirect IFA using ferret antibodies against the new virus isolate. Positive cultures were freeze-thawed three times, after which the supernatants were clarified by low-speed centrifugation, ahquoted and stored frozen at -70 °C. The 50% tissue culture infectious doses (TCID50) of virus in the culture supernatants were determined fohowing estabhshed techniques used in the field16.
Virus characterisation
Haemagglutination assays and chloroform sensitivity tests were performed fohowing weU estabhshed and described techniques used in the field1 . For EM analyses, virus was concentrated from infected ceU culture supernatants in a micro-centrifuge at 4 ° C at 17000 x g, after which the peUet was resuspended in PBS and inspected by negative contrast EM.
Antigen detection by indirect IFA
CoUected specimens were processed as described and sediment of the samples was spread on a multispot shde. After drying, the ceUs were fixed in aceton for 1 minute at room temperature.
Alternatively, virus was cultured on tMK ceUs in 24 weU slides containing glass shdes. These glass shdes were washed with PBS and fixed in aceton for 1 minute at room temperature. After washing with PBS the shdes were incubated for 30 minutes at 37 °C with polyclonal antibodies at a dilution of 1:50 to 1:100 in PBS. We used immunised ferrets and guinea pigs to obtain polyclonal antibodies, but these antibodies can be raised in various animals, and the working dilution of the polyclonal antibody can vary for each immunisation. After three washes with PBS and one wash with tap water, the shdes were incubated at 37°C for 30 minutes with FITC labeled goat-anti- ferret antibodies (KPL, Guilford, UK, 40 fold chluted). After three washes in PBS and one in tap water, the shdes were included in a glycerol PBS solution (Citifluor, UKC, Canterbury, UK) and covered. The shdes were analysed using an Axioscop fluorescence microscope (Carl Zeiss B.V, Weesp, the Netherlands). Detection of antibodies in humans, mammals, ruminants or other animals by indirect IFA
For the detection of virus specific antibodies, infected tMK ceUs with MPV were fixed with acetone on covershps (as described above), washed with PBS and incubated 30 minutes at 37°C with serum samples at a 1 to 16 dilution. After two washes with PBS and one with tap water, the shdes were incubated 30 minutes at 37°C with FITC- labeUed secondary antibodies to the species used (Dako). Shdes were processed as described above.
Antibodies can be labeUed directly with a fluorescent dye, which wiU result in a direct immuno fluorescence assay. FITC can be replaced with any fluorescent dye.
Animal immunisation
Ferret and guinea pig specific antisera for the newly discovered virus were generated by experimental intranasal infection of two specific pathogen free ferrets and two guinea pigs, housed in separate pressurised glove boxes. Two to three weeks later the animals were bled by cardiac puncture, and their sera were used as reference sera. The sera were tested for aU previous described viruses with indirect IFA as described below. Other animal species are also suitable for the generation of specific antibody preparations and other antigen preparations may be used.
Virus neutralisation assay (VN assay)
VN assays were performed with serial two-fold chlutions of human and animal sera starting at an eight-fold dhution. DUuted sera were incubated for one hour with 100 TCID50 of virus before inoculation of tMK ceUs grown in 96 well plates, after which the plates were centrifuged at 840 x g. The same culture media as described above was used. The media was changed after three and six days, and after 8 days IFA was performed (see above). The VN titre was defined as the lowest dilution of the serum sample resulting in negative IFA and inhibition of CPE in ceU cultures.
RNA isolation
RNA was isolated from the supernatant of infected ceU cultures or sucrose gradient fractions using a High Pure RNA Isolation kit according to instructions from the manufacturer (Roche Diagnostics, Almere, The Netherlands). RNA can also be isolated foUowing other procedures known in the field (Current Protocols in Molecular Biology).
RT-PCR
A one-step RT-PCR was performed in 50 μl reactions containing 50 mM Tris.HCl pH 8.5, 50 mM NaCl, 4 mM MgCl2, 2 mM dithiotreitol, 200 μM each dNTP, 10 units recombinant RNAsin (Promega, Leiden, the Netherlands), 10 units AMV RT (Promega, Leiden, The Netherlands), 5 units Amplitaq Gold DNA polymerase (PE Biosystems, Nieuwerkerk aan de Ijssel, The Netherlands) and 5 μl RNA. Cychng conditions were 45 min. at 42 °C and 7 min. at 95 °C once, 1 min at 95 °C, 2 min. at
42 °C and 3 min. at 72 °C repeated 40 times and 10 min. at 72 °C once.
Primers used for diagnostic PCR:
In the nucleoprotein: N3 (5'-GCACTCAAGAGATACCCTAG -3') and N4 (5'- AGACTTTCTGCTTTGCTGCCTG-3'), amphfying a 151 nucleotide fragment. In the matrixprotein: M3 (5'-CCCTGACAATAACCACTCTG-3') and M4 (5'- GCCAACTGATTTGGCTGAGCTC-3') amplifying a 252 nucleotide fragment In the polymerase protein: L6 (5'-CATGCCCACTATAAAAGGTCAG-3') and L7 (5'- CACCCCAGTCTTTCTTGAAA-3') amphfying a 173 nucleotide fragment. Other primers can be designed based on MPV sequences, and different buffers and assay conditions may be used for specific purposes.
Sequence analysis
Sequence analyses were performed using a Dyenamic ET terminator sequencing kit (Amersham Pharmacia Biotech, Roosendaal, The Netherlands) and an ABI 373 automatic DNA sequencer (PE Biosystem). AU techniques were performed according to the instructions of the manufacturer. PCR fragments were sequenced directly with the same ohgonucleotides used for PCR, or the fragments were purified from the gel with Qiaquick Gel Extraction kit (Qiagen, Leusden, The Netherlands) and cloned in pCR2.1 vector (Invitrogen, Groningen, The Netherlands) according to instructions from the manufacturer and subsequently sequenced with Ml3-specific ohgonucleotides.
Oligonucleotides used for analysing the 3'end of the genome (absence of NS1/NS2). Primer TR1 (5'-AAAGAATTCACGAGAAAAAAACGC-3') was designed based on pubhshed sequences of the traUer and leader for hRSV and APV, pubhshed by Randhawa (1997) and primer Nl (5'-CTGTGGTCTCTAGTCCCACTTC-3') was designed based on obtained sequences in the N protein. The RT-PCR assay and sequencing was performed as described above.
The RT-PCR gave a product of approximately 500 base pairs which is to smaU to contain information for two ORFS, and translation of these sequences did not reveal an ORF.
Detection of antibodies in humans, mammals, ruminants or other animals by ELISA
In Paramyxoviridae, the N protein is the most abundant protein, and the immune response to this protein occurs early in infection. For these reasons, a recombinant source of the N proteins is preferably used for developing an ELISA assay for detection of antibodies to MPV. Antigens suitable for antibody detection include any MPV protein that combines with any MPV-specific antibody of a patient exposed to or infected with MPV virus. Preferred antigens of the invention include those that predominantly engender the immune response in patients exposed to MPV, which therefore, typicaUy are recognised most reachly by antibodies of a patient. Particularly preferred antigens include the N, F and G proteins of MPV.
Antigens used for immunological techniques can be native antigens or can be modified versions thereof. WeU known techniques of molecular biology can be used to alter the amino acid sequence of a MPV antigen to produce modified versions of the antigen that may be used in immunologic techniques. Methods for cloning genes, for manipulating the genes to and from expression vectors, and for expressing the protein encoded by the gene in a heterologous host are weU-known, and these techniques can be used to provide the expression vectors, host ceUs, and the for expressing cloned genes encoding antigens in a host to produce recombinant antigens for use in diagnostic assays. See for instance: Molecular cloning, A laboratory manual and Current Protocols in Molecular Biology.
A variety of expression systems may be used to produce MPV antigens. For instance, a variety of expression vectors suitable to produce proteins in E.Coli, B.subtilis, yeast, insect ceUs and mammahan ceUs have been described, any of which might be used to produce a MPV antigen suitable to detect anti-MPV antibodies in exposed patients.
The baculovirus expression system has the advantage of providing necessary processing of proteins, and is therefor preferred. The system utilizes the polyhedrin promoter to direct expression of MPV antigens. (Matsuura et al. 1987, J.Gen.Virol. 68: 1233-1250).
Antigens produced by recombinant baculo-viruses can be used in a variety of immunological assays to detect anti-MPV antibodies in a patient. It is weU estabhshed, that recombinant antigens can be used in place of natural virus in practicaUy any immunological assay for detection of virus specific antibodies.
The assays include direct and indirect assays, sandwich assays, sohd phase assays such as those using plates or beads among others, and hquid phase assays. Assays suitable include those that use primary and secondary antibodies, and those that use antibody binding reagents such as protein A. Moreover, a variety of detection methods can be used in the invention, including colorimetric, fluorescent, phosphorescent, chemfluminescent, luminescent and radioactive methods.
Example 1 of indirect anti-MPV IgG EIA using recombinant N protein
An indirect IgG EIA using a recombinant N protein (produced with recombinant baculo-virus in insect (Sf9) ceUs) as antigen can be performed. For antigen preparation, Sf9 ceUs are infected with the recombinant baculovirus and harvested 3- 7 days post infection. The ceU suspension is washed twice in PBS, pH 7.2, adjusted to a ceU density of 5. OX 106ceUs/ml, and freeze-thawed three times. Large cellular debris is peUeted by low speed centrifugation (500 x g for 15 min.) and the supernatant is coUected and stored at -70°C until use. Uninfected ceUs are processed simUarly for negative control antigen.
100 μl of a freeze-thaw lysate is used to coat microtiter plates, at dilutions ranging from 1:50 to 1:1000. An uninfected ceU lysate is run in duphcate weUs and serves as a negative control. After incubation overnight, plates are washed twice with
PBS/0.05%Tween.Test sera are diluted 1:50 to 1:200 in ELISA buffer (PBS, supplemented to 2% with normal goat sera, and with 0.5% bovine serum albumine and 0.1% milk), foUowed by incubation weUs for 1 hour at 37°C.
Plates are washed two times with PBS/0.05%Tween. Horseradish peroxidase labeUed goat anti-human (or against other species) IgG, diluted 1:3000 to 1:5000 in ELISA buffer, added to weUs, and incubated for 1 hour at 37°. The plates are then washed two times with PBS/0.05%Tweeή and once with tap water, incubated for 15 minutes at room temperature with the enzyme substrate TMB, 3, 3', 5,5' tetramethylbenzidine, such as that obtained from Sigma, and the reaction is stopped with 100 μl of 2 M phosphoric acid. Colorimetric readings are measured at 450 nm using an automated microtiter plate reader.
Example 2: Capture anti-MPV IgM EIA using a recombinant nucleoprotein
A capture IgM EIA using the recombinant nucleoprotein or any other recombinant protein as antigen can be performed by modification of assays as previously described by Erdman et al (1990) J.Chn.Microb. 29: 1466-1471.
Affinity purified anti-human IgM capture antibody (or against other species), such as that obtained from Dako, is added to weUs of a microtiter plate in a concentration of 250 ng per weU in 0.1 M carbonate buffer pH 9.6. After overnight incubation at room temperature, the plates are washed two times with PBS/0.05% Tween. 100 μl of test serum diluted 1:200 to_l: 1000 in ELISA buffer is added to triphcate weUs and incubated for 1 hour at 37°C. The plates are then washed two times with in PBS/0.05%Tween.
The freeze-thawed (infected with recombinant virus) Sf21 ceU lysate is diluted 1:100 to 1: 500 in ELISA buffer is added to the weUs and incubated for 2 hours at 37°C. Uninfected ceU lysate serves as a negative control and is run in duphcate weUs. The plates are then washed three times in PBS/0.05% Tween and incubated for 1 hour at 37°C with 100 μl of a polyclonal antibody against MPV in a optimal dilution in ELISA buffer. After 2 washes with PBS/0.05% Tween , the plates are incubated with horseradish peroxide labeled secondary antibody (such as rabbit anti ferret), and the plates are incubated 20 minutes at 37°C.
The plates are then washed five times in PBS/0/05% Tween, incubated for 15 minutes at room temperature with the enzyme substrate TMB, 3, 3', 5, 5' tetramethylbenzidine, as, for instance obtained from "Sigma", and the reaction is stopped with 100 μl of 2M phosphoric acid. Colormetric readings are measured at 450 nm using automated microtiter plate reader..
The sensitivities of the capture IgM EIAs using the recombinant nucleoprotein (or other recombinant protein) and whole MPV virus are compared using acute-and convalescent-phase serum pairs form persons with chnical MPV virus infection. The specificity of the recombinant nucleoprotein capture EIA is determined by testing serum specimens from healthy persons and persons with other paramyxovirus infections.
Potential for EIAs for using recombinant MPV fusion and glycoprotein proteins produced by the baculovirus expression.
The glycoproteins G and F are the two transmembraneous envelope glycoproteins of the MPV virion and represent the major neutrahsation and protective antigens.
The expression of these glycoproteins in a vector virus system sych as a baculovirus system provides a source of recombinant antigens for use in assays for detection of MPV specific antibodies. Moreover, their use in combination with the nucleoprotein, for instance, further enhances the sensitivity of enzyme immunoassays in the detection of antibodies against MPV.
A variety of other immunological assays (Current Protocols in Immunology) may be used as alternative methods to those described here.
In order to find virus isolates nasopharyngeal aspirates, throat and nasal swabs, broncheo alveolar lavages and throat swabs preferable from but not hmited to humans, carnivores (dogs, cats, seals etc.), horses, ruminants (cattle, sheep, goats etc.), pigs, rabbits, birds (poultry, ostridges, etc) can be examined. From birds, cloaca and intestinal swabs and droppings can be examined as weU. For aU samples, serology (antibody and antigen detection etc.), virus isolation and nucleic acid detection techniques can be performed for the detection of virus. Monoclonal antibodies can be generated by immunising mice (or other animals) with purified MPV or parts thereof (proteins, peptides) and subsequently using estabhshed hybridoma technology (Current protocols in Immunology). Alternatively, phage display technology can be used for this purpose (Current protocols in Immunology). Simflarly, polyclonal antibodies can be obtained from infected humans or animals, or from immunised humans or animals (Current protocols in Immunology).
The detection of the presence or absence of NSl and NS2 proteins can be performed using western-blotting, IFA, immuno precipitation techniques using a variety of antibody preparations. The detection of the presence or absence of NSl and NS2 genes or homologues thereof in virus isolates can be performed using PCR with primer sets designed on the basis of known NSl and/or NS2 genes as weU as with a variety of nucleic acid hybridisation techniques. To determine whether NSl and NS2 genes are present at the 3' end of the viral genome, a PCR can be performed with primers specific for this 3' end of the genome. In our case, we used a primer specific for the 3' untranslated region of the viral genome and a primer in the N ORF. Other primers may be designed for the same purpose. The absence of the NS1/NS2 genes is revealed by the length and/or nucleotide sequence of the PCR product. Primers specific for NSl and/or NS2 genes may be used in combination with primers specific for other parts of the 3' end of the viral genome (such as the untranslated region or N, M or F ORFs) to aUow a positive identification of the presence of NSl or NS2 genes. In addition to PCR, a variety of techniques such as molecular cloning, nucleic acid hybridisation may be used for the same purpose.
Example 3: Different serotypes/subgroups of MPV
Two potential genetic clusters are identified by analyses of partial nucleotide sequences in the N, M, F and L ORFs of 9 virus isolates. 90 -100% nucleotide identity was observed within a cluster, and 81-88% identity was observed between the clusters. Sequence information obtained on more virus isolates confirmed the existence of two genotypes. Virus isolate ned/00/01 as prototype of cluster A, and virus isolate ned/99/01 as prototype of cluster B have been used in cross neutrahzation assays to test whether the genotypes are related to different serotypes or subgroups.
Results
Using RT-PCR assays with primers located in the polymerase gene, we identified 30 additional virus isolates from nasopharyngeal aspirate samples. Sequence information of parts of the matrix and polymerase genes of these new isolates together with those of the previous 9 isolates were used to construct phylogenetic trees (Figure 16). Analyses of these trees confirmed the presence of two genetic clusters, with virus isolate ned/00/00-1 as the prototype virus in group A and virus isolate ned/99/01 as the prototype virus in group B. The nucleotide sequence identity within a group was more than 92%, whUe between the clusters the identity was 81- 85%.
Virus isolates ned/00/01 and ned/99/01 have been used to inoculate ferrets to raise virus-specific antisera. These antisera were used in virus neutrahzation assays with both viruses.
Table 3:
Virus neutrahzation titers
Figure imgf000058_0001
For isolate 00-1 the titer differs 32 (64/2) fold For isolate 99-1 the titer differs 16 (64/4) fold
In addition, 6 guinea pigs have been inoculated with either one of the viruses (ned/00/01 and ned/99/01). RT-PCR assays on nasopharyngeal aspirate samples showed virus rephcation from day 2 till day 10 post infection. At day 70 post infection the guinea pigs have been chaUenged with either the homologous or the heterologous virus, and for in aU four cases virus rephcation has been noticed.
Table 4
Figure imgf000059_0001
note: for the secondary infection guinea pig 2 and 9 were not there any more
Virus neutrahzation assays with anti sera after the first chaUenge showed essentiaUy the same results as in the VN assays performed with the ferrets (> 16-fold difference in VN titer).
The results presented in this example confirm the existence of two genotypes, which correspond to two serotypes of MPV, and show the possibility of repeated infection with heterologous and homologous virus Example 4: Further sequence determination
This example describes the further analysis of the sequences of MPV open reading frames (ORFs) and intergenic sequences as weU as partial sequences of the genomic termini.
Sequence analyses of the nucleoprotein (N), phosphoprotein (P), matrixprotein (M) and fusion protein (F) genes of MPV revealed the highest degree of sequence homology with APV serotype C, the avian pneumovirus found primarily in birds in the United States. These analyses also revealed the absence of non-structural proteins NSl and NS2 at the 3'end of the viral genome and positioning of the fusion protein immediately adjacent to the matrix protein. Here we present the sequences of the 22K (M2) protein, the smaU hydrophobic (SH) protein, the attachment (G) protein and the polymerase (L) protein genes, the intergenic regions and the traher sequence. In combination with the sequences described previously the sequences presented here complete the genomic sequence of MPV with the exception of the extreme 12-15 nucleotides of the genomic termini and estabhsh the genomic organisation of MPV. Side by side comparisons of the sequences of the MPV genome with those of APV subtype A, B and C, RSV subtype A and B, PVM and other paramyxoviruses provides strong evidence for the classification of MPV in the Metapneumovirus genus.
Results
Sequence strategy
MPV isolate 00-1 (van den Hoogen et al., 2001) was propagated in tertiary monkey kidney (tMK) ceUs and RNA isolated from the supernatant 3 weeks after inoculation was used as template for RT-PCR analyses. Primers were designed on the basis of the partial sequence information available for MPV 00-1 (van den Hoogen et al, 2001) as weU as the leader and traUer sequences of APV and RSV (Randhawa et al, 1997; Mink et al, 1991). InitiaUy, fragments between the previously obtained products, ranging in size from 500 bp to 4 Kb in length, were generated by RT-PCR amplification and sequenced directly. The genomic sequence was subsequently confirmed by generating a series of overlapping RT-PCR fragments ranging in size from 500 to 800 bp that represented the entire MPV genome. For aU PCR fragments, both strands were sequenced directly to minimize amplification and sequencing errors. The nucleotide and amino acid sequences were used to search for homologies with sequences in the Genbank database using the BLAST software (www.ncbi.nlm.nih.gov/BLAST). protein names were assigned to open reading frames (ORFs) based on homology with known viral genes as weU as their location in the genome. Based on this information, a genomic map for MPV was constructed (Figure 7). The MPV genome is 13378 nucleotides in length and its organization is simflar to the genomic organization of APV. Below, we present a comparison between the ORFs and non-coding sequences of MPV and those of other paramyxoviruses and discuss the important simUarities and differences.
The nucleoprotein (N) gene
As shown, the first gene in the genomic map of MPV codes for a 394 amino acid (aa) protein and shows extensive homology with the N protein of other pneumoviruses. The length of the N ORF is identical to the length of the N ORF of APV-C (Table 5) and is smaUer than those of other paramyxoviruses (Barr et al., 1991). Analysis of the amino acid sequence revealed the highest homology with APV-C (88%), and only 7- 11% with other paramyxoviruses (Table 6).
Barr et al (1991) identified 3 regions of simUarity between viruses belonging to the order Mononegavirales: A, B and C (Figure 8). Although similarities are highest within a virus famfly, these regions are highly conserved between virus famUys. In aU three regions MPV revealed 97% aa sequence identity with APV-C, 89% with APV-B, 92% with APV-A, and 66-73% with RSV and PVM. The region between aa residues 160 and 340 appears to be highly conserved among metapneumoviruses and to a somewhat lesser extent the Pneumovirinae (Miyahara et al., 1992; Li et al., 1996; Barr et al, 1991). This is in agreement with MPV being a metapneumovirus, showing 100% simUarity with APV C.
The phosphoprotein (P) gene The second ORF in the genome map codes for a 294 aa protein which shares 68% aa sequence homology with the P protein of APV-C, and only 22-26% with the P protein of RSV (Table 6). The P gene of MPV contains one substantial ORF and in that respect is similar to P from many other paramyxoviruses (Reviewed in Lamb and Kolakofsky, 1996; Sedlmeier et al, 1998).
In contrast to APV A and B and PVM and simUar to RSV and APV-C the MPV P ORF lacks cysteine residues. Ling (1995) suggested that a region of high simUarity between aU pneumoviruses (aa 185-241) plays a role in either the RNA synthesis process or in maintaining the structural integrity of the nucleocapsid complex. This region of high simUarity is also found in MPV (Figure 9) especificaUy when conservative substitutions are taken in account, showing 100% simUarity with APV- C, 93 % with APV-A and B, and approximately 81% with RSV. The C-terminus of the MPV P protein is rich in glutamate residues as has been described for APVs (Ling et al, 1995).
The matrix (M) protein gene
The third ORF of the MPV genome encodes a 254 aa protein, which resembles the M ORFs of other pneumoviruses. The M ORF of MPV has exactly the same size as the M ORFs of other metapneumoviruses (Table 5) and shows high aa sequence homology with the matrix proteins of APV (78-87%), lower homology with those of RSV and
PVM (37-38%) and 10% or less homology with those of other paramyxoviruses (Table
6).
Easton (1997) compared the sequences of matrix proteins of aU pneumoviruses and found a conserved heptadpeptide at residue 14 to 19 that is also conserved in MPV (Figure 10). For RSN PVM and APV smaU secondary ORFs within or overlapping with the major ORF of M have been identified (52 aa and 51 aa in bRSV, 75 aa in RSN 46 aa in PVM and 51 aa in APV) (Yu et al, 1992; Easton et al, 1997; Samal et al, 1991; Satake et al, 1984). We noticed two smaU ORFs in the M ORF of MPV One smaU ORF of 54 aa residues was found within the major M ORF (fragment 1, Figure 7), starting at nucleotide 2281 and one smaU ORF of 33 aa residues was found overlapping with the major ORF of M starting at nucleotide 2893 (fragment 2, Figure 7). SimUar to the secondary ORFs of RSV and APV there is no significant homology between these secondary ORFs and secondary ORFs of the other pneumoviruses, and apparent start or stop signals are lacking. In addition, evidence for the synthesis of proteins corresponding to these secondary ORFs of APV and RSV has not been reported.
The fusion protein (F) gene The F ORF of MPV is located adjacent to the M ORF, which is characteristic for members of the Metapneumovirus genus. The F gene of MPV encodes a 539 aa protein, which is two aa residues longer than F of APV-C (Table 5). Analysis of the aa sequence revealed 81% homology with APV-C, 67% with APV-A and B, 33-39% with pneumovirus F proteins and only 10-18% with other paramyxoviruses (Table 6). One of the conserved features among F proteins of paramyxoviruses, and also seen in MPV is the distribution of cysteine residues (Morrison, 1988; Yu et al, 1991). The metapneumoviruses share 12 cysteine residues in Fl (7 are conserved among aU paramyxoviruses), and two in F2 (1 is conserved among all paramyxoviruses). Of the 3 potential N-hnked glycosylation sites present in the F ORF of MPN none are shared with RSV and two (position 74 and 389) are shared with APV. The third, unique, potential N-hnked glycosylation site for MPV is located at position 206 (Figure 11).
Despite the low sequence homology with other paramyxoviruses, the F protein of MPV revealed typical fusion protein characteristics consistent with those described for the F proteins of other Paramyxoviridae famUy members (Morrison, 1988). F proteins of Paramyxoviridae members are synthesized as inactive precursors (F0) that are cleaved by host ceU proteases which generate amino terminal F2 subunits and large carboxy terminal Fl subunits. The proposed cleavage site (Collins et al, 1996) is conserved among aU members of the Paramyxoviridae famUy. The cleavage site of MPV contains the residues RQSR. Both arginine (R) residues are shared with APV and RSN but the glutamine (Q) and serine (S) residues are shared with other paramyxoviruses such as human parainfluenza virus type 1, Sendai virus and morbilhviruses (data not shown). The hydrophobic region at the amino terminus of Fl is thought to function as the membrane fusion domain and shows high sequence simUarity among paramyxoviruses and morbilhviruses and to a lesser extent the pneumoviruses (Morrison, 1988). These 26 residues (position 137-163, Figure 11) are conserved between MPV and APV-C, which is in agreement with this region being highly conserved among the metapneumoviruses (Naylor et al, 1998; Seal et al, 2000). As is seen for the F2 subunits of APV and other paramyxoviruses, MPV revealed a deletion of 22 aa residues compared with RSV (position 107-128, Figure 11).
Furthermore, for RSV and APV, the signal peptide and anchor domain were found to be conserved within subtypes and displayed high variability between subtypes (Plows et al, 1995; Naylor et al, 1998). The signal peptide of MPV (aa 10-35, Figure 11) at the amino terminus of F2 exhibits some sequence simUarity with APV-C (18 out of 26 aa residues are simUar). and less conservation with other APVs or RSV. Much more variability is seen in the membrane anchor domain at the carboxy terminus of Fl, although some homology is stiU seen with APV-C.
The 22K (M2) protein
The M2 gene is unique to the Pneumovirinae and two overlapping ORFs have been observed in aU pneumoviruses. The first major ORF represents the M2-1 protein which enhances the processivity of the viral polymerase (Colhns et al, 1995; Collins, 1996) and its readthrough of intergenic regions (Hardy et al, 1998; Fearns et al, 1999). The M2-1 gene for MPV, located adjacent to the F gene, encodes a 187 aa protein (Table 5), and reveals the highest (84%) homology with M2-1 of APV-C (Table 6). Comparison of aU pneumovirus M2-1 proteins revealed the highest conservation in the amino-terminal half of the protein (Colhns et al, 1990; Zamora et al, 1992; Ahmadian et al, 1999), which is in agreement with the observation that MPV displays 100% simUarity with APV-C in the first 80 aa residues of the protein (Figure 12A). The MPV M2-1 protein contains 3 cysteine residues located within the first 30 aa residues that are conserved among aU pneumoviruses. Such a concentration of cysteines is frequently found in zinc-binding proteins (Ahmadian et al, 1991; Cuesta et al., 2000).
The secondary ORFs (M2-2) that overlap with the M2-1 ORFs of pneumoviruses are conserved in location but not in sequence and are thought to be involved in the control of the switch between virus RNA rephcation and transcription (CoUins et al, 1985; Elango et al, 1985; Baybutt et al, 1987; Colhns et al., 1990; Ling et al, 1992; Zamora et al, 1992; Alansari et al, 1994; Ahmadian et al, 1999; Bermingham et al, 1999). For MPV, the M2-2 ORF starts at nucleotide 512 in the M2-1 ORF (Figure 7), which is exactly the same start position as for APV-C. The length of the M2-2 ORFs are the same for APV-C and MPV, 71 aa residues (Table 5). Sequence comparison of the M2-2 ORF (Figure 12B) revealed 64% aa sequence homology between MPV and
APV-C and only 44-48% aa sequence homology between MPV and APV-A and B
(Table 6).
The small hydrophobic protein (SH) ORF
The gene located adjacent to M2 of hMPV probably encodes a 183 aa SH protein (Fig.
1 and 7). There is no discernible sequence identity between this ORF and other RNA virus genes or gene products. This is not surprising since sequence simUarity between pneumovirus SH proteins is generaUy low. The putative SH ORF of hMPV is the longest SH ORF known to date (Table 1). The aa composition of the SH ORF is relatively simUar to that of APV, RSV and PVM, with a high percentage of threonine and serine residues (22%, 18%, 19%, 20.0%, 21% and 28% for hMPV, APV, RSV A, RSV B, bRSV and PVM respectively). The SH ORF of hMPV contains 10 cysteine residues, whereas APV SH contains 16 cysteine residues. The SH ORF of hMPV contains two potential N-hnked glycosylation sites (aa 76 and 121), whereas APV has one, RSV has two or three and PVM has four.
The hydrophihcity profiles for the putative hMPV SH protein and SH of APV and RSV revealed simUar characteristics (Fig. 7B). The SH ORFs of APV and hMPV have a hydrophihc Ν-terminus, a central hydrophobic domain which can serve as a potential membrane spanning domain (aa 30-53 for hMPV), a second hydrophobic domain (aa 155-170) and a hydrophihc C-terminus. In contrast, RSN SH appears to lack the C-terminal part of the APV and hMPV ORFs. In aU pneumovirus SH proteins the hydrophobic domain is flanked by basic aa residues, which are also found in the SH ORF for hMPV (aa 29 and 54).
The attachment glycoprotein (G) ORF
The putative G ORF of hMPV is located adjacent to the putative SH gene and encodes a 236 aa protein (nt 6262-6972, Fig. 1). A secondary smaU ORF is found immediately foUowing this ORF, potentiaUy coding for 68 aa residues (nt 6973-7179) but lacking a start codon. A third potential ORF in the second reading frame of 194 aa residues is overlapping with both of these ORFs but also lacks a start codon (nt 6416-7000). This ORF is foUowed by a potential fourth ORF of 65 aa residues in the same reading frame (nt 7001-7198), again lacking a start codon. FinaUy, a potential ORF of 97 aa residues (but lacking a start codon) is found in the third reading frame (nt 6444-6737,
Fig. 1). Unlike the first ORF, the other ORFs do not have apparent gene start or gene end sequences (see below). Although the 236 aa G ORF probably represents at least a part of the hMPV attachment protein it can not be excluded that the additional coding sequences are expressed as separate proteins or as part of the attachment protein through some RNA editing event. It should be noted that for APV and RSV no secondary ORFs after the primary G ORF have been identified but that both APV and RSV have secondary ORFs within the major ORF of G. However, evidence for expression of these ORFs is lacking and there is no sequence identity between the predicted aa sequences for different viruses (Ling et al, 1992). The secondary ORFs in hMPV G do not reveal characteristics of other G proteins and whether the additional ORFs are expressed requires further investigation. BLAST analyses with aU ORFs revealed no discernible sequence identity at the nucleotide or aa sequence level with other known virus genes or gene products. This is in agreement with the low percentage sequence identity found for other G proteins such as those of hRSV A and B (53%) (Johnson et al, 1987) and APV A and B (38%) (Juhasz and Easton, 1994).
Whereas most of the hMPV ORFs resemble those of APV both in length and sequence, the putative G ORF of 236 aa residues of hMPV is considerably smaUer than the G ORF of APV (Table 1). The aa sequence revealed a serine and threonine content of 34%, which is even higher than the 32% for RSV and 24% for APV. The putative G ORF also contains 8.5% prohne residues, which is higher than the 8% for RSV and 7% for APV. The unusual abundance of prohne residues in the G proteins of APV, RSV and hMPV has also been observed in glycoproteins of mucinous origin where it is a major determinant of the proteins three dimensional structure (Colhns and Wertz, 1983; Wertz et al, 1985; Jentoft, 1990). The G ORF of hMPV contains five potential N-hnked glycosylation sites, whereas hRSV has seven, bRSV has five and APV has three to five. The predicted hydrophihcity profile of hMPV G revealed characteristics simUar to the other pneumoviruses. The Ν-terminus contains a hydrophilic region foUowed by a short hydrophobic area (aa 33-53 for hMPV) and a mainly hydrophihc C-terminus (Fig. 8B). This overaU organization is consistent with that of an anchored type II transmembrane protein and corresponds weU with these regions in the G protein of APV and RSV. The putative G ORF of hMPV contains only 1 cysteine residue in contrast to RSV and APV (5 and 20 respectively). Of note, only two of the four secondary ORFs in the G gene contained one additional cysteine residue and these four potential ORFs revealed 12-20% serine and threonine residues and 6-11% prohne residues.
The polymerase gene (L)
In analogy to other negative strand viruses, the last ORF of the MPV genome is the
RNA-dependent RNA polymerase component of the rephcation and transcription complexes. The L gene of MPV encodes a 2005 aa protein, which is 1 residue longer than the APV-A protein (Table 5). The L protein of MPV shares 64% homology with APV-A, 42-44% with RSV, and approximately 13% with other paramyxoviruses (Table 6). Poch et al. (1989; 1990) identified six conserved domains within the L proteins of non-segmented negative strand RNA viruses, from which domain III contained the four core polymerase motifs that are thought to be essential for polymerase function. These motifs (A, B, C and D) are weU conserved in the MPV L protein: in motifs A, B and C: MPV shares 100% simUarity with aU pneumoviruses and in motif D MPV shares 100 % simUarity with APV and 92% with RSVs. For the entire domain III (aa 627- 903 in the L ORF), MPV shares 77% identity with APV, 61- 62% with RSV and 23-27% with other paramyxoviruses (Figure 15). In addition to the polymerase motifs the pneumovirus L proteins contain a sequence which conforms to a consensus ATP binding motif K(X)2ιGEGAGN(X)2oK (Stec, 1991).The MPV L ORF contains a simUar motif as APV, in which the spacing of the intermediate residues is off by one: K(x)22GEGAGN(X)i9 K.
Phylogenetic analyses
As an indicator for the relationship between MPV and members of the Pneumovirinae, phylogenetic trees based on the N, P, M, and F ORFs have been constructed previously (van den Hoogen et al, 2001) and revealed a close relationship between MPV and APV-C. Because of the low homology of the MPV SH and G genes with those of other paramyxoviruses, rehable phylogenetic trees for these genes can not be constructed. In addition, the distinct genomic organization between members of the Pneumovirus and Metapneumovirus genera make it impossible to generate phylogenetic trees based on the entire genomic sequence. We therefore only constructed phylogenetic trees for the M2 and L genes in addition to those previously pubhshed. Both these trees confirmed the close relation between APV and MPV within the Pneumovirinae subfamUy (Figure 16).
MPV non-coding sequences The gene junctions of the genomes of paramyxoviruses contain short and highly conserved nucleotide sequences at the beginning and end of each gene (gene start and gene end signals), possibly playing a role in initiation and termination of transcription (Curran et al, 1999). Comparing the intergenic sequences between aU genes of MPV revealed a consensus sequence for the gene start signal of the N, P, M, F, M2 and G: GGGACAAGU (Figure 17A), which is identical to the consensus gene start signal of the metapneumoviruses (Ling et al, 1992; Yu et al, 1992; Li et al, 1996; Bayon-Auboyer et al, 2000). The gene start signals for the SH and L genes of MPV were found to be slightly different from this consensus (SH: GGGAUAAAU, L: GAGACAAAU). For APV the gene start signal of L was also found to be different from the consensus: AGGACCAAT (APV-A) (Randhawa et al, 1996) and GGGACCAGT (APV-D) (Bayon-Auboyer et al, 2000).
In contrast to the simUar gene start sequences of MPV and APV, the consensus gene end sequence of APV, UAGUUAAUU (Randhawa et al, 1996), could not be found in the MPV intergenic sequences. The repeated sequence found in most genes, except the G-L intergenic region, was U AAAAA U/A/C, which could possibly act as gene end signal. However, since we sequenced viral RNA rather than mRNA, definitive gene end signals could not be assigned and thus requires further investigation. The intergenic regions of pneumoviruses vary in size and sequence (Curran et al, 1999; Blumberg et al, 1991; Colhns et al., 1983;). The intergenic regions of MPV did not reveal homology with those of APV and RSV and range in size from 10 to 228 nucleotides (Figure 17B). The intergenic region between the M and F ORFs of MPV contains part of a secondary ORF, which starts in the primary M ORF (see above). The intergenic region between SH and G contains 192 nucleotides, and does not appear to have coding potential based on the presence of numerous stop-codons in aU three reading frames. The intergenic region between G and L contains 241 nucleotides, which may include additional ORFs (see above). Interestingly, the start of the L ORF is located in these secondary ORFs. Whereas the L gene of APV does not start in the preceding G ORF, the L ORF of RSV also starts in the preceding M2 gene. At the 3' and 5' extremities of the genome of paramyxoviruses short extragenic region are referred to as the leader and traUer sequences, and approximately the first
12 nucleotides of the leader and last 12 nucleotides of the traUer are complementary, probably because they each contain basic elements of the viral promoter (Curran et al, 1999; Blumberg et al, 1991; Mink et al, 1986). The 3'leader of MPV and APV are both 41 nucleotides in length, and some homology is seen in the region between nucleotide 16 and 41 of both viruses (18 out of 26 nucleotides) (Figure 17B). As mentioned before the first 15 nucleotides of the MPV genomic map are based on a primer sequence based on the APV genome. The length of the 5'traUer of MPV (188 nucleotides) resembles the size of the RSV 5'traUer (155 nucleotides), which is considerably longer than that of APV (40 nucleotides). Alignments of the extreme 40 nucleotides of the traUer of MPV and the traUer of APV revealed 21 out of 32 nucleotides homology, apart from the extreme 12 nucleotides which represent primer sequences based on the genomic sequence of APV. Our sequence analyses revealed the absence of NSl and NS2 genes at the 3'end of the genome and a genomic organisation resembhng the organisation of metapneumoviruses (3'-N-P-M-F-M2-SH- G-L-5'). The high sequence homology found between MPV and APV genes further emphasises the close relationship between these two viruses. For the N, P, M, F, M2- 1 and M2-2 genes of MPV an overaU amino acid homology of 79% is found with APV- C. In fact, for these genes APV-C and MPV revealed sequence homologies which are in the same range as sequence homologies found between subgroups of other genera, such as RSV- A and B or APV-A and B. This close relationship between APV-C and MPV is also seen in the phylogenetic analyses which revealed MPV and APV-C always in the same branch, sep rate from the branch containing APV-A and B. The identical genomic organisation, the sequence homologies and phylogentic analyses are aU in favour of the classification of MPV as the first member in the
Metapneumovirus genus that is isolatable from mammals. It should be noted that the found sequence variation between different virus isolates of MPV in the N, M, F and L genes revealed the possible existence of different genotypes (van den Hoogen et al, 2001). The close relationship between MPV and APV-C is not reflected in the host range, since APV infects birds in contrast to MPV (van den Hoogen et al, 2001). This difference in host range may be determined by the differences between the SH and G proteins of both viruses that are highly divergent. The SH and G proteins of MPV did not reveal significant aa sequence homology with SH and G proteins of any other virus. Although the amino acid content and hydrophobicity plots are in favour of defining these ORFs as SH and G, experimental data are required to assess their function. Such analyses will also shed hght on the role of the additional overlapping
ORFs in these SH and G genes. In addition, sequence analyses on the SH and G genes of APV-C might provide more insight in the function of the SH and G proteins of MPV and their relationship with those of APV-C. The noncoding regions of MPV were found to be fairly simUar to those of APV. The 3'leader and 5' traUer sequences of APV and MPV displayed a high degree of homology. Although the lengths of the intergenic regions were not always the same for APV and MPV, the consensus gene start signals of most of the ORFs were found to be identical. In contrast, the gene end signals of APV were not found in the MPV genome. Although we did find a repetitive sequence (U AAAAA U/A/C) in most intergenic regions, sequence analysis of viral mRNAs is required to formaUy dehneate those gene end sequences. It should be noted that sequence information for 15 nucleotides at the extreme 3'end and 12 nucleotides at the extreme 5'end is obtained by using modified rapid amplification of cDNA ends (RACE) procedures. This technique has been proven to be successful by others for related viruses (Randhawa, J.S. et al., Rescue of synthetic minirephcons establishes the absence of the NSl and NS2 genes from avian pneumovirus. J. Virol, 71, 9849- 9854 (1997); Mink, M.A., et al. Nucleotide sequences of the 3' leader and 5' traUer regions of human respiratory syncytial virus genomic RNA. Virology 185, 615-24 (1991).) To determine the sequence of the 3' vRNA leader sequence, a homopolymer A taU is added to purified vRNA using poly-A-polymerase and the leader sequence subsequently amplified by PCR using a poly-T primer and a primer in the N gene. To determine the sequence of the 5' vRNA traUer sequence, a cDNA copy of the traUer sequence is made using reverse transcriptase and a primer in the L gene, foUowed by homopolymer dG tailing of the cDNA with terminal transferase. Subsequently, the traUer region is amplified using a poly-C primer and a primer in the L gene. As an alternative strategy, vRNA is hgated to itself or synthetic hnkers, after which the leader and traUer regions are amplified using primers in the L and N genes and linker-specific primers. For the 5' traUer sequence direct dideoxynucleotide sequencing of purified vRNA is also feasible (Randhawa, 1997). Using these approaches, we can analyse the exact sequence of the ends of the hMPV genome.. The sequence information provided here is of importance for the generation of diagnostic tests, vaccines and antivirals for MPV and MPV infections. Materials and Methods Sequence analysis
Virus isolate 00-1 was propagated to high titers (approximately 10,000 TCID50/ml) on tertiary monkey kidney ceUs as described previously (van den Hoogen et al, 2001). Viral RNA was isolated from supernatants from infected ceUs using a High Pure RNA Isolating Kit according to instructions from the manufacturer (Roch Diagnostics, Almere, The Netherlands). Primers were designed based on sequences pubhshed previously (van den Hoogen et al, 2001) in addition to sequences pubhshed for the leader and traUer of APV/RSV (Randhawa et al, 1997; Mink et al, 1991) and are avaUable upon request. RT-PCR assays were conducted with viral RNA, using a one- tube assay in a total volume of 50μl with 50 mM Tris pH 8.5, 50 mM NaCl, 4.5 mM MgCl2, 2 mM DTT, 1 μM forward primer, lμM reverse primer, 0.6 mM dNTP's, 20 units RNAsin (Promega, Leiden, The Netherlands), 10 U AMV reverse transcriptase (Promega, Leiden, The Netherlands), and 5 units Taq Polymerase (PE Apphed Biosystems, Nieuwerkerk aan de IJssel, The Netherlands). Reverse transcription was conducted at 42°C for 30 minutes, foUowed by 8 minutes inactivation at 95°C. The cDNA was amphfied during 40 cycles of 95°C, 1 min.; 42°C, 2 min.72°C, 3 min. with a final extension at 72°C for 10 minutes. After examination on a 1% agarose gel, the RT-PCR products were purified from the gel using a Qiaquick Gel Extraction kit (Qiagen, Leusden, The Netherlands) and sequenced directly using a Dyenamic ET terminator sequencing kit (Amersham Pharmacia Biotech, Roosendaal, the Netherlands) and an ABI 373 automatic DNA sequencer (PE Apphed Biosystem, Nieuwerkerk aan den IJssel, the Netherlands), according to the instructions of the manufacturer.
Sequence ahgnments were made using the clustal software package avaUable in the software package of BioEdit version5.0.6. (http://jwbrown.mbio.ncsu.edu/ Bioedit// bioedit.html; HaU, 1999).
Phylogenetic analysis
To construct phylogenetic trees, DNA sequences were ahgned using the ClustalW software package and maximum likelihood trees were generated using the DNA-ML software package of the Phyhp 3.5 program using 100 bootstraps and 3 jumbles. Bootstrap values were computed for consensus trees created with the consense package (Felsenstein, 1989).
The MPV genomic sequence is avaUable from Genbank under accession number AF371337. AU other sequences used here are avaUable from Genbank under accession numbers AB046218 (measles virus, aU ORFs), NC-001796 (human parainfluenza virus type 3, aU ORFs), NC-001552 (Sendai virus, aU ORFs), X57559 (human parainfluenza virus type 2, aU ORFs), NC-002617 (New Castle Disease virus, aU ORFs), NC-002728 (Nipah virus, aU ORFs), NC-001989 (bRSV, aU ORFs), M11486 (hRSV A, aU ORFs except L), NC-001803 (hRSV, L ORF), NC-001781 (hRSV B, aU ORFs), D 10331 (PVM, N ORF), U09649 (PVM, P ORF), U66893 (PVM, M ORF), U66893 (PVM, SH ORF), D11130 (PVM, G ORF), D11128 (F ORF). The PVM M2 ORF was taken from Ahmadian (1999), AF176590 (APV-C, N ORF), U39295 (APV-A, N ORF), U39296 (APV-B, N ORF), AF262571 (APV-C, M ORF), U37586 (APV-B, M ORF), X58639 (APV-A, M ORF), AF176591 (APV-C, P ORF), AF325443 (APV-B, P
ORF), U22110 (APV-A, P ORF), AF187152 (APV-C, F ORF), Y14292 (APV-B, F ORF), D00850 (APV-A, F ORF), AF176592 (APV-C, M2 ORF), AF35650 (APV-B, M2 ORF), X63408 (APV-A, M2 ORF), U65312 (APV-A, L ORF), S40185 (APV-A, SH ORF).
Table 5: Lengths of the ORFs of MPV and other paramyxoviruses.
N1 P M F M2- M2- SH G L 1 2
MPV 394 294 254 539 187 71 183 236 2005
APV A 391 278 254 538 186 73 174 391 2004
APV B 391 279 254 538 186 73 .2 414 .2
APV C 394 294 254 537 184 71 .2 .2 .2
APV D .2 .2 .2 .2 .2 .2 .2 389 .2 hRSV A 391 241 256 574 194 90 64 298 2165 hRSV B 391 241 249 574 195 93 65 299 2166 bRSV 391 241 256 569 186 93 81 257 2162
PVM 393 295 257 537 176 77 92 396 .2 others3 418- 225- 335- 539- .4 .4 .4 .4 2183-
542 709 393 565 2262
Footnotes:
1. length in amino acid residues.
2 . sequences not avaUable
3. others: human parainfluenza virus type 2 and 3, Sendai virus, measles virus, nipah virus, phocine distemper virus, and New Castle Disease virus.
4. . ORF not present in viral genome
Table 6: Amino acid sequence identity between the ORFs of MPV and those of other paramyxoviruses1.
N P M F M2- M2- L 1 2
APV A 69 55 78 67 72 26 64
APV B 69 51 76 67 71 27 .2
APV C 88 68 87 81 84 56 .2 hRSV A 42 24 38 34 36 18 42 hRSV B 41 23 37 33 35 19 44 bRSV 42 22 38 34 35 13 44
PVM 45 26 37 39 33 12 .2 others3 7-11 4-9 7-10 10- .4 .4 13-
18 14
Footnotes:
1. No sequence homologies were found with known G and SH proteins and were thus excluded
2. Sequences not avaUable.
3. See hst in table 5, footnote 3.
4. ORF absent in viral genome.
References
Current Protocols in Molecular Biology, volume 1-3 (1994-1998). Ed. by Ausubel, F.M., Brent, R., Kinston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A. and Struhl, K. Pubhshed by John WUey and sons, Inc., USA.
Current Protocols in Immunology, volume 1-3. Ed. by Cohgan, J.E., Kruisbeek, A.M., Marguhes, D.H., Shevach, E.M. and Strobe, W. Pubhshed by John WUey and sons, Inc., USA.
Sambrook et al. Molecular cloning, a laboratory manual, second ed., vol. 1-3. (Cold Spring Harbor Laboratory, 1989).
Fields, Virology. 1996. Vol. 1-2 3rd. Edition , Ed. by: Fields, B.N., Knipe, D.M. and Howley, P.M. Lippincott-Raven, PhUadelpia, USA.
1. Pringle, C . Virus taxonomy at the Xith international congress of virology, Sydney, Austraha 1999. Arch. Virol. 144/2, 2065-2070 (1999).
2. Domachowske, J.B. & Rosenberg, H.F. Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. Chn. Microbio. Rev. 12(2), 298-309 (1999). Review.
3. Giraud, P., Bennejean, G., Guittet, M. & Toquin, D. Turkey rhinotracheitis in France: prehminary investigations on a cUiostatic virus. Vet. Rec. 119, 606-607 (1986). 4. Ling, R., Easton, A.J. & Pringle, CR. Sequence analysis of the 22K, SH and G genes of turkey rhinotracheitis virus and their intergenic regions reveals a gene order different from that of other pneumoviruses. J. Gen.Virol. 73, 1709-1715 (1992).
5. Yu, Q., Davis, P.J., Li, J. & Cavanagh, D. Cloning and sequencing of the matrix protein (M) gene of turkey rhinotracheitis virus reveal a gene order different from that of respiratory syncytial virus. Virology 186, 426-434 (1992).
6. Randhawa, J.S., Marriott, A.C., Pringle, CR. & Easton, A.J. Rescue of synthetic minirephcons estabhshes the absence of the NSl and NS2 genes from avian pneumovirus. J.Virol. 71, 9849-9854 (1997). 7. Evans, A.S. In: Viral Infections of Humans. Epidemiology and control. 3th edn. (ed. Evans, A.S) 22-28 (Plenum Publishing Corporation, New York, 1989).
8. Osterhaus, A.D.M.E., Yang, H., Spijkers, H.E.M., Groen, J., Teppema, J.S. & van Steenis, G. The isolation and partial characterization of a highly pathogenic herpesvirus from the Harbor Seal (Phoca vitulina). Arch.of Virol. 86, 239-251 (1985).
9. K.B. Chua et al. Nipah virus: a recently emergent deadly paramyxovirus. Science 288, 1432-1435 (2000).
10. Welsh, J., Chada, K, Dalai, S.S., Cheng, R., Ralph, D. & McCleUand, M. Arbitrarily primed PCR fingerprinting of RNA. NAR. 20, 4965-4970 (1992). 11. Bayon-Auboyer, M., Arnauld, C, Toquin, D. & Eterradossi, N. Nucleotide sequences of the F, L and G protein genes of two non-A/non-B avian pneumoviruses (APV) reveal a novel APV subgroup. J. of Gen. Virol. 81, 2723-2733 (2000).
12. Mulder, J. & Masurel, N. Pre-epidemic antibody against 1957 strain of asiatic influenza in serum of older people hving in The Netherlands. The Lancet, april 19, 810-814 (1958).
13. Pringle, CR. In: The Paramyxoviruses. lth edn.(ed. D.W. Kingsbury) 1-39 ( Plenum Press, New York, 1991).
14. Rothbarth, P.H., Groen, J., Bohnen, AM., Groot, de R., & Osterhaus, A.D.M.E. Influenza virus serology-a comparative study. J. of Virol. Methods 78, 163-169 (1999).
15. Brandenburg, A.H., Groen, J., van Steensel-MoU, H.A., Claas, E.J.C, Rothbarth, P.H., Neijens, H.J. & Osterhaus, A.D.M.E. Respiratory syncytial virus specific serum antibodies in infants under six months of age: hmited serological response upon infection. J.Med.Virol. 52, 97-104 (1997). 16. Lennette, D.A. et al. In: Diagnostic procedures for viral, rickettsial, and chlamydial infections. 7th edn. (eds. Lennette, E.H., Lennette, D.A. & Lennette, E.T.) 3-25; 37-138; 431-463; 481-494; 539-563 (American pubhc health association, Washington, 1995).
15. Felsenstein, J. Department of Genetics, Universtity of Washington. Http .7/evolution. genetics. Washington, edu/phvhp . html
16. SchneU et al EMBO J 13, 4195-4203, 1994
17. Colhns, P.L., HU1, M.G., Camargo, E., Grosfeld, H., Chanock, R.M. & Murphy, B.R. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an esential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capabUity for vaccine development. PNAS 92, 11563-11567 (1995).
18. Hoffmann, E., Neumann, G., Kawakao, Y., Hobom, G. & Webster, R.G. A DNA transfection system for generation of influenza virus from eight plasmids. PNAS 97, 6108-6113 (2000).
19. Bridgen, A., Elliot, R.M. Rescue of a segmented negative-strand virus entirely from cloned complementary DNAs. PNAS 93, 15400-15404 (1996).
20. Palese, P., Zheng, H., Engelhardt, O.G., Pleschka, S. & Garcia-Sastre, A. Negative-strand RNA viruses: genetic engineering and apphcations. PNAS 93, 11354- 11358 (1996).
21. Peeters, B.P., de Leeuw, O.S., Koch, G. & Gielkens, A.L. Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J.Virol. 73, 5001-5009 (1999).
22. Durbin, A.P., HaU, S.L., Siew, J.W., Whitehead, S.S., Collins, P.L. & Murphy, B.R. Recovery of infectious human parainfluenza virus type 3 from cDNA. Virology
235, 323-332 (1997).
23. Tao, T.; Durbin, A.P., Whitehead, S.S., Davoodi, F., Collins, P.L. & Murphy, B.R. Recovery of a fuUy viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1. J. Virol. 72, 2955-2961 (1998).
24. Durbin, A.P., Skiadopoulos, M.H., McAuliffe, J.M., Riggs, J.M., Surman, S.R., Colhns, P.L. & Murphy, B.R. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy. J.Virol. 74, 6821- 6831 (2000).
25. Skiadopoulos, M.H., Durbin, A.P., Tatem, J.M., Wu, S.L., Paschahs, M., Tao, T., Colhns, P.L. & Murphy, B.R. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 hve attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J. Virol. 72, 1762-1768 (1998).
26.Teng, N., Whitehead, S.S., Bermingham, A., St.Claire, M., Elkins, W.R., Murphy, B.R. & Collins, P.L. J.Virol 74, 9317-9321 (2000). 27. Masurel, N. Relation between Hong Kong virus and former human A2 isolates and the A/EQU12 virus in human sera coUected before 1957. The Lancet May 3, 907- 910 (1969).
Further references used with example 4.
AHMADIAN, G., CHAMBERS, P., and EASTON, A. J. (1999). Detection and characterisation of proteins encoded by the second ORF of the M2 gene of pneumoviruses. J Gen Virol 80, 2011-6. ALANSARI, H., and POTGIETER, L. N. (1994). Molecular cloning and sequence analysis of the phosphoprotein, nucleocapsid protein, matrix protein and 22K (M2) protein of the ovine respiratory syncytial virus. J Gen Virol 75, 3597-601. BARR, J., CHAMBERS, P., PRINGLE, C R., and EASTON, A. J. (1991). Sequence of the major nucleocapsid protein gene of pneumonia virus of mice: sequence comparisons suggest structural homology between nucleocapsid proteins of pneumoviruses, paramyxoviruses, rhabdoviruses and filoviruses. J Gen Virol 72, 677-85. BAYBUTT, H. N., and PRINGLE, C. R. (1987). Molecular cloning and sequencing of the F and 22K membrane protein genes of the RSS-2 strain of respiratory syncytial virus. J Gen Virol 68, 2789-96. BAYON-AUBOYER, M. H., ARNAULD, C, TOQUIN, D., and ETERRADOSSI, N. (2000).
Nucleotide sequences of the F, L and G protein genes of two non-A non-B avian pneumoviruses (APV) reveal a novel APV subgroup. J Gen Virol 81, 2723-33. BERMINGHAM, A., and COLLINS, P. L. (1999). The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA rephcation and transcription. Proc Natl Acad Sci U SA 96, 11259-64.
BLUMBERG, B.M., CHAN, J., AND UDEM, S.A. (1991). Function of Paramyxovirus 3' and 5'end sequences: In therory and practice. In "the Paramyxoviruses" (D. Kingsbury, Ed.), pp. 235-247. Plenum, New York.
COLLINS, P. L., and WERTZ, G. W. (1983). cDNA cloning and transcriptional mapping of nine polyadenylylated RNAs encoded by the genome of human respiratory syncytial virus. Proc Natl Acad Sci U S A 80, 3208-12. COLLINS, P. L., and WERTZ, G. W. (1985). The envelope-associated 22K protein of human respiratory syncytial virus: nucleotide SEQUENCE of the mRNA and a related polytranscript. J Virol 54, 65-71. COLLINS, P.L., DICKENS, L.E., BUCKLER- WHITE, A., OLMSTED, R.A., SPRIGGS, M.K.,
CAMARGO, E., AND COELINGH, K.V.W. (1986). Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order. Proc Natl Acad Sci U S A 83, 4594-98. COLLINS, P. L., HILL, M. G., and JOHNSON, P. R. (1990). The two open reading frames of the 22K mRNA of human respiratory syncytial virus: sequence comparison of antigenic subgroups A and B and expression in vitro. J Gen Virol 71, 3015-20.
COLLINS, P. L., HILL, M. G., CAMARGO, E., GROSFELD, H., CHANOCK, R. M., and MURPHY,
B. R. (1995). Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capabUity for vaccine development. Proc Natl Acad Sci U SA 92,
11563-7. COLLINS, P. L., MCINTOSH, K. AND CHANOCK, R.M. (1996). "Respiratory syncytial virus." In: Fields virology (B. N. Knipe, Howley, P.M., Ed.) Lippencott-Raven,
PhUadelphia. COOK, J. K. (2000). Avian rhinotracheitis. Rev Sci Tech 19, 602-13. CUESTA, I, GENG, X., ASENJO, A., AND VlLLANUEVA, N. (2000). Structural phosphoprotein M2-1 of the human respiratory syncytial virus is an RNA binding protein. J. Gen. Virol 74, 9858-67.
CURRAN, J., AND KOLAKOFSKY, D. (1999). Rephcation of paramyxoviruses. Adv. Virus
Res. 50, 403-422. EASTON, A. J., and CHAMBERS, P. (1997). Nucleotide sequence of the genes encoding the matrix and smaU hydrophobic proteins of pneumonia virus of mice. Virus Res 48, 27-33.
ELANGO, N., SATAKE, M., and VENKATESAN, S. (1985). mRNA sequence of three respiratory syncytial virus genes encoding two nonstructural proteins and a 22K structural protein. J Virol 55, 101-10. FEARNS, R., and COLLINS, P. L. (1999). Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription. J Virol 73, 5852-
64. FELSENSTEIN, J. (1989). "PHYLIP-Phylogeny Inference Package (Version 3.2. Cladistics
5).". GlRAUD, P., BENNEJΈAN, G., GUITTET, M., and TOQUIN, D. (1986). Turkey rhinotracheitis in France: preliminary investigations on a eiliostatic virus. Vet Rec 119, 606-7. Hall, T.A. (1999). BioEdit: a user-friendly biological sequence ahgnment editor and analysis program for Windows 95/98/NT. Nucl Acids. Symp. Ser. 41, 95-98. HARDY, R. W., and WERTZ, G. W. (1998). The product of the respiratory syncytial virus
M2 gene ORF1 enhances readthrough of intergenic junctions during viral transcription. J Virol 72, 520-6. HORVATH, C. M., and LAMB, R. A. (1992). Studies on the fusion peptide of a paramyxovirus fusion glycoprotein: roles of conserved residues in ceU fusion. J Virol 66, 2443-55.
JENTOFT, N. (1990). Why are proteins O-glycosylated? Trends Biochem Sci 15, 291-4.
JOHNSON, P. R., JR., OLMSTED, R. A., PRINCE, G. A., MURPHY, B. R., ALLING, D. W.,
WALSH, E. E., and COLLINS, P. L. (1987). Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol 61, 3163-6.
JUHASZ, K., and EASTON, A. J. (1994). Extensive sequence variation in the attachment
(G) protein gene of avian pneumovirus: evidence for two distinct subgroups. J Gen
Virol 75, 2873-80 Kyte, J. and Doohttle, R.F. (1982). A Simple Method for Displaying the Hydrophobic Character of a Protein. J. Mol Biol. 157, 105-142.
LAMB, R. A., AND KOLAKOFSKY, D. (1996). "Paramyxoviridae: the viruses and their rephcation". In: Fields virology (B. N. Knipe, Howley, P.M., Ed.) Lippencott-
Raven, PhUadelphia. Li, J., LING, R., RANDHAWA, J. S., SHAW, , DAVIS, P. J., JUHASZ, K, PRINGLE, C R., EASTON, A. J., and CAVANAGH, D. (1996). Sequence of the nucleocapsid protein gene of subgroup A and B avian pneumoviruses. Vii'us Res 41, 185-91. LING, R., EASTON, A. J., and PRINGLE, C R. (1992). Sequence analysis of the 22K, SH and G genes of turkey rhinotracheitis virus and their intergenic regions reveals a gene order different from that of other pneumoviruses. J Gen Virol 73, 1709-15. LING, R., DAVIS, P. J., Yu, Q., WOOD, C M., PRINGLE, C. R., CAVANAGH, D., and EASTON,
A. J. (1995). Sequence and in vitro expression of the phosphoprotein gene of avian pneumovirus. Virus Res 36, 247-57. MARRIOT, A.C., SMITH, J.M., AND EASTON, A. (2001). Fidelity of leader and traUer sequence usage by the respiratory syncytial virus and avian pneumovirus rephcation complexes. J. Virol. 75, 6265-72.
MINK, M. A., STEC, D. S., and COLLINS, P. L. (1991). Nucleotide sequences of the 3' leader and 5' traUer regions of human respiratory syncytial virus genomic RNA.
Virology 185, 615-24.
MIYAHARA, K.; KITADA, S., YOSHIMOTO, M., MATSUMURA, H., KAWANO, M., KOMADA, H.,
TSURUDOME, M., KUSAGAWA, S., NlSHIO, M., and ITO, Y. (1992). Molecular evolution of human paramyxoviruses. Nucleotide sequence analyses of the human parainfluenza type 1 virus NP and M protein genes and construction of phylogenetic trees for aU the human paramyxoviruses. Arch Virol 124, 255-68. MORRISON, T. G. (1988). Structure, function, and intraceUular processing of paramyxovirus membrane proteins. Virus Res 10, 113-35. NAYLOR, C J., BRITTON, P., and CAVANAGH, D. (1998). The ectodomains but not the transmembrane domains of the fusion proteins of subtypes A and B avian pneumovirus are conserved to a simUar extent as those of human respiratory syncytial virus. J Gen Virol 79, 1393-8. PLOWS, D. J., and PRINGLE, C R. (1995). Variation in the fusion glycoprotein gene of human respiratory syncytial virus subgroup A. Virus Genes 11, 37-45. POCH, O., BLUMBERG, B. M., BOUGUELERET, L., and TORDO, N. (1990). Sequence comparison of five polymerases (L proteins) of unsegmented negative-strand RNA viruses: theoretical assignment of functional domains. J Gen Virol 71, 1153-62. POCH, O., SAUVAGET, I., DELARUE, M., and TORDO, N. (1989). Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. Embo J 8, 3867-74.
RANDHAWA, J. S., MARRIOTT, A. C, PRINGLE, C R., and EASTON, A. J. (1997). Rescue of synthetic minirephcons estabhshes the absence of the NSl and NS2 genes from avian pneumovirus. J Virol 71, 9849-54.
RANDHAWA, J. S., WILSON, S. D., TOLLEY, K. P., CAVANAGH, D., PRINGLE, C R., and EASTON, A. J. (1996). Nucleotide sequence of the gene encoding the viral polymerase of avian pneumovirus. J Gen Virol 77, 3047-51. SAMAL, S. K., and ZAMORA, M. (1991). Nucleotide sequence analysis of a matrix and smaU hydrophobic protein dicistronic mRNA of bovine respiratory syncytial virus demonstrates extensive sequence divergence of the smaU hydrophobic protein from that of human respiratory syncytial virus. J Gen Virol 72, 1715-20.
SATAKE, M., and VENKATESAN, S. (1984). Nucleotide sequence of the gene encoding respiratory syncytial virus matrix protein. J Virol 50, 92-9. SEAL, B. S., SELLERS, H. S., and MEINERSMANN, R. J. (2000). Fusion protein predicted amino acid sequence of the first US avian pneumovirus isolate and lack of heterogeneity among other US isolates. Virus Res 66, 139-47. SEDLMEIER, R., and NEUBERT, W. J. (1998). The rephcative complex of paramyxoviruses: structure and function. Adv Virus Res 50, 101-39. STEC, D.S., HILL, M.G., 3RD, AND COLLINS, P.L. (1991). Sequence analysis of the polymerase L gene of human respiratory syncytial virus and predicted phylogeny of nonsegmented negative-strand viruses. Virology 183, 273-87
VANDENHOOGEN, B. G., DE JONG, J. C, GROEN, J., KUIKEN, T., DE GROOT, R.,
FOUCHIER, R. A., and OSTERHAUS, A. D. (2001). A newly discovered human pneumovirus isolated from young chUdren with respiratory tract disease. Nat Med
7(6), 719-24. VIRUS TAXONOMY (2000). Seventh report of the international Committee on Taxonomy of Viruses.
WERTZ, G. W., COLLINS, P. L., HUANG, Y., GRUBER, C, LEVINE, S., and BALL, L. A. (1985). Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein. Proc Natl Acad Sci USA 82, 4075-9. YU, Q., DAVIS, P. J., BARRETT, T., BlNNS, M. M., BOURSNELL, M. E., and CAVANAGH, D. (1991). Deduced amino acid sequence of the fusion glycoprotein of turkey rhinotracheitis virus has greater identity with that of human respiratory syncytial virus, a pneumovirus, than that of paramyxoviruses and morbilhviruses. J Gen Virol 72, 75-81. YU, Q., DAVIS, P. J., Li, J., and CAVANAGH, D. (1992). Cloning and sequencing of the matrix protein (M) gene of turkey rhinotracheitis virus reveal a gene order different from that of respiratory syncytial virus. Virology 186, 426-34.
ZAMORA, M., and SAMAL, S. K. (1992). Sequence analysis of M2 mRNA of bovine respiratory syncytial virus obtained from an F-M2 dicistronic mRNA suggests structural homology with that of human respiratory syncytial virus. J Gen Virol 73, 737-41. Primers used for RT-PCR detection of known paramyxo-viruses. Primers for hPIV-1 to 4, mumps, measles, Tupaia, Mapuera and Hendra are developed in house and based on aUignments of avaUable sequences. Primers for New Castle Disease Virus are taken from Seal, J., J. et al; Chn. Microb., 2624-2630, 1995. Primers for Nipah and general paramyxovirus-PCR are taken from: Chua, K.B., et al; Science, 288 26 may 2000
Virus primers located in protein
HPIV-1 fwd 5'-TGTTGTCGAGACTATTCCAA-3' HN
Rev 5'-TGTTG(T/A)ACCAGTTGCAGTCT-3'
HPIV-2 Fwd 5'-TGCTGCTTCTATTGAGAAACGCC-3' N
Rev 5'-GGTGAC/T TC(T/C)AATAGGGCCA-3'
HPIV-3 Fwd 5'-CTCGAGGTTGTCAGGATATAG-3' HN
Rev 5'-CTTTGGGAGTTGAACACAGTT-3'
HPIV-4 Fwd 5'-TTC(A/G)GTTTTAGCTGCTTACG-3' N
Rev 5'-AGGCAAATCTCTGGATAATGC-3'
Mumps Fwd 5'-TCGTAACGTCTCGTGACC-3' SH
Rev 5'-GGAGATCTTTCTAGAGTGAG-3'
NDV Fwd 5'-CCTTGGTGAiTCTATCCGIAG-3' F
Rev 5'-CTGCCACTGCTAGTTGiGATAATCC-3'
Tupaia Fwd 5'-GGGCTTCTAAGCGACCCAGATCTTG-3' N
Rev 5'-GAATTTCCTTATGGACAAGCTCTGTGC-3'
Mapuera Fwd 5'-GGAGCAGGAACTCCAAGACCTGGAG-3' N
Rev: 5'-GCTCAACCTCATCACATACTAACCC-3'
Hendra Fwd 5'-GAGATGGGCGGGCAAGTGCGGCAACAG-3' N
Rev 5'-GCCTTTGCAATCAGGATCCAAATTTGGG-3'
Nipah Fwd 5'-CTGCTGCAGTTCAGGAAACATCAG-3' N
Rev 5'-ACCGGATGTGCTCACAGAACTG-3'
HRSV Fwd 5'-TTTGTTATAGGCATATCATTG-3' F
Rev 5'-TTAACCAGCAAAGTGTTA-3'
Measles Fwd 5'-TTAGGGCAAGAGATGGTAAGG-3' N
Rev 5'-TTATAACAATGATGGAGGG-3'
General Paramyxoviridae : Fwd 5'-CATTAAAAAGGGCACAGACGC-3' Rev 5'-TGGACATTCTCCGCAGT-3' Primers for RAP-PCR:
ZF1: 5'-CCCACCACCAGAGAGAAA-3' ZF4: 5'-ACCACCAGAGAGAAACCC-3' ZF7: 5'-ACCAGAGAGAAACCCACC-3' ZF10: 5'-AGAGAGAAACCCACCACC-3' ZF13: 5'-GAGAAACCCACCACCAGA-3' ZF16: 5'-AAACCCACCACCAGAGAG-3'
CS1: 5'-GGAGGCAAGCGAACGCAA-3' CS4: 5'-GGCAAGCGAACGCAAGGA-3' CS7: 5'-AAGCGAACGCAAGGAGGC-3' CS 10: 5'-CGAACGCAAGGAGGCAAG-3' CS 13:5'-ACGCAAGGAGGCAAGCGA-3' CS16:5'-CAAGGAGGCAAGCGAACG-3'
20 fragments successfuUy purified and sequenced:
10 fragments found with sequence homology in APV
Fragment 1 ZF 7, 335 bp N gene
Fragment 2 ZF 10, 235 bp N gene
Fragment 3 ZF 10, 800 bp M gene
Fragment 4 CS 1, 1250 bp F gene
Fragment 5 CS 10, 400 bp F gene
Fragment 6 CS 13, 1450 bp F gene
Fragment 7 CS 13, 750 bp F gene
Fragment 8 ZF 4, 780 bp L gene (protein level)
Fragment 9 ZF 10, 330 bp L gene (protein level)
Fragment 10 ZF10, 250bp L gene (protein level)
Primers used for RAP-PCR amphfication of nucleic acids from the prototype isolate. Example 5
Further exploration of the two subtypes of hMPV
Based on phylogenetic analysis of the different isolates of hMPV obtained so far, two genotypes have been identified with virus isolate 00-1 being the prototype of genotype A and isolate 99-1 the prototype of genotype B.
We hypothesise that the genotypes are related to subtypes and that re-infection with viruses from both subgroups occur in the presence of pre-existing immunity and the antigenic variation may not be strictly required to aUow re-infection.
Furthermore, hMPV appears to be closely related to avian pneumovirus, a virus primarUy found in poultry. The nucleotide sequences of both viruses show high percentages of homology, with the exception of the SH and G proteins. Here we show that the viruses are cross-reacting in tests, which are based primarUy on the nucleoprotein and matrixprotein, but they respond differently in tests, which are based on the attachment proteins. The differences in virus neutralisation titers provide further proof that the two genotypes of hMPV are two different serotypes of one virus, where APV is a different virus.
The cross reaction between the two serotypes and the cross reaction between APV an hMPV
Methods
Protocol for IgG , IgA and IgM antibody detection for hMPV:
The indirect IgG EIA for hMPV was performed in microtitre plates essentiaUy as described previously (Rothbarth, P.H. et al., 1999; Influenza virus serology-a comparative study. J. of Vir. Methods 78 (1999) 163-169. Briefly, concentrated hMPV was solubUized by treatment with 1% Triton X-100 an coated for 16 hr at room temperature into microtitre plates in PBS after determination of the optimal working dilution by checkerboard titration. Subsequently, 100 ul volumes of 1:100 chluted human serum samples in EIA buffer were added to the weUs and incubated for 1 h at 37C. Binding of human IgG was detected by adding a goat anti-human IgG peroxidase conjugate (Biosource, USA). Adding TMB as substrate developed plates and OD was measured at 450 nm. the results were expressed as the S(ignal)/N(egative) ratio of the OD. A serum was considered positive for IgG, if the S/N ratio was beyond the negative control plus three times the standard.
hMPV antibodies of the IgM and IgA classes were detected in sera by capture EIA essentiaUy as described previously (Rothbarth, P.H et al. 1999; Influenza virus serolgy-a comparative study. J. Vir. methods 78 (1999) 163-169. For the detection of
IgA and IgM commerciaUy avaUable microtiter plates coated with anti human IgM or IgA specific monoclonal antibodies were used. Sera were diluted 1:100 and after incubation of 1 hr at 37C, an optimal working dilution of hMPV is added at each well (100 ul). Incubated 1 hr 37C After washing polyclonal anti hMPV labeled with peroxidase was added, the plate was incubated 1 hr 37C Adding TMB as substrate developed plates and OD was measured at 450 nm. the results were expressed as the S(ignal)/N(egative) ratio of the OD. A serum was considered positive for IgG, if the S/N ratio was beyond the negative control plus three times the standard.
AVP antibodies were detected in an AVP inhibition assay. Protocol for APV inhibition test is included the APV-Ab SVANOVIR ® enzyme immunoassay which is manufactured by SVANOVA Biotech AB, Uppsal Science Park Glunten SE-751 83 Uppsala Sweden. The results were expressed as the S(ignal)/N(egative) ratio of the OD. A serum was considered positive for IgG, if the S/N ratio was beyond the negative control plus three times the standard.
1. Guinea pigs
A. (re) infection of guinea pigs with both subtypes of hMPV
Virus isolates ned 00/01 (subtype A) and ned/99/01 (subtype B) have been used to inoculate 6 guinea pigs per subtype (intratracheal, nose and eyes). 6 GP's infected with hMPV 00-1 (10e6,5 TCID50) 6 GP's infected with hMPV 99-1 (10e4,l TCID50) 54 Days after the primary infection, the guinea pigs have been inoculated with the homologous and heterologous subtypes (10e4 TCID50/ml):
2 guinea pigs: 1st infection 00-1; 2nd 99-1 (heterologous) 3 guinea pigs: 1st infection 00-1; 2nd 00-1 (homologous)
2 guinea pigs: 1st infection 99-1; 2nd 00-1 (heterologous)
3 guinea pigs: 1st infection 99-1; 2nd 99-1 (homologous)
Throat and nose swabs have been coUected for 12 days (1st infection) or 8 days (2nd infection) post infection, and have been tested for presence of the virus by RT-PCR assays.
Results of RT-PCR assay: Figure 29
Summary of results: guinea pigs inoculated with virus isolate ned/00/01 show infection of the upper respiratory tract day 1 to 10 post infection. Guinea pigs inoculated with ned/99/01 show infection of the upper respiratory tract day 1 to 5 post infection. Infection with ned/99/01 appears to be less severe than infection with ned/00/01. A second inoculation of the guinea pigs with the heterologous virus results in re-infection in 3 out of 4 guinea pigs and with the homologous virus in 2 out of 6 guinea pigs. No or only little clinical symptoms were noted in those animals that became re-infected, and no clinical symptoms were seen in those animals that were protected against the re-infections, demonstrating that even with wild-type virus, a protective effect of the first infection is evident, showing the possible use of heterologous (and of course homologues) isolates as a vaccine, even in an unattenuated form.
Both subtypes of hMPV are able to infect guinea pigs, although infection with subtype B (ned/99/01) seems less severe (shorter period of presence of the virus in nose and throat) than infection with subtype A (ned/00/01). This may be due to the higher dose given for subtype A, or to the lower virulence of subtype B. Although the presence of pre-existing immunity does not completely protect against re-infection with both the homologous and heterologous virus, the infection appears to be less prominent in that a shorter period of presence of virus was noted and not aU animals became virus positive. B. Serology of guinea pigs infected with both subtypes of hMPV
At day 0, 52, 70, 80, 90, 110, 126 and 160 sera were coUected from the guinea pigs and tested at a 1:100 dUution in a whole virus ELISA against ned/00/01 and ned/99/01 antigen.
Figure 30 A and B: IgG response against ned/00/01 and ned/99/01 for each individual guinea pig Figure 31: Specificity of the ned/00/01 and ned/99/01 ELISA. Only data from homologous reinfected guinea pigs have been used.
Figure 32: Mean IgG response against ned/00/01 and ned/99/01 ELISA of 3 homologous (00-1/00-1), 2 homologous (99-1/99-1), 2 heterologous (99-1/00-1) and 2 heterologous (00-1/99-1) infected guinea pigs.
Summary of results:
Only a minor difference in response to the two different ELISA's is observed. Whole virus ELISA against 00-1 or 99-1 cannot be used to discriminate between the two subtypes.
CReactivitv of sera raised against hMPV in guinea pigs with APV antigen
Sera coUected from the infected guinea pigs have been tested with an APY inhibition ELISA
Figure 33: Mean percentage of APV inhibition of hMPV infected guinea pigs.
Summary of results: Sera raised against hMPV in guinea pigs, react in the APV inhibition test in a same manner as they react in the hMPV IgG ELISA's.
Sera raised against ned/99/01 reveal a lower percentage of inhibition in the APV inhibition ELISA than sera raised against ned/00/01. Guinea pigs infected with ned/99/01 might have a lower titer (as is seen in the hMPV ELISA's) or the cross- reaction of ned/99/01 with APV is less than that of ned 00/01. Nevertheless, the APV- Ab inhibition ELISA can be used to detect hMPV antibodies in guinea pigs.
(D. Virus neutrahsation assays with sera raised against hMPV in guinea pigs.
Sera coUected at day 0, day 52, 70 and 80 post infection were used in a virus (cross) neutrahsation assay with ned/00/01, ned/99/01 and APV-C. Starting dUution was 1 to
10 and 100 TCID50 virus per weU was used. After neutralisation, the virus was brought on tMK ceUs, 15 min. centrifuged at 3500 RPM, after which the media was refreshed.
The APV tests were grown for 4 days and the hMPV tests were grown for 7 days.
CeUs were fixed with 80% aceton, and IFA's were conducted with monkey-anti hMPV fitc labeled. WeUs that were negative in the staining were considered as the neutralising titer. For each virus a 10-log titration of the virus stock and 2 fold titration of the working solution was included.
Figure 34: Virus neutrahsation titers of ned 00/01 and ned/99/01 infected guinea pigs against ned/00/01, ned/99/01 and APV-C
2. Cynomologous macaques
A. (re) infection of cynomologous macaques with both subtypes of hMPV
Virus isolates ned/00/01 (subtype A) and ned/99/01 (subtype B) (le5 TCID50) have been used to inoculate 2 cynomologous macaques per subtype (intratracheal, nose and eyes). Six months after the primary infection, the macaque have been inoculated for the second time with ned/00/01. Throat swabs have been coUected for 14 days (1st infection) or 8 days (2nd infection) post infection, and have been tested for presence of the virus by RT-PCR assays.
Figure 35: Results of RT-PCR assays on throat swabs of cynomolgous macaques inoculated (twice) with ned/00/01.
Summary of results: Summary of results: cynomologous macaques inoculated with virus isolate ned/00/01 show infection of the upper respiratory tract day 1 to 10 post infection. Chnical symptoms included a suppurative rhinitis. A second inoculation of the macaques with the homologous virus results in re-infection, as demonstrated by PCR, however, no chnical symptoms were seen.
B. Serology on sera coUected of hMPV infected cynomologous macaques.
From the macaques which received ned/00/01 sera were coUected during 6 months after the primary infection (re-infcetion occurred at day 240 for monkey 3 and day
239 for monkey 6).
Sera were used to test for the presence of IgG antibodies against either ned/00/01 or
APV, and for the presence against IgA and IgM antibodies against ned/00/01.
Results: Figure 36A
IgA, IgM and IgG response against ned/00/01 of 2 cynomologous macaques
(re)infected with ned/00/01.
Figure 36B IgG response against APV of 2 cynbomologous macaques infected with ned/00/01.
Summary of results:
Two macaques have been succesfuUy infected with ned/00/01 and in the presence of antibodies against ned/00/01 been reinfected with the homologous virus. The response to IgA and IgM antibodies shows the raise in IgM antibodies after the first infection, and the absence of it after the reinfection. IgA antibodies are only detected after the re-infection, showing the immediacy of the immune response after a first infection. Sera raised against hMPV in macaques which were tested in an APV inhibition ELISA show a simUar response as to the hMPV IgG ELISA.
Discussion/conclusion hMPV antibodies in cynomologous macaques are detected with the APV inhibition
ELISA with a simUar sensitivity as with an hMPV ELISA, and therefore the APV inhibition EIA is suitable for testing human samples for the presence of hMPV antibodies.
CNirus (cross) neutrahsation assays with sera coUected from hMPV infected cynomologous macaques
Summary of results: The sera taken from day 0 to day 229 post primary infection show only low virus neutralisation titers against ned/00/01 (0-80), the sera taken after the secondary infection show high neutrahsation titers against ned/00/01: >1280. Only sera taken after the secondary infection show neutrahsation titers against ned/99/01 (80-640), and none of the sera neutrahse the APV C virus.
There is no cross reaction between APV-C and hMPV in virus (cross)neutrahsation assays, where there is a cross reaction between ned/00/01 and ned/99/01 after a boost of the antibody response.
3. Humans
Sera of patients ranging in age of <6 months to >20 years of age have previously been tested in IFA and virus neutrahsation assays against ned/00/01. (See tabel 1 of patent). Here we have tested a number of these sera for the presence of IgG, IgM and IgA antibodies in an ELISA against ned/00/01, and we tested the samples in the APV inhibition ELISA.
Results: Figure 37 Comparison of the use of the hMPV ELISA and the APV inhibition ELISA for the detection of IgG antibodies in human sera, there is a strong correlation between the IgG hMPV test and the APV-Ab test, therefore the APV-Ab test is essentiaUy able to detect IgG antibodies to hmPV in humans. 4. Poultry
96 chickens have been tested in both the APV inhibition ELISA and the ned/00/01 ELISA for the presence of IgG antibodies against APV.
Summary of results: Both the hMPV ELISA and the APV inhibition ELISA detect antibodies against APV (data not shown).
Summary of results.
We found two genotypes of hMPV with ned/00/01 being the prototype of subgroup A and ned/99/01 the prototype of subgroup B.
"According to classical serogical analyses (as for example known Francki, R.I.B., Fauquet, CM., Knudson, D.L., and Brown, F., Classification and nomenclature of viruses. Fifth report of the international Committee on Taxonomy of Viruses. Arch Virol, 1991. Supplement 2: p. 140-144), two subtypes can be defined on the basis of its immunological distinctiveness, as determined by quantitative neutrahzation assays with animal antisera. Two distinct serotypes have either no cross-reaction with eachother or show a homologous-to heterologous titer ratio >16 in both directions. If neutrahzation shows a certain degree of cross-reaction between two viruses in either or both directions (homologous-to-heterologous titer ration of eight or 16), distinctiveness of serotype is assumed if substantial biophysical/biochemical differences of DNA's exist. If neutrahzation shows a distinct degree of cross-reaction between two viruses in either or both directions (homologous-to-heterologous titer ration of smaUer than eight), identity of serotype of the isolates under study is assumed."
For RSV it is known that re-infection occurs in the presence of pre-existing immunity (both homologous and heterologous). Infection of guinea pigs and cynomologous macaques with both the homologous and heterologous serotypes of hMPV revealed that this is also true for hMPV. In addition, IgA and IgM ELISA's against hMPV revealed the reaction of IgA antibodies only occurs after re-infection. Sera raised against hMPV or APV respond in an equal way in APV and hMPV ELISAs. From the nucleotide sequence comparisons, it is known that the viruses show about 80% amino acid homology for the N, P, M, and F genes. In ELISA's the N and M proteins are the main antigens to react. Virus neutrahsation assays (known to react against the surface glycoproteins G, SH and F) show a difference between the two different sera.
Although APV en hMPV cross react in ELISAs, phylogenetic analyses of the nucleotide sequences of hMPV and APV, the differences in virus neutrahsation titers of sera raised against the two different viruses, and the differences in host usage again reveal that APV-C and hMPV are two different viruses. Based on the results we speculate that hMPV infection in mammals is possible a result of a zoonotic event from birds to mammals. But the virus has adapted in such a way (i.e. the G and SH proteins) that a return (from mammals to birds) zoonotic event seems unlikely, considering the presence of AVP in birds.
Addendum
Background information on Pneumovirinae
The famUy oi Paramyxoviridae contains two subfamUys: the Paramyxovirinae and the Pneumovirinae. The subfamUy Pneumovirinae consists of two genera: Pneumovirus and Metapneumovirus. The genus Pneumovirus contains the human, bovine, ovine and caprine respiratory syncytial viruses and the pneumonia virus of mice (PVM). The genus Metapneumovirus contains the avian pneumoviruses (APV, also referred to as TRTV).
The classification of the genera in the subfamUy Pneumovirinae is based on classical virus characteristics, gene order and gene consteUation. Viruses of the genus Pneumovirus are unique in the famUy of Paramyxoviridae in having two nonstructural proteins at the 3'end of the genome (3'-NS 1-NS2-N-P-M-SH-G-F-M2-L- 5'). In contrast, viruses in the genus Metapneumovirus lack the NSl and NS2 genes and the organisation of genes between the M and L coding regions is different: 3'-N-P- M-F-M2-SH-G-L-5'. AU members of the subfamUy Paramyxovirinae have haemagluttinating activity, but this function is not a defining feature for the subfamUy Pneumovirinae, being absent in RSV and APV but present in PMV. Neuraminidase activity is present in members of the genera Paramyxovirus and Rubulavirus (subfamUy Paramyxovirinae) but is absent in the genus Morbillivirus (subfamUy Paramyxovirinae) and the genera Pneumovirus and Metapneumovirus (subfamUy Pneumovirinae). A second distinguishing feature of the subfamUy Pneumovirinae is the apparent hmited utilization of alternative ORFs within mRNA by RSN In contrast, several members of the subfamUy Paramyxovirinae, such as Sendai and Measles viruses, access alternative ORFs within the mRΝA encoding the phosphoprotein (P) to direct the synthesis of a novel protein. The G protein of the Pneumovirinae does not have sequence relatedness or structural simUarity to the HΝ or H proteins oi Paramyxovirinae and is only approximately half the size of their chain length. In addition, the Ν and P proteins are smaUer than their counterparts in the Paramyxovirinae and lack unambigous sequence homology. Most nonsegmented negative stranded RΝA viruses have a single matrix (M) protein. Members of the subfamUy Pneumovirinae are an exception in having two such proteins, M and M2. The M protein is smaUer than its Paramyxovirinae counterparts and lacks sequence relatedness with Paramyxovirinae.
When grown in ceU cultures, members of the subfamUy Pneumovirinae show typical cytopathic effects; they induce characteristic syncytia formation of ceUs.
(Colhns, 1996).
The subfamily Pneumovirinae, genus Pneumovirus hRSV is the type-species of the genus Pneumovirus and is a major and widespread cause of lower respiratory tract illness during infancy and early childhood (Selwyn, 1990). In addition, hRSV is increasingly recognised as an important pathogen in other patient groups, including immune compromised individuals and the elderly. RSV is also an important cause of community-acquired pneumonia among hospitahsed adults of all ages (Englund, 1991; Falsey, 2000; DoweU, 1996). Two major antigenic types for RSV (A and B) have been identified based on differences in their reactivity with monoclonal and polyclonal antibodies and by nucleic acid sequence analyses (Anderson, 1985; Johnson, 1987; SuUender, 2000). In particular the G protein is used in distinguishing the two subtypes. RSV-A and B share only 53% amino acid sequence homology in G, whereas the other proteins show higher homologies between the subtypes (table 1) (Colhns, 1996). Detection of RSV infections has been described using monoclonal and polyclonal antibodies in immunofluorescence techniques (DIF, IFA), virus neutrahsation assays and ELISA or RT-PCR assays (Rothbarth, 1988; Van MUaan, 1994; Coggins, 1998). Closely related to hRSV are the bovine (bRSV), ovine (oRSN and caprine RSV (oRSV), from which bRSV has been studied most extensively. Based on sequence homology with hRSV, the ruminant RSVs are classified within the Pneumovirus genus, subfamUy Pneumovirinae (Colhns, 1996). Diagnosis of ruminant RSV infection and subtyping is based on the combined use of serology, antigen detection, virus isolation and RT-PCR assays (Uttenthal, 1996;Valarcher, 1999; Oberst, 1993; VUcek, 1994).
Several analyses on the molecular organisation of bRSV have been performed using human and bovine antisera, monoclonal antibodies and cDNA probes. These analyses revealed that the protein composition of hRSV and bRSV are very simUar and the genomic organisation of bRSV resembles that of hRSV. For both bRSV and hRSV, the
G and F proteins represent the major neutrahsation and protective antigens. The G protein is highly variable between the hRSV subtypes and between hRSV and bRSV
(53 and 28% respectively) (Prozzi, 1997; Lerch, 1990). The F proteins of hRSV and bRSV strains present comparable structural characteristics and antigenic relatedness. The F protein of bRSV shows 80-81% homology with hRSV, whUe the two hRSV subtypes share 90% homology in F (Walravens, K. 1990).
Studies based on the use of hRSV and bRSV specific monoclonal antibodies have suggested the existence of different antigenic subtypes of bRSV. Subtypes A, B, and AB are distinguished based on reaction patterns of monoclonal antibodies specific for the G protein (Furze, 1994; Prozzi, 1997; Elvander, 1998). The epidemiology of bRSV is very simUar to that of hRSV. Spontaneous infection in young cattle is frequently associated with severe respiratory signs, whereas experimental infection generaUy results in mUder disease with shght pathologic changes (Elvander, 1996). RSV has also been isolated from naturaUy infected sheep (oRSV) (LeaMaster, 1983) and goats (cRSV) (Lehmkuhl, 1980). Both strains share 96% nucleotide sequence with the bovine RSV and are antigenicaUy crossre acting. Therefore, these viruses are also classified within the Pneumovirus genus. A distinct member of the subfamUy Pneumovirinae, genus Pneumovirus is the Pneumonia virus of mice (PVM).
PVM is a common pathogen in laboratory animal colonies, particularly those containing atymic mice. The naturaUy acquired infection is thought to be asymptomatic, though passage of virus in mouse lungs resulted in overt signs of disease ranging from an upper respiratory tract infection to a fatal pneumonia (Richter, 1988; Weir, 1988).
Restricted serological crossreactivity between the nucleocapsid protein (N) and the phosphoprotein (P) of PVM and hRSV has been described but none of the external proteins show cross-reactivity, and the viruses can be distinguished from each other in virus neutrahsation assays (Chambers, 1990a; Gimenez, 1984; Ling, 1989a). The glycoproteins of PVM appear to differ from those of other paramyxoviruses and resemble those of RSV in terms of their pattern of glycosylation. They differ, however, in terms of processing. Unlike RSV, but simUar to the other paramyxoviruses, PVM has haemagglutinating activity with murine erythrocytes, for which the G protein appears to be responsible since a monoclonal antibody to this protein inhibits haemagglutination (Ling, 1989b).
The genome of PVM resembles that of hRSV, including two nonstructural proteins at its 3'end and a simUar genomic organisation (Chambers, 1990a; Chambers, 1990b). The nucleotide sequences of the PVM NS1/NS2 genes are not detectably homologous with those of hRSV (Chambers, 1991). Some proteins of PVM show strong homology with hRSV (N: 60%, and F: 38 to 40%) whUe G is distinctly different (the amino acid sequence is 31 % longer) (Barr, 1991; Barr, 1994; Chambers, 1992). The PVM P gene, but not that of RSV or APV, has been reported to encode a second ORF, representing a unique PVM protein (CoUins, 1996). New PVM isolates are identified by virus isolation, heamagglutination assays, virus neutrahsation assay and various immunofluorescence techniques.
Table with addedum: Amino acid homology between the different viruses within the genus Pneumovirus of the subfamUy Pneumovirinae.
Figure imgf000097_0001
* No detectable sequence homology The genus Metapneumovirus
Avian pneumoviruses (APV) has been identified as the aetiological agent of turkey rhinotracheitis (McDougaU, 1986; CoUins, 1988) and is therefore often referred to as turkey rhinotracheitis virus (TRTV). The disease is an upper respiratory tract infection of turkeys, resulting in high morbidity and variable, but often high, mortahty. In turkey hens, the virus can also induce substantial reductions in egg production. The same virus can also infect chickens, but in this species, the role of the virus as a primary pathogen is less clearly defined, although it is commonly associated with swoUen head syndrome (SHS) in breeder chicken (Cook, 2000).
The virions are pleiomorphic, though mainly spherical, with sizes ranging from 70 to
600 nm and the nucleocapsid, containing the hnear, non-segmented, negative-sense
RNA genome, shows hehcal symmetry (Colhns, 1986; Giraud, 1986). This morphology resembles that of members of the famUy Paramyxoviridae. Analyses of the APV- encoded proteins and RNAs suggested that of the two subfamUys of this famUy (Paramyxovirinae and Pneumovirinae), APV most closely resembled the Pneumovirinae (CoUins, 1988; Ling, 1988; Cavanagh, 1988). APV has no non-structural proteins (NSl and NS2) and the gene order (3'-N-P-M-F- M2-SH-G-L-5') is different from that of mammahan pneumoviruses such as RSV. APV has therefore recently been classified as the type species for the new genus Metapneumovirus (Pringle, 1999).
Differences in neutrahsation patterns, ELISA and reactivity with monoclonal antibodies have revealed the existence of different antigenic types of APV. Nucleotide sequencing of the G gene led to the definition of two virus subtypes (A and B), which share only 38% amino acid homology (Colhns, 1993; Juhasz, 1994). An APV isolated from Colorado, USA (Cook, 1999), was shown to cross-neutrahze poorly with subtype A and B viruses and based on sequence information was designated to a novel subtype, C (Seal, 1998; Seal 2000). Two non-A/non-B APVs were isolated in France, and were shown to be antigenicaUy distinct from subtypes A, B and C Based on amino acid sequences of the F, L and G genes, these viruses were classified again as a novel subtype, D (Bayon-Auboyer, 2000).
Diagnosis of APV infection can be achieved by virus isolation in chicken or turkey tracheal organ cultures (TOCs) or in Vero ceU cultures. A cytopathic effect (CPE) is generaUy observed after one or two additional passages. This CPE is characterised by scattered focal areas of ceU rounding leading to synctyial formation (Buys, 1989). A number of serology assays, including IF and virus neutrahsation assays have been developed. Detection of antibodies to APV by ELISA is the most commonly used method (O'Loan, 1989; Gulati, 2000). Recently, the polymerase chain reaction (PCR) has been used to diagnose APV infections. Swabs taken from the oesophagus can be used as the starting material (Bayon-Auboyer, 1999; Shin, 2000)
Alansari, H. and Potgieter, L.N.D. 1994. Nucleotide and predicted amino acid sequence analysis of the ovine respiratory syncytial virus non-structural IC and IB genes and the smaU hydrophobic protein gene. J.Gen.Virol. 75: 401-404.
Alansari, H., Duncan R.B., Baker, J.C. and Potgieter, L.N. 1999. Analysis of ruminant respiratory syncytial virus isolates by RNAse protection of the G glycoprotein transcripts. J.Net.Diagn.Invest. 11: 215-20
Anderson, L.J, Hierholzer, J.C, Tsou, C, Hendry, R.M., Fernic, B.F., Stone, Y. and Mclntosh, K. 1985. Antigenic characterisation of respiratory syncytial virus strains with monoclonal antibodies. J. Inf. Dis. 151: 626-633.
Barr, J., Chambers, Pringle, CR., Easton, A.J. 1991. Sequence of the major nucleocapsid protein gene of pneumonia virus of mice: sequence comparisons suggest structural homology between nucleocapsid proteins of pneumoviruses, paramyxoviruses, rhabdoviruses and filoviruses. J.Gen.Virol. 72: 677-685.
Barr, J., Chambers, P., Harriott, P., Pringle, CR. and Easton, A.J. 1994. Sequence of the phosphoprotein gene of pneumonia virus of mice: expression of multiple proteins from two overlapping rading frames. J. Virol. 68: 5330-5334.
Bayon-Auboyer, M.H., Jestin, V., Toquin, D., Cherbonnel, M. and Eterradosi, Ν. 1999. Comparison of F-, G- and Ν-based RT-PCR protocols with conventional virological procedures for the detection and typing of turkey rhinotracheitis virus. ArchNir. 144: 1091-1109.
Bayon-Auboyer, M.H., Arnauld, C, Toquin, D., and Eterradossi, Ν. 2000. Nucleotide sequences of the F, L and G protein genes of two non-A/non-B avian pneumoviruses (APV) reveal a novel APV subgroup. J.Gen.Virol. 81: 2723-2733. Buys, S.B., Du Preez, J.H. and Els, H.J. 1989. The isolation and attenuation of a virus causing rhinotracheitis in turkeys in South Africa. Onderstepoort J.Vet.Res. 56:
87-98.
Cavanagh, D. and Barrett, T. 1988. Pneumovirus-like characteristics of the mRNA and proteins of turkey rhinotracheitis virus. Virus Res. 11: 241-256.
Chambers, P., Pringle, CR. and Easton, A.J. 1990a. Molecular cloning of pneumonia virus of mice. J. Virol. 64: 1869-1872.
Chambers, P., Matthews, D.A, Pringle, CR. and Easton, A. J. 1990b. The nucleotide sequences of intergenic regions between nine genes of pneumonia virus of mice estabhsh the physical order of these genes in the viral genome. Virus Res. 18: 263- 270.
Chambers, P., Pringle, C.R., and Easton, A.J. 1991. Genes 1 and 2 of pneumonia virus of mice encode proteins which have httle homology with the IC and IB proteins of human respiratory syncytial virus. J.Gen.Vir. 72: 2545-2549.
Chambers, P. Pringle CR, Easton AJ. 1992. Sequence analysis of the gene encding the fusion glycoprotein of pneumonia virus of mice suggests possible conserved secondary structure elements in pramyxovirus fusion glycoproteins. J. Gen. Virol. 73: 1717- 1724.
Coggins, W.B., Lefkowitz, E.J. and SuUender, W.M. 1998. Genetic variabihty among group A and group B respiratory syncytial viruses in a chUdren's hospital. J. Clin. Microbiol. 36: 3552-3557.
CoUins, M.S. and Gough, R.E., Lister, S A, Chettle, N. and Eddy, R. 1986. Further characterisation of a virus associated with turkey rhiotracheitis. Vet. Rec. 119: 606.
CoUins, M.S. and Gough, R.E. 1988. Characterisation of a virus associated with turkey rhinotracheitis. J. Gen.Virol. 69: 909-916. Colhns, M.S., Gough, R.E., and Alexander, D.J. 1993. Antigenic differentiation of avian pneumovirus isolates using polyclonal antisera and mouse monoclonal antibodies. Avian Pathology 22: 469-479.
CoUins, P.L., Mclntosh, K., Chanock, R.M. 1996. Respiratory syncytial virus. P. 1313- 1351. In: B.N. Fields, D.M. Knipe, and P.M. Howley (ed.). Fields virology, 3rd ed., vol. 1 Lippincott-Raven, PhUadelphia, Pa, USA.
Cook,, J.K.A., Huggins, M.B., OrbeU, S.J. and Senne, D.A. 1999. Prehminiary antigenic characterization of an avian pneumovirus isolated from commercial turkeys in Colorado, USA. Avian pathol. 28: 607-617.
Cook, J.K.A. 2000. Avian rhinotracheitis. Rev. Sci. tech. off int. Epiz. 19 : 602-613.
DoweU, S.F., Anderson, L.J.,Gary, H.E., Erdman, D.D., Plouffe, J.F., FUe, T.M.,
Marston, B. J. and Breiman, R.F. 1996. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitahzed adults. J. Infect .Dis.174: 456-462.
Elvander, M. 1996. Severe respiratory disease in dairy cows caused by infection with bovine respiratory syncytial virus. Vet. Rec. 138: 101-105.
Elvander, M., VUcek, S., Baule, C, Uttenthal, A., BaUagi-Pordany, A. and Belak, S. 1998. Genetic and antigenic analysis of the G attachment protein of bovine respiratory syncytial virus strains. J. Gen. Virol. 79: 2939-2946.
Englund, J.A., Anderson, L.J., and Rha e, F.S. 1991. Nosocomial transmission of respiratory syncytial virus in immunocompromised adults. J. Chn. Microbiol. 29: 115- 119.
Falsey, A.R. and Walsh, E.E. 2000. Respiratory syncytial virus infection in adults. Chn. Microb. Rev. 13: 371-84. Furze, J., Wertz, G., Lerch, R. and Taylor, G. 1994. Antigenic heterogeneity of the attachment protein of bovine respiratory syncytial virus. J. Gen. Virol. 75: 363-370.
Gimenez, H.B., Cash, P. and Melvin, W.T. 1984. Monoclonal antibodies to human respiratory syncytial virus and their use in comparison of different virus isolates. J. Gen. Virol. 65: 963-971.
Gulati, B.R., Cameron, K.T., Seal, B.S, Goyal, S.M., Halvorson, D.A. and Njenga, M.K. 2000. Development of a highly sensitive and specific enzyme-hnked immunosorbent assay based on recombinant matrix protein for detection of avian pneumovirus antibodies. J. Chn. Microbiol. 38: 4010-4.
Johnson, P.R., Spriggs M.K., Olmsted, R.A. and Colhns, P.L. 1987. The G glycoprotein of human respiratory syncytial virus subgroups A and B: extensive sequence divergence between antigenicaUy related proteins. Proc. Natl. Acad. Sci. USA 84: 5625-5629.
Juhasz, K. and Easton, A. J. 1994. Extensive sequence variation in the attachment (G) protein gene of avian pneumovirus: evidence for two distinct subgroups. J. Gen. Virol. 75: 2873-2880.
LeaMaster, B.R., Evermann, J.F., MueUer, M.K., Prieur, M.K. and Schhe, J.V. 1983. Serologic studies on naturaUy occurring respiratory syncytial virus and Haemophilus sommus infections in sheep. American Association of Veterinary Laboratory Diagnosticians 26: 265-276.
Lehmkuhl, H.D., Smith, M.H., Cuthp, R.C. 1980. Morphogenesis and structure of caprine respiratory syncytial virus. Arch.Vir. 65: 269-76.
Lerch, R.A., Anderson, K and Wertz, G.W. 1990. Nucleotide sequence analysis and expression from recombinant vectors demonstrate that the attachment protein G of bovine respiratory syncytial virus is distinct from that of human respiratory syncytial virus. J.Virol. 64: 5559-5569. Ling, R. and Pringle, CR. 1988. Turkey rhinotracheitis virus: in vivo and in vitro polypeptide synthesis. J. Gen. Virol. 69: 917-923.
Ling, R. and Pringle, CR. 1989a. Polypeptides of pneumonia virus of mice. I.
Immunological cross-reactions and post-translational modifications. J. Gen. Virol. 70: 1427-1440.
Ling, R. and Pringle, CR. 1989b. Polypeptides of pneumonia virus of mice. II. Characterization of the glycoproteins. J.Gen.Virol. 70: 1441-1452.
McDougaU, J.S. and Cook, J.K.A. 1986. Turkey rhinotracheitis: preliminary investigations. Vet. Rec. 118: 206-207.
Oberst, R.D., M.P. Hays, KJ. Hennessy, L.C Stine, J.F. Evermann, and KeUing, CL. 1993. Characteristic differences in reverse transcription polymerase chain reaction products of ovine, bovine and human respiratory syncytial viruses. J. Vet. Diagn. Investig. 5: 322-328.
O'Loan, C.J., AUan, G., Baxter-Jones, C and McNulty, M.S. 1989. An improved
ELISA and serum neutrahsation test for the detection of turkey rhinotracheitis virus antibodies. J. Virol. Meth. 25: 271-282.
Paccaud, M.F. and Jacquier, C, 1970. A respiratory syncytial virus of bovine origin. Arch. Ges.Virusforsch. 30: 327-342.
Pringle, CR. 1999 Virus taxonomy at the Xith international congress of virology, Sydney, Australia 1999. Arch. Virol. 144/2: 2065-2070.
Prozzi, D., Walravens, K., Langedijk, J.P.M , Daus, F., Kramps, J.A. and Letesson, J.J. 1997. Antigenic and molecular analysis of the variabihty of bovine respiratory syncytial virus G glycoprotein. J. Gen. Virol. 78: 359-366. Randhawa, j.S., Marriott, A.C, Pringle, CR., and A.J. Easton 1997. Rescue of synthetic minirephcons estabhsh the absence of the NSl and NS2 genes from avian pneumoviruses. J. Virol. 71: 9849-9854.
RiehterAB., Thigpen, J.E., Richter, CS. and Mackenzie, J.M. 1988. Fatal pneumonia with terminal emaciation in nude mice caused by pneumonia vrius of mice. Lab. Anim. Sci. 38: 255-261.
Rothbarth, P.H., Habova, J.J. and Masurel, N. 1988. Rapid diagnosis of infections caused by respiratory syncytial virus. Infection 16:252.
Seal, B.S. 1998. Matrix protein gene nucleotide and predicted amino acid sequence demonstrate that the first US avian pneumovirus isolate is distinct form European strans. Virus Res. 58, 45-52.
Seal, B.S., Sellers, H.S., Meinersmann, R.J. 2000. Fusion protein predicted amino acid sequence of the first US avian pneumovirus isolate and lack of heterogeneity among other US isolates. Virus Res. 66: 139-147.
Selwyn, B. J. 1990. The epidemiology of acute respiratory tract infection in young chUdren: comparison findings from several developing countries. Rev. Infect. Dis. 12: S870-S888.
Shin, H.J., Rajashekara, G., Jirjis, F.F., Shaw, D.P., Goyal, S.M., Halvorson, D.A. and Nagaraja, KN 2000. Specific detection of avian pneumovirus (APV) US isolates by RT-PCR. Arch. Virol. 145: 1239-1246.
SuUender, W.M. 2000. Respiratory syncytial virus genetic and antigenic diversity. Chn. Microb. Rev. 13: 1-15.
Trudel, M., Νadon, F., Sinnard, C, Belanger, F., Alain, R., Seguin, C and Lussier, G. 1989. Comparison of caprine, human and bovine strains of respiratory syncytial virus. Arch. Vir. 107: 141-149. Uttenthal, A., Jensen, N.P.B. and Blom, J.Y. 1996. Viral aetiology of enzootic pneumonia in Danish dairy herds, diagnostic tools and epidemiology. Vet. Rec. 139, 114-117.
Valarcher, J., Bourhy, H., Gelfi, J. and Schelcher, F. 1999. Evaluation of a nested reverse transcription-PCR assay based on the nucleoprotein gene for diagnosis of spontaneous and experimental bovine respiratory syncytial virus infections. J. Chn. Microb. 37: 1858-1862
Van MUaan, A.J., Sprenger, J.J., Rothbarth, P.H., Brandenburg, A.H., Masurel, N. and Claas, E.G. 1994. Detection of respiratory syncytial virus by RNA-polymerase chain reaction and differentiation of subgroups with ohgonucleotide probes. J.MedNirol. 44:80-87.
VUcek, S, Elvander, M., BaUagi-Pordany, A., and Belak, S. 1994. Development of nested PCR assays for detection of bovine respiratory syncytial virus in chnical samples. J. Chn. Microb. 32: 2225-2231.
Walravens, K., Kettmann, R., CoUard, A., Coppe, P. and Burny, A.. 1990. Sequence comparison between the fusion protein of human and bovine respiratory syncytial viruses. J. Gen. Virol. 71: 3009-3014.
Weir, E.C, Brownstein, D.G., Smith, NL. and Johnson, E.A. 1988. Respiratory disease and wasting in athymic mice infected with pneumonia virus of mice. Lab. Anim. Sci. 34: 35-37.

Claims

Claims
1. An isolated essentiaUy mammahan negative-sense single stranded RNA virus
(MPV) belonging to the sub-famUy Pneumovirinae oi the famUy Paramyxoviridae and identifiable as phylogeneticaUy corresponding to the genus Metapneumovirus
2.An isolated negative-sense single stranded RNA virus (MPV) belonging to the subfamUy Pneumovirinae of the famUy Paramyxoviridae and identifiable as phylogeneticaUy corresponding to the genus Metapneumovirus by determining a nucleic acid sequence of said virus and testing it in phylogenetic tree analyses wherein maximum hkehhood trees are generated using 100 bootstraps and 3 jumbles and finding it to be more closely phylogeneticaUy corresponding to a virus isolate deposited as 1-2614 with CNCM, Paris than it is corresponding to a virus isolate of avian pneumovirus (APV) also known as turkey rhinotracheitis virus (TRTV), the aetiological agent of avian rhinotracheitis.
3. A virus according to claim 2 wherein said avian pneumovirus comprises APV type C (APV-C).
4. A virus according to claim 1 to 3 wherein said nucleic acid sequence comprises an open reading frame (ORF) encoding a viral protein of said virus.
5. A virus according to claim 4 wherein said open reading frame is selected from the group of ORFs encoding the N, P, M, and F proteins.
6. A virus according to claim 5 wherein said open reading frame is selected from the group of ORFs encoding the SH or G proteins.
7. A virus according to anyone of claims 1 to 6 comprising a nucleic acid or functional fragment phylogeneticaUy corresponding to a sequence shown in figure 6.
8. A virus according to anyone of claims 1 to 7 comprising an MPV isolate deposited as 1-2614 with CNCM, Institute Pasteur, Paris or a virus isolate phylogeneticaUy corresponding therewith.
9. A virus according to claim 8 isolatable from a human with respiratory tract illness.
10. An isolated or recombinant nucleic acid or MPV-specific functional fragment thereof obtainable from a virus according to anyone of claims 1 to 9.
11. A vector comprising a nucleic acid according to claim 10.
12. A host ceU comprising a nucleic acid according to claim 10 or a vector according to claim 11.
13. An isolated or recombinant proteinaceous molecule or MPV-specific functional fragment thereof encoded by a nucleic acid according to claim 10.
14. An antigen comprising a proteinaceous molecule or MPV-specific functional fragment thereof according to claim 13.
15. An antibody specificaUy directed against an antigen according to claim 14.
16. A method for identifying a viral isolate as an MPV comprising reacting said viral isolate or a component thereof with an antibody according to claim 15.
17. A method for identifying a viral isolate as an MPV comprising reacting said viral isolate or a component thereof with a nucleic acid according to claim 10.
18. A method according to claim 16 or 17 wherein said MPV comprises a human MPV.
19. A viral isolate identifiable with a method according to anyone of claims 16 to 18 as a mammahan negative-sense single stranded RNA virus within the sub-famUy Pneumovirinae of the famUy Paramyxoviridae and identifiable as phylogeneticaUy corresponding to the genus Metapneumovirus.
20. A method for virologicaUy diagnosing an MPV infection of a mammal comprising determining in a sample of said mammal the presence of a viral isolate or component thereof by reacting said sample with a nucleic acid according to claim 10 or an antibody according to claim 15.
21. A method for serologicaUy diagnosing an MPV infection of a mammal comprising determining in a sample of said mammal the presence of an antibody specificaUy directed against an MPV or component thereof by reacting said sample with a proteinaceous molecule or fragment thereof according to claim 13 or an antigen according to claim 14.
22. A diagnostic kit for diagnosing an MPV infection comprising a virus according to anyone of claims 1 to 9, a nucleic acid according to claim 10, a proteinaceous molecule or fragment thereof according to claim 13, an antigen according to claim 14 and/or an antibody according to claim 15.
23. Use of a virus according to any one claims 1 to 9, a nucleic acid according to claim 10, a vector according to claim 11, a host ceU according to claim 12, a proteinaceous molecule or fragment thereof according to claim 13, an antigen according to claim 14, or an antibody according to claim 15 for the production of a pharmaceutical composition.
24. Use according to claim 23 for the production of a pharmaceutical composition for the treatment or prevention of an MPV infection.
25. Use according to claim 23 or 24 for the production of a pharmaceutical composition for the treatment or prevention of respiratory tract illnesses.
26. A pharmaceutical composition comprising a virus according to any one claims 1 to 9, a nucleic acid according to claim 10, a vector according to claim 11, a host ceU according to claim 12, a proteinaceous molecule or fragment thereof according to claim 13, an antigen according to claim 14, or an antibody according to claim 15.
27. A method for the treatment or prevention of an MPV infection comprising providing an individual with a pharmaceutical composition according to claim 26.
28. A method for the treatment or prevention of a respiratory illness comprising providing an individual with a pharmaceutical composition according to claim 26.
29. A method according to claim 27 or 28 wherein said individual comprises a human.
30. A method to obtain an antiviral agent useful in the treatment of respiratory tract Ulness comprising estabhshing a ceU culture or experimental animal comprising a virus according to any one of claims 1 to 9, treating said culture or animal with an candidate antiviral agent, determining the effect of said agent on said virus or its infection of said culture or animal, and selecting an anitviral agent with the desired effect.
31. An antiviral agent obtainable according to the method of claim 30.
32. Use of an antiviral agent according to claim 31 for the preparation of a pharmaceutical composition.
33. Use according to claim 33 for the preparation of a pharmaceutical composition for the treatment of respiratory tract Ulness.
34. Use according to claim 32 or 33 for the preparation of a pharmaceutical composition for the treatment of an MPV infection.
35. A pharmaceutical composition comprising an antiviral agent according to claim 31.
36. A method for the treatment or prevention of an MPV infection comprising providing an individual with a pharmaceutical composition according to claim 35.
37. A method for the treatment or prevention of a respiratory Ulness comprising providing an individual with a pharmaceutical composition according to claim 35.
38. A method according to claim 36 or 37 wherein said individual comprises a human.
39. A method for virologicaUy diagnosing an MPV infection of an animal comprising determining in a sample of said animal the presence of a viral isolate or component thereof by reacting said sample with a nucleic acid or an antibody specificaUy reactive with a component of an avian pneumovirus (APV), said nucleic acid or antibody being cross-reactive with a component MPV.
40. A method for serologicaUy diagnosing an MPV infection of an animal comprising determining in a sample of said animal the presence of an antibody directed against an MPV or component thereof by reacting said sample with a proteinaceous molecule or fragment thereof or antigen derived from an APV isolate or component thereof, said molecule, fragment or antigen selected for being essentiaUy homologous with a component of MPV.
41. A method for virologicaUy diagnosing an APV infection of a bird comprising determining in a sample of said bird the presence of a viral isolate or component thereof by reacting said sample with a nucleic acid according to claim 10 or an antibody according to claim 15 said nucleic acid or antibody being cross-reactive with a component of APV
42. A method for serologicaUy diagnosing an APV infection of a bird comprising determining in a sample of said bird the presence of an antibody specificaUy directed against an APV or component thereof by reacting said sample with a proteinaceous molecule or fragment thereof according to claim 13 or an antigen according to claim 14, said molecule, fragment or antigen selected for being essentiaUy homologous with a component of APV.
43. A method according to anyone of claims 39 to 42 wherein said APV comprises APV-C.
44. Use of a diagnostic test designed to detect APV specific antibodies for the detection of an antibody directed against MPV.
45 Use according to claim 44 wherein said test comprises an enzyme immune assay (EIA).
46. A method for the detection of an antibody directed against MPV in a sample comprising testing said sample in a diagnostic test designed to detect APV specific antibodies.
47. A method according to claim 46 wherein said test comprises an enzyme immune assay (EIA).
PCT/NL2002/000040 2001-01-19 2002-01-18 A virus causing respiratory tract illness in susceptible mammals WO2002057302A2 (en)

Priority Applications (35)

Application Number Priority Date Filing Date Title
AU2002228471A AU2002228471B2 (en) 2001-01-19 2002-01-18 A virus causing respiratory tract illness in susceptible mammals
DK02710551.9T DK1351981T3 (en) 2001-01-19 2002-01-18 A virus that causes respiratory disease in susceptible mammals
NZ527221A NZ527221A (en) 2001-01-19 2002-01-18 A negative-sense single stranded RNA virus causing respiratory tract illness in susceptible mammals
JP2002557978A JP5503096B2 (en) 2001-01-19 2002-01-18 Virus that causes respiratory tract disease in susceptible mammals
CA2435180A CA2435180C (en) 2001-01-19 2002-01-18 A virus causing respiratory tract illness in susceptible mammals
KR1020117020851A KR101412317B1 (en) 2001-01-19 2002-01-18 A virus causing respiratory tract illness in susceptible mammals
EA200300810A EA006879B1 (en) 2001-01-19 2002-01-18 A virus causing respiratory tract illness in susceptible mammals
US10/466,811 US8927206B2 (en) 2001-01-19 2002-01-18 Virus causing respiratory tract illness in susceptible mammals
EP02710551A EP1351981B1 (en) 2001-01-19 2002-01-18 A virus causing respiratory tract illness in susceptible mammals
ES02710551T ES2393468T3 (en) 2001-01-19 2002-01-18 A virus that causes respiratory disease in susceptible mammals
BR0206591-6A BR0206591A (en) 2001-01-19 2002-01-18 Isolated negative-sense single stranded rna virus, isolated or recombinant nucleic acid or its specific functional mpv fragment, vector, host cell, isolated or recombinant proteinaceous molecule or its specific functional mpv fragment, antigen, antibody, method for identifying a viral isolate as a mpv, viral isolate, methods for virologically and serologically diagnosing a mammalian mpv infection, diagnostic kit for diagnosing a mpv infection, uses of a virus, a nucleic acid, a vector, a cell host, a proteinaceous molecule or fragment thereof, an antigen, or an antibody, pharmaceutical composition, methods for treating or preventing an mpv infection and respiratory disease, and for obtaining an antiviral agent useful in the treatment of disease. of the respiratory tract, antiviral agent, use of a viral agent, methods for virologically diagnosing and serum logically a bird apv infection, use of a diagnostic test, and method for detecting an antibody directed against mpv in a sample
CN028067630A CN1524088B (en) 2001-01-19 2002-01-18 A virus causing respiratory tract illness in susceptible mammals
KR10-2003-7009602A KR20040002853A (en) 2001-01-19 2002-01-18 A virus causing respiratory tract illness in susceptible mammals
IL15700302A IL157003A0 (en) 2001-01-19 2002-01-18 A virus causing respiratory tract illness in susceptible mammals
MXPA03006430A MXPA03006430A (en) 2001-01-19 2002-01-18 A virus causing respiratory tract illness in susceptible mammals.
HU0500244A HUP0500244A3 (en) 2001-01-19 2002-01-18 A virus causing respiratory tract illness in suspectible mammals
UA2003087814A UA93981C2 (en) 2001-01-19 2002-01-18 Virus causing respiratory tract illness in susceptible mammals
KR1020107005359A KR101105984B1 (en) 2001-01-19 2002-01-18 A virus causing respiratory tract illness in susceptible mammals
US10/371,122 US7531342B2 (en) 2001-01-19 2003-02-21 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
US10/371,264 US20030232061A1 (en) 2001-10-18 2003-02-21 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
NO20033272A NO335551B1 (en) 2001-01-19 2003-07-18 Isolated negative sense single stranded RNA mammal metapneumovirus, isolated nucleic acid, vector, host cell, protein, antibody and pharmaceutical composition as well as detection and diagnostic methods and a diagnostic kit
ZA200305655A ZA200305655B (en) 2001-01-19 2003-07-22 A virus causing respiratory tract illness in susceptible mammals.
US10/722,045 US8715922B2 (en) 2001-01-19 2003-11-25 Virus causing respiratory tract illness in susceptible mammals
HK05101405.2A HK1068898A1 (en) 2001-01-19 2005-02-18 A virus causing respiratory tract illness in susceptible mammals
US12/001,458 US20100278813A1 (en) 2001-01-19 2007-12-11 Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
AU2008202111A AU2008202111B2 (en) 2001-01-19 2008-05-13 A virus causing respiratory tract illness in susceptible mammals
US12/317,496 US20100297730A1 (en) 2001-01-19 2008-12-22 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
US12/319,152 US8722341B2 (en) 2001-01-19 2008-12-31 Metapneumovirus strains and their use in vaccine formulations and sequences
US14/270,237 US9376726B2 (en) 2001-01-19 2014-05-05 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
US14/553,957 US9334543B2 (en) 2001-01-19 2014-11-25 Virus causing respiratory tract illness in susceptible mammals
US15/147,653 US9593386B2 (en) 2001-01-19 2016-05-05 Virus causing respiratory tract illness in susceptible mammals
US15/453,764 US9803252B2 (en) 2001-01-19 2017-03-08 Virus causing respiratory tract illness in susceptible mammals
US15/796,500 US10167524B2 (en) 2001-01-19 2017-10-27 Virus causing respiratory tract illness in susceptible mammals
US16/235,030 US10519517B2 (en) 2001-01-19 2018-12-28 Virus causing respiratory tract illness in susceptible mammals
US16/730,429 US11162148B2 (en) 2001-01-19 2019-12-30 Virus causing respiratory tract illness in susceptible mammals

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01200213 2001-01-19
EP01200213.5 2001-01-19
EP01203985 2001-10-18
EP01203985.5 2001-10-18

Related Child Applications (6)

Application Number Title Priority Date Filing Date
US10/466,811 A-371-Of-International US8927206B2 (en) 2001-01-19 2002-01-18 Virus causing respiratory tract illness in susceptible mammals
US10/371,099 Continuation-In-Part US7449324B2 (en) 2001-01-19 2003-02-21 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
US10/371,122 Continuation-In-Part US7531342B2 (en) 2001-01-19 2003-02-21 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
US10/371,264 Continuation-In-Part US20030232061A1 (en) 2001-01-19 2003-02-21 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
US10/722,045 Continuation US8715922B2 (en) 2001-01-19 2003-11-25 Virus causing respiratory tract illness in susceptible mammals
US14/553,957 Continuation US9334543B2 (en) 2001-01-19 2014-11-25 Virus causing respiratory tract illness in susceptible mammals

Publications (3)

Publication Number Publication Date
WO2002057302A2 true WO2002057302A2 (en) 2002-07-25
WO2002057302A3 WO2002057302A3 (en) 2002-12-27
WO2002057302A8 WO2002057302A8 (en) 2003-11-13

Family

ID=26076820

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2002/000040 WO2002057302A2 (en) 2001-01-19 2002-01-18 A virus causing respiratory tract illness in susceptible mammals

Country Status (22)

Country Link
US (10) US8927206B2 (en)
EP (1) EP1351981B1 (en)
JP (3) JP5503096B2 (en)
KR (4) KR101105984B1 (en)
CN (2) CN1524088B (en)
AU (1) AU2002228471B2 (en)
BR (1) BR0206591A (en)
CA (1) CA2435180C (en)
DK (1) DK1351981T3 (en)
EA (1) EA006879B1 (en)
ES (1) ES2393468T3 (en)
HK (1) HK1068898A1 (en)
HU (1) HUP0500244A3 (en)
IL (1) IL157003A0 (en)
MX (1) MXPA03006430A (en)
NO (1) NO335551B1 (en)
NZ (2) NZ527221A (en)
PL (1) PL213926B1 (en)
SG (1) SG149684A1 (en)
UA (1) UA93981C2 (en)
WO (1) WO2002057302A2 (en)
ZA (1) ZA200305655B (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1351981A2 (en) 2001-01-19 2003-10-15 Vironovative B.V. A virus causing respiratory tract illness in susceptible mammals
WO2003097089A3 (en) * 2002-05-16 2004-02-05 Lohmann Animal Health Gmbh Attenuation of metapneumovirus
WO2004057021A2 (en) * 2002-12-19 2004-07-08 UNIVERSITé LAVAL Molecular methods and compositions for detecting and quantifying respiratory viruses
EP1473037A1 (en) * 2003-05-02 2004-11-03 Vironovative B.V. Treatment of hPMV infections with Ribavirin
WO2004096993A2 (en) 2003-04-25 2004-11-11 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
WO2005014626A2 (en) 2003-02-28 2005-02-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant human metapneumovirus and its use
WO2005028673A1 (en) * 2003-09-22 2005-03-31 Institut Pasteur A method for detecting nipah virus and method for providing immunoprotection against henipaviruses
JP2005518208A (en) * 2002-02-21 2005-06-23 メドイミューン ワクチンズ，インコーポレーテッド Recombinant parainfluenza virus expression system and a vaccine containing a heterologous antigen obtained from metapneumovirus
EP1613345A2 (en) * 2003-03-28 2006-01-11 MedImmune Vaccines, Inc. Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
WO2009062532A1 (en) * 2007-11-16 2009-05-22 Vironovative Bv Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
US7547512B2 (en) 2003-03-24 2009-06-16 The University Of Hong Kong High-throughput diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)
WO2010048615A2 (en) 2008-10-24 2010-04-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services, Center For Disease Control And Prevention Human ebola virus species and compositions and methods thereof
JP2011167197A (en) * 2003-04-25 2011-09-01 Medimmune Llc Recombinant parainfluenza virus expression system and vaccine comprising heterologous antigen derived from metapneumovirus
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
WO2014115893A1 (en) 2013-01-28 2014-07-31 株式会社イーベック Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
US9157915B2 (en) 2006-04-24 2015-10-13 Diagnostic Hybrids, Inc. Devices and methods for detecting human metapneumovirus
US9689018B2 (en) 1998-04-24 2017-06-27 Diagnostic Hybrids, Inc. Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses
WO2018029383A1 (en) 2016-08-12 2018-02-15 Anicon Labor Gmbh Infectious bronchitis (ib) virus variants and related compositions, uses and method

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232061A1 (en) * 2001-10-18 2003-12-18 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
CA2494485A1 (en) * 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
AU2003297602A1 (en) * 2002-12-02 2004-06-23 University Of Maryland, College Park Avian pneumovirus genes, recombinant avian pneumoviruses and methods of making
CA2521826C (en) * 2003-04-11 2013-08-06 Jennifer L. Reed Recombinant il-9 antibodies and uses thereof
US7691379B2 (en) 2004-04-12 2010-04-06 Medimmune, Llc Anti-IL-9 antibody formulations
JP4546212B2 (en) * 2004-10-21 2010-09-15 三菱化学メディエンス株式会社 Antibody measurement method using cells expressing antigenic protein
US20060216700A1 (en) * 2005-03-10 2006-09-28 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
WO2009012155A2 (en) * 2007-07-13 2009-01-22 Medimmune, Llc Preparation of negative-stranded rna viruses by electroporation
US20090186050A1 (en) * 2007-11-16 2009-07-23 Fouchier Ron A M Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
KR101073991B1 (en) * 2009-10-27 2011-10-21 대한민국 Avian metapneumovirus type B SC1509 strain isolated from chicken in Korea and the use thereof
CN101880732B (en) * 2010-06-29 2012-10-10 中国药品生物制品检定所 Simian parainfluenza virus 5 RT-PCR (Reverse Transcription-Polymerase Chain Reaction) detection method and kit
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19177059T1 (en) 2010-10-01 2021-10-07 Modernatx, Inc. RIBONUCLEIC ACID CONTAINING N1-METHYL-PSEUDOURACILE AND USES
DE12722942T1 (en) 2011-03-31 2021-09-30 Modernatx, Inc. RELEASE AND FORMULATION OF MANIPULATED NUCLEIC ACIDS
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (en) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Modified nucleosides, nucleotides and nucleic acids and methods for their use
MX2014007233A (en) 2011-12-16 2015-02-04 Moderna Therapeutics Inc Modified nucleoside, nucleotide, and nucleic acid compositions.
DK2828293T3 (en) 2012-03-20 2018-01-08 Humabs Biomed S A ANTIBODIES NEUTRALIZING RSV, MPV AND PVM AND USE THEREOF
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc Modified polynucleotides
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EA039682B1 (en) * 2012-06-04 2022-02-28 Хумабс Биомед Са Antibodies that neutralize rsv, mpv and pvm and uses thereof
CN102676701B (en) * 2012-06-11 2013-08-14 广东温氏食品集团股份有限公司 Universal RT-PCR (Reverse Transcription Polymerase Chain Reaction) detection primer and detection method for avian pneumovirus
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CN103360472B (en) * 2013-07-30 2015-02-25 北京市农林科学院 Acian Metapneumovirus antibody ELISA detection kit
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
CL2013002829A1 (en) 2013-10-01 2014-04-04 Univ Pontificia Catolica Chile Immunogenic formulation containing live recombinant bcg expressing metapneumovirus (hmpv) antigens in a suspension that is prepared from a lyophilisate without the need for adjuvant; its pharmaceutical use; hmpv vaccine
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US10774114B2 (en) * 2014-03-10 2020-09-15 Fondation The Ark Respiratory syncytial virus (RSV) replication inhibitors
HRP20220872T1 (en) 2015-10-22 2022-12-23 Modernatx, Inc. Respiratory virus vaccines
US10232033B2 (en) * 2016-10-31 2019-03-19 Wuhan Sanli BioTechnology Company Limited Respiratory syncytial virus vaccine
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. Respiratory virus nucleic acid vaccines
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
AU2019261570A1 (en) * 2018-04-23 2020-11-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric vectors
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
WO2022258755A1 (en) 2021-06-09 2022-12-15 Universität Duisburg-Essen Method for immortalising vesicle-secreting cells
WO2023004307A1 (en) * 2021-07-19 2023-01-26 Epivax, Inc. T cell epitopes and related compositions useful in the prevention and treatment of respiratory syncytial virus infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020600A1 (en) * 1998-10-05 2000-04-13 Akzo Nobel N.V. Avian pneumovirus vaccine and diagnostic agent
FR2801607A1 (en) * 1999-11-26 2001-06-01 Merial Sas New avian pneumovirus CNCM I-2353, useful for making therapeutic or protective vaccines for birds, particularly ducks

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0413695B1 (en) 1988-04-22 1994-05-04 The Upjohn Company Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3.
US5137819A (en) 1988-07-08 1992-08-11 University Of British Columbia Cellulose binding fusion proteins for immobilization and purification of polypeptides
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
GB9200117D0 (en) 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
DE69507022T2 (en) 1994-04-19 1999-06-24 Sanquin Bloedvoorziening METHODS TO Distinguish Between The Variants Of The Human Immunodeficiency Virus That Induce Syncytes And Those That Do Not Induce Syncytes And Primers For Use In The Methods
SE504386C2 (en) 1994-05-30 1997-01-27 Bengt Wilhelm Toernqvist Bottom construction on a displacement hull
PT702085E (en) 1994-07-18 2004-04-30 Karl Klaus Conzelmann NON-SEGMENTED CHEMICAL RNA VIRUS INFECTIOUS RECOMBINANT
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DK0780475T4 (en) 1995-08-09 2006-10-23 Schweiz Serum & Impfinst Method of producing infectious negative-strand RNA virus
JPH11512609A (en) 1995-09-27 1999-11-02 アメリカ合衆国 Production of infectious respiratory syncytial virus from cloned nucleotide sequence
US5869036A (en) 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
ES2109189B1 (en) 1996-03-14 1998-05-16 Iberica Cyanamid VECTORS BASED ON RECOMBINANT DEFECTIVE VIRAL GENOMES AND THEIR USE IN THE FORMULATION OF VACCINES.
US6180398B1 (en) 1996-07-12 2001-01-30 Virogeneitics Corporation Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation
JP4413999B2 (en) 1996-07-15 2010-02-10 アメリカ合衆国 Production of attenuated respiratory syncytium virus vaccines from cloned nucleotide sequences.
BR9712138A (en) 1996-09-27 2000-01-18 American Cyanamid Co Isolated RNA virus, vaccine, process to immunize an individual to induce protection against a non-segmented, negative, single-stranded RNA virus of the mononegaviral order and to produce RNA virus, isolated nucleic acid molecule and composition.
US5817494A (en) 1997-05-21 1998-10-06 Incyte Pharmaceuticals, Inc. Ubiquitin conjugation proteins
CN1250725C (en) 1997-05-23 2006-04-12 美国政府健康及人类服务部 Prodn of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
US7192593B2 (en) 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
WO1999002657A1 (en) 1997-07-11 1999-01-21 Yale University Rhabdoviruses with reengineered coats
JP2001517448A (en) 1997-09-19 2001-10-09 アメリカン・サイアナミド・カンパニー Attenuated respiratory syncytial virus
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
KR20070058607A (en) 1999-05-18 2007-06-08 가부시키가이샤 디나벡크 겐큐쇼 Paramyxoviridae virus vector defective in envelope gene
KR100940776B1 (en) 1999-07-09 2010-02-11 더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈 Attenuated Human-Bovine Chimeric Parainfluenza Virus PIV Vaccines
EA003289B1 (en) 1999-07-29 2003-04-24 Хатебур Умформмашинен Аг Device for producing a lifting and lowering movement
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
IL144831A0 (en) 1999-12-10 2002-06-30 Us Health USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
US6387586B1 (en) 2000-11-06 2002-05-14 Eastman Kodak Company High contrast visually adaptive radiographic film and imaging assembly for thoracic imaging
JP4268407B2 (en) 2000-11-28 2009-05-27 アヴィロン，インコーポレーテッド Recombinant RSV virus expression system and vaccine
US6632459B2 (en) 2000-12-11 2003-10-14 Nutricia N.V. Chlorogenic acid and an analog thereof for immune system stimulation
US20030232061A1 (en) 2001-10-18 2003-12-18 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
US8927206B2 (en) 2001-01-19 2015-01-06 Vironovative B.V. Virus causing respiratory tract illness in susceptible mammals
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
CA2467958A1 (en) 2001-11-21 2003-05-30 Brian R. Murphy Recovery of recombinant human parainfluenza virus type 1 (hpivi) from cdna
MXPA04008088A (en) 2002-02-21 2005-09-30 Medimmune Vaccines Inc Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus.
DE10221836A1 (en) 2002-05-16 2003-12-04 Lohmann Animal Health Gmbh Attenuation of metapneumovirus
CA2494485A1 (en) 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
US6605283B1 (en) * 2002-11-01 2003-08-12 The United States Of America As Represented By The Secretary Of Agriculture Nucleotide sequence for the Avian Metapneumovirus (Colorado) attachment glycoprotein gene
WO2004057021A2 (en) 2002-12-19 2004-07-08 UNIVERSITé LAVAL Molecular methods and compositions for detecting and quantifying respiratory viruses
JP2007524372A (en) 2003-02-28 2007-08-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Recombinant human metapneumovirus and uses thereof
EP1602103A1 (en) 2003-03-05 2005-12-07 Koninklijke Philips Electronics N.V. Apparatus and method of determining a power parameter for writing/erasing information on an optical medium.
EP1613650A2 (en) 2003-04-08 2006-01-11 CoroNovative B.V. Severe acute respiratory syndrome (sars) causing coronavirus
EP2494986A1 (en) 2003-04-25 2012-09-05 MedImmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
KR101187955B1 (en) 2003-04-25 2012-10-08 비로노바티브 비브이 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
US20040229219A1 (en) 2003-04-30 2004-11-18 Gallaher William R. Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)
EP1533370A1 (en) 2003-11-18 2005-05-25 ViroNovative B.V. Novel atypical pneumonia-causing virus
EP1548748A1 (en) 2003-12-17 2005-06-29 Interuniversitaire Microelectronica Centrum vzw ( IMEC) A method for making probes for atomic force microscopy
WO2005080991A1 (en) 2004-02-20 2005-09-01 Erasmus Universiteit Rotterdam Method to detect antigen-specific cytolytic activity
US8318423B2 (en) 2004-07-06 2012-11-27 Focus Diagnostics, Inc. Methods and compositions for detecting rhinoviruses
CA2587451A1 (en) 2004-11-11 2006-05-18 Solvay Pharmaceuticals B.V. Defective influenza virus particles
AU2005318087B2 (en) 2004-12-24 2011-04-21 Abbott Biologicals B.V. Rescue of influenza virus
US20060216700A1 (en) 2005-03-10 2006-09-28 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
WO2006110214A2 (en) 2005-04-08 2006-10-19 Medimmune, Inc. Antibodies against mammalian metapneumovirus
EP1748447B1 (en) 2005-07-28 2008-10-22 Interuniversitair Microelektronica Centrum ( Imec) Dual tip atomic force microscopy probe and method for producing such a probe
EP1925318A1 (en) 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US20090186050A1 (en) 2007-11-16 2009-07-23 Fouchier Ron A M Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
CN103052401A (en) 2010-07-23 2013-04-17 伊斯克诺瓦公司 Influenza vaccine
JP5923723B2 (en) 2011-06-02 2016-05-25 パナソニックＩｐマネジメント株式会社 Person attribute estimation system, person attribute estimation apparatus, and person attribute estimation method
KR20150064104A (en) 2012-09-23 2015-06-10 에라스무스 유니버시티 메디컬 센터 로테르담 Human Betacoronavirus Lineage C and Identification of N-terminal Dipeptidyl Peptidase as Its Virus Receptor
CN109402065B (en) * 2018-08-08 2021-07-30 温氏食品集团股份有限公司 Muscovy duck subtype C avian metapneumovirus attenuated strain and preparation and application thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020600A1 (en) * 1998-10-05 2000-04-13 Akzo Nobel N.V. Avian pneumovirus vaccine and diagnostic agent
FR2801607A1 (en) * 1999-11-26 2001-06-01 Merial Sas New avian pneumovirus CNCM I-2353, useful for making therapeutic or protective vaccines for birds, particularly ducks

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
AHMADIAN G ET AL: "Detection and characterization of proteins encoded by the second ORF of the M2 gene of pneumoviruses" JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 80, no. 8, August 1999 (1999-08), pages 2011-2016, XP002176552 ISSN: 0022-1317 *
BAYON-AUBOYER M H ET AL: "Comparison of F-, G- and N-based RT-PCR protocols with conventional virological procedures for the detection and typing of turkey rhinotracheitis virus." ARCHIVES OF VIROLOGY, vol. 144, no. 6, 1999, pages 1091-1109, XP002213815 ISSN: 0304-8608 *
BAYON-AUBOYER MARIE-HELENE ET AL: "Nucleotide sequences of the F, L and G protein genes of two non-A/non-B avian pneumoviruses (APV) reveal a novel APV subgroup" JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 81, no. 11, November 2000 (2000-11), pages 2723-2733, XP002176553 ISSN: 0022-1317 *
DATABASE EBI [Online] SWALL; 1 December 2001 (2001-12-01) "Fusion protein" Database accession no. Q91F55 XP002213823 -& DATABASE EBI [Online] SWALL; 1 May 2000 (2000-05-01) "Fusion protein" Database accession no. Q9QDI1 XP002213824 *
DATABASE EBI [Online] SWALL; 1 December 2001 (2001-12-01) "Matrix protein" Database accession no. Q91F56 XP002213821 -& DATABASE EBI [Online] SWALL; 1 November 1998 (1998-11-01) "Matrix protein" Database accession no. O90244 XP002213822 *
DATABASE EBI [Online] SWALL; 1 December 2001 (2001-12-01) "Nucleoprotein" Database accession no. Q91F57 XP002213817 -& DATABASE EBI [Online] SWALL; 1 May 2000 (2000-05-01) "Nucleocapsid protein" Database accession no. Q9QF48 XP002213818 *
DATABASE EBI [Online] SWALL; 1 December 2001 (2001-12-01) "Phosphoprotein" Database accession no. Q91KZ5 XP002213819 -& DATABASE EBI [Online] SWALL; 1 May 2000 (2000-05-01) "Phosphoprotein" Database accession no. Q9QF47 XP002213820 *
DATABASE EBI [Online] SWALL; 1 December 2001 (2001-12-01) "RNA-dependent RNA polymerase" Database accession no. Q91L20 XP002213825 -& DATABASE EBI [Online] SWALL; 1 May 1997 (1997-05-01) "RNA-dependent RNA polymerase" Database accession no. P87509 XP002213826 *
HOOGEN VAN DEN BERNADETTE G ET AL: "A newly discovered human pneumovirus isolated from young children with respiratory tract disease" NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 7, no. 6, June 2001 (2001-06), pages 719-724, XP002176554 ISSN: 1078-8956 *
PRINGLE C R: "Virus Taxonomy at the XIth International Congress of Virology, Sydney, Australia, August 9-13, 1999." ARCHIVES OF VIROLOGY, vol. 144, no. 10, 1999, pages 2065-2070, XP002213816 ISSN: 0304-8608 *
RANDHAWA J S ET AL: "Rescue of synthetic minireplicons establishes the absence of the NS1 and NS2 genes from avian pneumovirus" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 71, no. 12, 1 December 1997 (1997-12-01), pages 9849-9854, XP002083386 ISSN: 0022-538X *
YU Q ET AL: "Deduced amino acid sequence of the fusion glycoprotein of turkey rhinotracheitis virus has greater identity with that of human respiratory syncytial virus, a pneomovirus, than that of paramyxoviruses and morbilliviruses" JOURNAL OF GENERAL VIROLOGY, READING, BERKS, GB, vol. 72, no. 1, 1991, pages 75-81, XP002095554 ISSN: 0022-1317 *

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9689018B2 (en) 1998-04-24 2017-06-27 Diagnostic Hybrids, Inc. Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses
US8927206B2 (en) 2001-01-19 2015-01-06 Vironovative B.V. Virus causing respiratory tract illness in susceptible mammals
US8722341B2 (en) 2001-01-19 2014-05-13 Vironovative B.V. Metapneumovirus strains and their use in vaccine formulations and sequences
EP1351981A2 (en) 2001-01-19 2003-10-15 Vironovative B.V. A virus causing respiratory tract illness in susceptible mammals
US11162148B2 (en) 2001-01-19 2021-11-02 Erasmus University Medical Center Rotterdam Virus causing respiratory tract illness in susceptible mammals
US10519517B2 (en) 2001-01-19 2019-12-31 Vironovative Bv Virus causing respiratory tract illness in susceptible mammals
US9334543B2 (en) 2001-01-19 2016-05-10 Erasmus University Medical Center Rotterdam Virus causing respiratory tract illness in susceptible mammals
US9376726B2 (en) 2001-01-19 2016-06-28 Erasmus University Medical Center Rotterdam Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
US9593386B2 (en) 2001-01-19 2017-03-14 Erasmus Universiteit Medical Center Rotterdam Virus causing respiratory tract illness in susceptible mammals
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
US7531342B2 (en) 2001-01-19 2009-05-12 Medimmune, Llc Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
US9803252B2 (en) 2001-01-19 2017-10-31 Erasmus University Medical Center Rotterdam Virus causing respiratory tract illness in susceptible mammals
US10167524B2 (en) 2001-01-19 2019-01-01 Erasmus University Medical Center Rotterdam Virus causing respiratory tract illness in susceptible mammals
JP2005518208A (en) * 2002-02-21 2005-06-23 メドイミューン ワクチンズ，インコーポレーテッド Recombinant parainfluenza virus expression system and a vaccine containing a heterologous antigen obtained from metapneumovirus
TWI405851B (en) * 2002-02-21 2013-08-21 Medimmune Llc Metapneumovirus strains as vaccine formulations and as vectors for expression of heterologous antigenic sequences
JP2006500907A (en) * 2002-02-21 2006-01-12 メドイミューン ワクチンズ，インコーポレーテッド Metapneumovirus strains and their use in vaccine formulations and as vectors for antigen sequence expression
US9834824B2 (en) 2002-02-21 2017-12-05 Erasmus University Medical Center Rotterdam Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
JP2012105661A (en) * 2002-02-21 2012-06-07 Medimmune Llc Metapneumovirus strain and its use in vaccine formulation and as vector for expression of antigenic sequence
EP1576090A2 (en) * 2002-02-21 2005-09-21 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vector for expression of antigenic sequences
EP1576090A4 (en) * 2002-02-21 2008-07-16 Medimmune Vaccines Inc Metapneumovirus strains and their use in vaccine formulations and as vector for expression of antigenic sequences
US7449324B2 (en) 2002-02-21 2008-11-11 Vironovative Bv Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
US11220718B2 (en) 2002-02-21 2022-01-11 Erasmus University Medical Center Rotterdam Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
EP2327418A1 (en) 2002-02-21 2011-06-01 MedImmune, LLC Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from other viruses
JP2009114204A (en) * 2002-02-21 2009-05-28 Medimmune Vaccines Inc Metapneumovirus strain and its use in vaccine formulation and as vector for expression of antigenic sequence
US9944997B2 (en) 2002-02-21 2018-04-17 Erasmus University Medical Center Rotterdam Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
US10287640B2 (en) 2002-02-21 2019-05-14 Erasmus University Medical Center Rotterdam Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
US9567653B2 (en) 2002-02-21 2017-02-14 Erasmus University Medical Center Rotterdam Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
US8841433B2 (en) 2002-02-21 2014-09-23 Vironovative Bv Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
WO2003097089A3 (en) * 2002-05-16 2004-02-05 Lohmann Animal Health Gmbh Attenuation of metapneumovirus
WO2004057021A2 (en) * 2002-12-19 2004-07-08 UNIVERSITé LAVAL Molecular methods and compositions for detecting and quantifying respiratory viruses
WO2004057021A3 (en) * 2002-12-19 2005-08-11 Univ Laval Molecular methods and compositions for detecting and quantifying respiratory viruses
US7704491B2 (en) 2003-02-28 2010-04-27 The United States Of America As Represented By The Department Of Health And Human Services Recombinant human metapneumovirus and its use
WO2005014626A2 (en) 2003-02-28 2005-02-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant human metapneumovirus and its use
AU2004262624B2 (en) * 2003-02-28 2009-11-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant human metapneumovirus and its use
WO2005014626A3 (en) * 2003-02-28 2005-04-28 Us Health Recombinant human metapneumovirus and its use
JP2007524372A (en) * 2003-02-28 2007-08-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Recombinant human metapneumovirus and uses thereof
US7547512B2 (en) 2003-03-24 2009-06-16 The University Of Hong Kong High-throughput diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)
JP2006524053A (en) * 2003-03-28 2006-10-26 メッドイミューン バクシーンズ、インコーポレイティド Compositions and methods related to respiratory syncytial virus subgroup B strain 9320
JP4783726B2 (en) * 2003-03-28 2011-09-28 メディミューン，エルエルシー Compositions and methods related to respiratory syncytial virus subgroup B strain 9320
EP1613345A2 (en) * 2003-03-28 2006-01-11 MedImmune Vaccines, Inc. Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
EP1613345A4 (en) * 2003-03-28 2007-01-10 Medimmune Vaccines Inc Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
US8163530B2 (en) 2003-03-28 2012-04-24 Medimmune, Llc Nucleic acids encoding respiratory syncytial virus subgroup B strain 9320
US7572904B2 (en) 2003-03-28 2009-08-11 Medimmune, Llc Nucleic acids encoding respiratory syncytial virus subgroup B strain 9320
EP1623006A4 (en) * 2003-04-25 2009-10-28 Medimmune Vaccines Inc Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
CN1813061B (en) * 2003-04-25 2013-05-29 免疫医疗有限责任公司 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
JP2011167197A (en) * 2003-04-25 2011-09-01 Medimmune Llc Recombinant parainfluenza virus expression system and vaccine comprising heterologous antigen derived from metapneumovirus
WO2004096993A2 (en) 2003-04-25 2004-11-11 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
EP1623006A2 (en) * 2003-04-25 2006-02-08 MedImmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
US7704720B2 (en) 2003-04-25 2010-04-27 Medimmune, Llc Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
EP2494986A1 (en) 2003-04-25 2012-09-05 MedImmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
EP2494987A1 (en) 2003-04-25 2012-09-05 MedImmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
JP2011250786A (en) * 2003-04-25 2011-12-15 Medimmune Llc Metapneumovirus strain and its use in vaccine formulation and its use as vector for expression of antigenic sequence, and method for propagating virus
JP2007525178A (en) * 2003-04-25 2007-09-06 メッドイミューン バクシーンズ，インコーポレイティド Metapneumovirus strain, its use in vaccine formulations, use as a vector for expression of antigenic sequences, and virus propagation method
WO2004096241A1 (en) * 2003-05-02 2004-11-11 Vironovative B.V. Hmpv treatment with ribavirin and anti-hmpv antibody
EP1473037A1 (en) * 2003-05-02 2004-11-03 Vironovative B.V. Treatment of hPMV infections with Ribavirin
WO2005028673A1 (en) * 2003-09-22 2005-03-31 Institut Pasteur A method for detecting nipah virus and method for providing immunoprotection against henipaviruses
US9535066B2 (en) 2006-04-24 2017-01-03 Diagnostic Hybrids, Inc. Methods for detecting human metapneumovirus
US9157915B2 (en) 2006-04-24 2015-10-13 Diagnostic Hybrids, Inc. Devices and methods for detecting human metapneumovirus
WO2009062532A1 (en) * 2007-11-16 2009-05-22 Vironovative Bv Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
WO2010048615A2 (en) 2008-10-24 2010-04-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services, Center For Disease Control And Prevention Human ebola virus species and compositions and methods thereof
EP3351628A1 (en) 2008-10-24 2018-07-25 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services Human ebola virus species and compositions and methods thereof
WO2014115893A1 (en) 2013-01-28 2014-07-31 株式会社イーベック Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
WO2018029383A1 (en) 2016-08-12 2018-02-15 Anicon Labor Gmbh Infectious bronchitis (ib) virus variants and related compositions, uses and method
DE102016215118A1 (en) 2016-08-12 2018-02-15 Anicon Labor Gmbh Infectious Bronchitis (IB) Virus Variants and Related Compositions, Uses and Methods

Also Published As

Publication number Publication date
JP2004531220A (en) 2004-10-14
MXPA03006430A (en) 2004-10-15
CN1524088A (en) 2004-08-25
JP2011177173A (en) 2011-09-15
US8927206B2 (en) 2015-01-06
ES2393468T3 (en) 2012-12-21
CA2435180C (en) 2019-04-09
AU2002228471B2 (en) 2008-02-14
US20200140964A1 (en) 2020-05-07
US11162148B2 (en) 2021-11-02
JP2014027930A (en) 2014-02-13
US8722341B2 (en) 2014-05-13
NZ555567A (en) 2008-07-31
IL157003A0 (en) 2004-02-08
JP5503096B2 (en) 2014-05-28
EA006879B1 (en) 2006-04-28
KR20090006236A (en) 2009-01-14
NO335551B1 (en) 2014-12-29
PL213926B1 (en) 2013-05-31
JP5813060B2 (en) 2015-11-17
KR20040002853A (en) 2004-01-07
US20160244850A1 (en) 2016-08-25
EP1351981B1 (en) 2012-08-08
US10167524B2 (en) 2019-01-01
US20050118195A1 (en) 2005-06-02
US9334543B2 (en) 2016-05-10
US20190119762A1 (en) 2019-04-25
HK1068898A1 (en) 2005-05-06
US20140295409A1 (en) 2014-10-02
KR100964413B1 (en) 2010-06-15
HUP0500244A3 (en) 2011-03-28
EP1351981A2 (en) 2003-10-15
HUP0500244A2 (en) 2005-05-30
US20180057893A1 (en) 2018-03-01
WO2002057302A8 (en) 2003-11-13
NO20033272D0 (en) 2003-07-18
KR20110113658A (en) 2011-10-17
CA2435180A1 (en) 2002-07-25
DK1351981T3 (en) 2012-11-26
SG149684A1 (en) 2009-02-27
CN1524088B (en) 2012-11-07
US7531342B2 (en) 2009-05-12
KR20100034059A (en) 2010-03-31
BR0206591A (en) 2005-02-01
WO2002057302A3 (en) 2002-12-27
US20040005544A1 (en) 2004-01-08
US20170183747A1 (en) 2017-06-29
US20150093746A1 (en) 2015-04-02
US9593386B2 (en) 2017-03-14
US20100143407A1 (en) 2010-06-10
PL367826A1 (en) 2005-03-07
EA200300810A1 (en) 2003-12-25
NO20033272L (en) 2003-09-18
US9803252B2 (en) 2017-10-31
UA93981C2 (en) 2011-03-25
US9376726B2 (en) 2016-06-28
US10519517B2 (en) 2019-12-31
KR101105984B1 (en) 2012-01-18
NZ527221A (en) 2006-09-29
CN101921732A (en) 2010-12-22
KR101412317B1 (en) 2014-07-24
ZA200305655B (en) 2004-07-22

Similar Documents

Publication Publication Date Title
US11162148B2 (en) Virus causing respiratory tract illness in susceptible mammals
AU2002228471A1 (en) A virus causing respiratory tract illness in susceptible mammals
CA2477234C (en) Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
US8715922B2 (en) Virus causing respiratory tract illness in susceptible mammals
AU2008202111B2 (en) A virus causing respiratory tract illness in susceptible mammals
DE et al. Patent 2435180 Summary

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 157003

Country of ref document: IL

Ref document number: 2002557978

Country of ref document: JP

Ref document number: 2435180

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/006430

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020037009602

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003/05655

Country of ref document: ZA

Ref document number: 200305655

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002228471

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 527221

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002710551

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1272/CHENP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200300810

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 028067630

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002710551

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 30/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION.

Free format text: IN PCT GAZETTE 30/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION.

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020037009602

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10466811

Country of ref document: US